{ "schema_version": "1.0", "research_parent_version": "ADC-20261007-R1", "base_presentation_version": "ADC-20261007-R1-LAYERED-HTML-R2-1.0", "presentation_version": "ADC-20261007-R1-LAYERED-HTML-R2-EVIDENCE-1.0", "research_as_of": "2026-10-07", "research_timezone": "Asia/Taipei", "compiled_at": "2026-10-07T18:57:46+08:00", "base_zip_sha256": "0bc0264e77d744a400f48cc59b62c1be32a8511a6a37d9043d130f1d33020bea", "base_binding_as_supplied": "42329f4e5f37e6ce2f0fb6a568b5a05362a21c78acf502a03cfdf73fdc0dc3b5", "base_binding_method": "Not supplied; retained verbatim, not independently recomputed.", "scope": { "specified_source_ids": 46, "specified_bilingual_locations": 146, "R03_additional_case_detail_locations": 2, "unchanged_previously_verified_claim_source_ids": [ "C01", "C02", "C03", "C06", "C08", "C13", "C15", "C18", "C19", "C20", "D01", "D02", "D06", "D16", "D17", "D35", "R02", "R03", "R04", "R06", "R07", "R10" ], "qualification": "The 22 IDs denote previously verified claims, not a statement that their entire source texts were verified." }, "source_status_before_correction": { "unverifiable": 2, "supported": 35, "partially_supported": 9 }, "R03_case_status": "unverifiable; exact clause removed in both languages", "quotation_policy": "Minimal original quotations are in one hashed UTF-8 evidence material per source. CSV/JSON point to that supplied material; retrieval failure logs are explicitly not original article evidence.", "original_artifact_policy": "A saved excerpt hash identifies the excerpt record, not the original webpage/PDF. Original artifact SHA256 is null unless actual response bytes were saved.", "date_policy": "Original source_date/data_date are retained verbatim. checked_at records the actual current review time and timezone; observation dates and unavailable historical network timestamps are separate.", "sources": [ { "source_id": "R03", "original_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12079096/", "title": "Abelman et al. — TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer", "source_date": "2025-01-02", "data_date": "2020-09至2024-01檢測資料；卷期2025-05-15", "checked_at": "2026-10-07T18:40:15+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "prior_reference_reread_returned_access_wall", "read_level": "no_article_content_obtained", "access_result": "reCAPTCHA; stopped", "evidence_materials": [ { "path": "evidence/R03_access_result.json", "bytes": 860, "sha256": "55037086a8f1871385c9165a3b03ed5a001f1327019963f957a357a7334f6f98", "kind": "access_result_log_not_article_excerpt" } ], "original_artifact_sha256": null, "locators": [ { "requested": "Table 1 or individual-case passage", "verified": null } ], "numeric_support": [], "claim_assessments": [ { "claim_location_id": "R03-ZH-L0259", "status": "unverifiable", "supported_scope": "Existing abstract-supported 4/31, 3/420, percentages and general functional cross-resistance claims are out of this recheck and remain unchanged.", "gap": "No actual Table 1/case passage obtained to verify one baseline low-level mutation among the four cases.", "resolution": "Delete only the baseline-case clause; do not replace it with a contrary scientific claim.", "language": "ZH", "line": 259, "section": "06", "subsection": "TOP1 mutation / cross-resistance paragraph", "exact_correction_ids": [ "R03-ZH-L0259" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "R03-EN-L0259", "status": "unverifiable", "supported_scope": "Existing abstract-supported 4/31, 3/420, percentages and general functional cross-resistance claims are out of this recheck and remain unchanged.", "gap": "No actual Table 1/case passage obtained to verify one baseline low-level mutation among the four cases.", "resolution": "Delete only the baseline-case clause; do not replace it with a contrary scientific claim.", "language": "EN", "line": 259, "section": "06", "subsection": "TOP1 mutation / cross-resistance paragraph", "exact_correction_ids": [ "R03-EN-L0259" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" } ], "overall_status": "unverifiable", "precise_gap": "The only reopened claim is the baseline low-level mutation detail. Table 1/case original text was not obtained; prior author summaries do not close this gap.", "web_refs": [ "turn114view0" ], "unchanged_verified_scope": "4/31, 3/420, 12.9%, 0.7% and existing abstract-supported mechanism scope; not rechecked.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": null, "claim_location_ids": [ { "claim_location_id": "R03-ZH-L0259", "language": "ZH", "line": 259, "section": "06", "subsection": "TOP1 mutation / cross-resistance paragraph" }, { "claim_location_id": "R03-EN-L0259", "language": "EN", "line": 259, "section": "06", "subsection": "TOP1 mutation / cross-resistance paragraph" } ], "applied_corrections": [ "R03-ZH-L0259", "R03-EN-L0259" ], "current_disposition": "Specified unavailable source-dependent example/detail removed; historical records retained; original evidence gap remains.", "reader_source_note": { "source_id": "R03", "supports_zh": "保留既有摘要已支持的4/31、3/420及交叉抗藥機制範圍；未核得的單一baseline個案細節已移除。", "supports_en": "The existing abstract-supported 4/31, 3/420 and cross-resistance scope are retained. The unverified individual baseline-case detail has been removed.", "access_scope_zh": "本次只補Table 1／病例段的baseline細節，原頁回傳reCAPTCHA後停止；未取得該段。其餘既有摘要支持範圍未重查。", "access_scope_en": "Only the baseline detail in Table 1 or the case passage was reopened. The original page returned reCAPTCHA and reading stopped; that passage was not obtained. The existing abstract-supported scope was not rechecked.", "locator_zh": "既有摘要範圍沿用；Table 1／病例段本次未取得。", "locator_en": "Existing abstract scope carried forward; Table 1 / case passage not obtained in this check." } }, { "source_id": "R05", "original_url": "https://pubmed.ncbi.nlm.nih.gov/26076429/", "title": "Lyon et al. — Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index", "source_date": "2015-06-15", "data_date": "2015年臨床前研究", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "本輪未取得 PubMed 摘要；本地 foundations.json 的 claims 為作者摘要，未當原文", "retrieval_mode": "public_url_web_tool_failed", "access_result": "直接原 URL 回 Internal Error；原已用 turn40view0 讀回只有 HHS Vulnerability Disclosure 空殼，沒有摘要。停止，未用替代 route。", "locators": [], "numeric_support": [], "web_refs": [ "turn111view2", "turn116view1" ], "overall_status": "unverifiable", "precise_gap": "無本輪可核原摘要，不對 Lyon 原研究「降低高負載 ADC 疏水性影響清除及治療指數」作新驗證。原作者整理和研究題名不足以代替所需原文，亦不據讀取失敗判定原主張錯誤。", "editorial_disposition": "停止作正文有效依據；原始數值、研究紀錄與歷史來源保留，由證據 sidecar 標示未核；正文精確刪修由主編輯整合。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "network_time_note": "checked_at 是本輪完成讀取後的核對記錄時間；工具未提供精確 HTTP 取得時間。", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0193", "status": "unverifiable", "supported_scope": "本輪無可用原文支持；保留原主張為待核，不認定其錯誤。", "gap": "無本輪可核原摘要，不對 Lyon 原研究「降低高負載 ADC 疏水性影響清除及治療指數」作新驗證。原作者整理和研究題名不足以代替所需原文，亦不據讀取失敗判定原主張錯誤。", "language": "ZH", "line": 193, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？", "exact_correction_ids": [ "ZH-L0193" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "ZH-L0199", "status": "unverifiable", "supported_scope": "本輪無可用原文支持；保留原主張為待核，不認定其錯誤。", "gap": "無本輪可核原摘要，不對 Lyon 原研究「降低高負載 ADC 疏水性影響清除及治療指數」作新驗證。原作者整理和研究題名不足以代替所需原文，亦不據讀取失敗判定原主張錯誤。", "language": "ZH", "line": 199, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？", "exact_correction_ids": [ "ZH-L0199" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0193", "status": "unverifiable", "supported_scope": "本輪無可用原文支持；保留原主張為待核，不認定其錯誤。", "gap": "無本輪可核原摘要，不對 Lyon 原研究「降低高負載 ADC 疏水性影響清除及治療指數」作新驗證。原作者整理和研究題名不足以代替所需原文，亦不據讀取失敗判定原主張錯誤。", "language": "EN", "line": 193, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?", "exact_correction_ids": [ "EN-L0193" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0199", "status": "unverifiable", "supported_scope": "本輪無可用原文支持；保留原主張為待核，不認定其錯誤。", "gap": "無本輪可核原摘要，不對 Lyon 原研究「降低高負載 ADC 疏水性影響清除及治療指數」作新驗證。原作者整理和研究題名不足以代替所需原文，亦不據讀取失敗判定原主張錯誤。", "language": "EN", "line": 199, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?", "exact_correction_ids": [ "EN-L0199" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" } ], "verbatim_word_count": 0, "evidence_materials": [ { "path": "evidence/R05.txt", "bytes": 1139, "sha256": "b5b71a251a6e40ea5bc5f25c4abdfae3a5f9fdf345b89b9fcb0937b8ee4cc74a", "kind": "retrieval_failure_log_not_source_evidence" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": null, "claim_location_ids": [ { "claim_location_id": "ZH-L0193", "language": "ZH", "line": 193, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？" }, { "claim_location_id": "ZH-L0199", "language": "ZH", "line": 199, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？" }, { "claim_location_id": "EN-L0193", "language": "EN", "line": 193, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?" }, { "claim_location_id": "EN-L0199", "language": "EN", "line": 199, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?" } ], "applied_corrections": [ "ZH-L0187", "ZH-L0193", "ZH-L0199", "EN-L0187", "EN-L0193", "EN-L0199" ], "current_disposition": "Specified unavailable source-dependent example/detail removed; historical records retained; original evidence gap remains.", "reader_source_note": { "source_id": "R05", "supports_zh": "Lyon 具名研究實例及引用已移出正文有效依據；此來源保留待核，原始研究紀錄不刪改。", "supports_en": "The named Lyon study example and citation have been removed from the text’s active evidence. This reference remains pending verification; the original research records are preserved.", "access_scope_zh": "本輪原 URL 讀取失敗，舊 ref 僅回 HHS 空殼；未取得原始摘要，也未使用替代途徑。", "access_scope_en": "The original URL failed in this round, and the old reference returned only an HHS shell. The original abstract was not retrieved, and no alternative route was used.", "locator_zh": "無可核原文定位；本輪錯誤紀錄見 R05.txt。", "locator_en": "No verifiable original-text locator; the retrieval record is in R05.txt.", "source_date": "2015-06-15", "data_date": "2015年臨床前研究" } }, { "source_id": "R08", "original_url": "https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-completes-equity-investment-in-summit-therapeutics.html", "title": "AstraZeneca 完成對 Summit Therapeutics 的 20 億美元股權投資", "source_date": "2026-10-05", "data_date": "2026-10-05", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "AstraZeneca equity completion announcement; retrieved lines 182–188, especially 184–186.", "evidence_materials": [ { "path": "evidence/R08.txt", "bytes": 2364, "sha256": "824b6c902148177235f4a7ed7a423ab0d06c657c7dc8b032d12d35ba1860f612", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "AstraZeneca equity completion announcement; retrieved lines 182–188, especially 184–186.", "web_ref": "turn131view0" } ], "minimum_excerpt_total_english_words": 11, "numeric_support": [ { "field": "completion_announcement_date", "original_value": "5 October 2026", "unit_or_role": "calendar date", "locator": "L182" }, { "field": "completed_equity_investment", "original_value": 2, "unit_or_role": "USD billion; equity, not ADC license fee", "locator": "L184" }, { "field": "separate_Datroway_collaboration", "original_value": "separate agreement announced on Friday", "unit_or_role": "agreement type; no new calendar date inferred", "locator": "L186" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0166", "status": "supported", "supported_scope": "Directly supports completed USD2bn equity investment on October 5, 2026 and distinguishes clinical collaboration agreements. It does not establish ADC licensing consideration or efficacy.", "gap": null, "language": "ZH", "line": 166, "section": "03　企業如何把平台接成可交付的產品", "subsection": "2026年10月的組合合作，把競爭單位推向完整療程", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0436", "status": "partially_supported", "supported_scope": "Directly supports completed USD2bn equity investment on October 5, 2026 and distinguishes clinical collaboration agreements. It does not establish ADC licensing consideration or efficacy.", "gap": "Supports the USD2bn completed equity portion and existence of a separate Datroway collaboration; retained drug rights remain attributed to R07.", "language": "ZH", "line": 436, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0439", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 439, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0581", "status": "partially_supported", "supported_scope": "Directly supports completed USD2bn equity investment on October 5, 2026 and distinguishes clinical collaboration agreements. It does not establish ADC licensing consideration or efficacy.", "gap": "Supports separate AZ equity investment and reference to clinical collaboration; no clinical benefit established.", "language": "ZH", "line": 581, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0166", "status": "supported", "supported_scope": "Directly supports completed USD2bn equity investment on October 5, 2026 and distinguishes clinical collaboration agreements. It does not establish ADC licensing consideration or efficacy.", "gap": null, "language": "EN", "line": 166, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "The October 2026 Combination Collaboration Extends Competition to the Regimen", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0436", "status": "partially_supported", "supported_scope": "Directly supports completed USD2bn equity investment on October 5, 2026 and distinguishes clinical collaboration agreements. It does not establish ADC licensing consideration or efficacy.", "gap": "Supports the USD2bn completed equity portion and existence of a separate Datroway collaboration; retained drug rights remain attributed to R07.", "language": "EN", "line": 436, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0439", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 439, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0581", "status": "partially_supported", "supported_scope": "Directly supports completed USD2bn equity investment on October 5, 2026 and distinguishes clinical collaboration agreements. It does not establish ADC licensing consideration or efficacy.", "gap": "Supports separate AZ equity investment and reference to clinical collaboration; no clinical benefit established.", "language": "EN", "line": 581, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn63search5", "turn131view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/R08.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0166", "language": "ZH", "line": 166, "section": "03　企業如何把平台接成可交付的產品", "subsection": "2026年10月的組合合作，把競爭單位推向完整療程" }, { "claim_location_id": "ZH-L0436", "language": "ZH", "line": 436, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾" }, { "claim_location_id": "ZH-L0439", "language": "ZH", "line": 439, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾" }, { "claim_location_id": "ZH-L0581", "language": "ZH", "line": 581, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0166", "language": "EN", "line": 166, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "The October 2026 Combination Collaboration Extends Competition to the Regimen" }, { "claim_location_id": "EN-L0436", "language": "EN", "line": 436, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments" }, { "claim_location_id": "EN-L0439", "language": "EN", "line": 439, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments" }, { "claim_location_id": "EN-L0581", "language": "EN", "line": 581, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "R08", "supports_zh": "支持 AstraZeneca 於 2026 年 10 月 5 日宣布完成對 Summit 的 20 億美元股權投資，並將其與臨床合作及另一份 Datroway 協議分開。", "supports_en": "Supports AstraZeneca’s October 5, 2026 announcement that it completed a USD 2 billion equity investment in Summit, distinguished from clinical collaborations and a separate Datroway agreement.", "access_scope_zh": "讀取股權完成公告的相關段落；股權投資不是 ADC 授權金，也不構成療效證據。", "access_scope_en": "Relevant paragraphs of the equity-completion announcement were read; the equity investment is not an ADC license fee and does not establish efficacy.", "locator_zh": "日期及交易第 182–188 行；股權完成第 184 行；分開的合作與協議第 185–186 行。", "locator_en": "Date and transaction at lines 182–188; equity completion at 184; separate collaborations and agreement at 185–186." } }, { "source_id": "R09", "original_url": "https://heidelberg-pharma.com/images/managed/HDP-101-01_AACR2024_final.pdf", "title": "Kaufman et al. — HDP-101: The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma (AACR 2024, CT067)", "source_date": "2024", "data_date": "2024年AACR海報；本稿僅引用機制段落", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "原 URL 一頁 AACR 2024 海報 PDF 文字；僅 Introduction / Background 機制段", "retrieval_mode": "public_url_web_tool", "access_result": "正常取得原 URL PDF 文字", "locators": [ "PDF 第1頁 Introduction L24–27；Background L30–35；年份與 poster CT067 L44–46" ], "numeric_support": [ { "locator": "p1 Background L30–35", "drug": "HDP-101", "target": "BCMA", "payload": "synthetic amanitin", "payload_target": "RNA polymerase II", "action": "抑制轉錄；此處只作機制辨識，不作臨床增益證明" } ], "web_refs": [ "turn116view3", "turn135view1" ], "overall_status": "supported", "precise_gap": "支持 HDP-101 合成 amanitin / RNA polymerase II 機制；2024 海報較舊的臨床數據完全不作 2026 人體進展證據。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "network_time_note": "checked_at 是本輪完成讀取後的核對記錄時間；工具未提供精確 HTTP 取得時間。", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0229", "status": "supported", "supported_scope": "HDP-101 合成 amanitin / RNA polymerase II 機制；不把舊海報臨床數據搬成 2026 狀態。", "gap": "", "language": "ZH", "line": 229, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0229", "status": "supported", "supported_scope": "HDP-101 合成 amanitin / RNA polymerase II 機制；不把舊海報臨床數據搬成 2026 狀態。", "gap": "", "language": "EN", "line": 229, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "verbatim_word_count": 10, "evidence_materials": [ { "path": "evidence/R09.txt", "bytes": 1317, "sha256": "d68ccad82f0f8443c5b4740754e4c889cc1cd2627f16a46e12036fe36e02e486", "kind": "public_minimum_excerpt_and_extracted_values" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/R09.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0229", "language": "ZH", "line": 229, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "EN-L0229", "language": "EN", "line": 229, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "R09", "supports_zh": "只支持 HDP-101 合成 amanitin 抑制 RNA polymerase II 的負載機制；不以 2024 海報的舊臨床結果代表 2026 狀態。", "supports_en": "Supports only the mechanism of HDP-101’s synthetic amanitin payload inhibiting RNA polymerase II. The poster’s older clinical results do not represent its 2026 status.", "access_scope_zh": "本輪讀原 URL 單頁海報的 PDF 文字，僅引用 Introduction／Background 必要機制段。", "access_scope_en": "The one-page poster text at the original URL was read; only the necessary Introduction/Background mechanism passages are used.", "locator_zh": "第1頁 Introduction L24–27、Background L30–35；年份／CT067 L44–46。", "locator_en": "Page 1: Introduction, lines 24–27; Background, 30–35; year/CT067, 44–46.", "source_date": "2024", "data_date": "2024年AACR海報；本稿僅引用機制段落" } }, { "source_id": "C09", "original_url": "https://pubmed.ncbi.nlm.nih.gov/40454632/", "title": "Shitara et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer", "source_date": "2025-05-31", "data_date": "", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "本輪未取得摘要或全文；既有 clinical_records 為作者整理，未作原文證據", "retrieval_mode": "public_url_web_tool_failed", "access_result": "原 URL 429 Too Many Requests；原已用 ref 仍回同一 429。停止，不改 URL、不加 headers。", "locators": [], "numeric_support": [], "web_refs": [ "turn111view0", "turn116view0" ], "overall_status": "unverifiable", "precise_gap": "缺可重新核對的原始摘要，不能本輪確認 Gastric04 的再活檢條件、OS 14.7/11.4 個月及 HR 0.70（95% CI 0.55–0.90）；未因此判定原數值錯誤。", "editorial_disposition": "停止作正文有效依據；原始數值、研究紀錄與歷史來源保留，由證據 sidecar 標示未核；正文精確刪修由主編輯整合。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "network_time_note": "checked_at 是本輪完成讀取後的核對記錄時間；工具未提供精確 HTTP 取得時間。", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0201", "status": "unverifiable", "supported_scope": "本輪無可用原文支持；保留原主張為待核，不認定其錯誤。", "gap": "缺可重新核對的原始摘要，不能本輪確認 Gastric04 的再活檢條件、OS 14.7/11.4 個月及 HR 0.70（95% CI 0.55–0.90）；未因此判定原數值錯誤。", "language": "ZH", "line": 201, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？", "exact_correction_ids": [ "ZH-L0201" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0201", "status": "unverifiable", "supported_scope": "本輪無可用原文支持；保留原主張為待核，不認定其錯誤。", "gap": "缺可重新核對的原始摘要，不能本輪確認 Gastric04 的再活檢條件、OS 14.7/11.4 個月及 HR 0.70（95% CI 0.55–0.90）；未因此判定原數值錯誤。", "language": "EN", "line": 201, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?", "exact_correction_ids": [ "EN-L0201" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" } ], "verbatim_word_count": 0, "evidence_materials": [ { "path": "evidence/C09.txt", "bytes": 1010, "sha256": "2b0e8a39b8af3786f4efd128fa522659d4a4b0166271a39e927a5ffc28f40ebd", "kind": "retrieval_failure_log_not_source_evidence" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": null, "claim_location_ids": [ { "claim_location_id": "ZH-L0201", "language": "ZH", "line": 201, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？" }, { "claim_location_id": "EN-L0201", "language": "EN", "line": 201, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?" } ], "applied_corrections": [ "ZH-L0201", "EN-L0201" ], "current_disposition": "Specified unavailable source-dependent example/detail removed; historical records retained; original evidence gap remains.", "reader_source_note": { "source_id": "C09", "supports_zh": "原 Gastric04 數值及再活檢實例已移出正文；此來源保留為待核歷史線索，不作本版有效證據。", "supports_en": "The Gastric04 numerical and repeat-biopsy example has been removed from the text. This source remains a historical reference awaiting verification, not active evidence for this version.", "access_scope_zh": "本輪原 PubMed URL 回 429，未取得摘要或全文；未改走替代途徑。", "access_scope_en": "The original PubMed URL returned HTTP 429 in this round; neither the abstract nor full text was retrieved. No alternative route was used.", "locator_zh": "無可核原文定位；本輪錯誤紀錄見 C09.txt。", "locator_en": "No verifiable original-text locator; the retrieval record is in C09.txt.", "source_date": "2025-05-31", "data_date": "" } }, { "source_id": "C10", "original_url": "https://pubmed.ncbi.nlm.nih.gov/41125110/", "title": "Yang et al. Izalontamab brengitecan versus chemotherapy in recurrent/metastatic NPC", "source_date": "2025-10-19", "data_date": "", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "PubMed 原始論文公開摘要及書目；未讀期刊全文", "retrieval_mode": "public_url_web_tool", "access_result": "正常取得原 URL 公開摘要", "locators": [ "PubMed PMID 41125110；Abstract / Methods，L296–298；Findings，L299–300（turn135view0）", "書目 Epub 2025 Oct 19，L244" ], "numeric_support": [ { "locator": "Abstract Methods L296–298", "trial": "BL-B01D1-303 / NCT06118333", "phase": 3, "centres": 55, "country": "China", "population": "復發或轉移鼻咽癌；至少二線全身化療，含至少一個含鉑療程，且接受過 PD-1 或 PD-L1 抑制劑", "comparator": "chemotherapy", "analysis": "first planned interim analysis" }, { "locator": "Abstract Findings L299", "endpoint": "masked independent central review ORR", "unit": "percent", "iza_bren": 54.6, "chemotherapy": 27.0, "iza_bren_95ci": [ 45.2, 63.8 ], "chemotherapy_95ci": [ 19.1, 36.0 ], "N_total": 386, "N_iza_bren": 191, "N_chemotherapy": 195 }, { "locator": "Abstract Findings L300", "endpoint": "grade >=3 treatment-related adverse events", "unit": "percent", "iza_bren": 80, "chemotherapy": 62, "OS_maturity": "immature at data cutoff", "trial_data_cutoff": null } ], "web_refs": [ "turn111view1", "turn135view0" ], "overall_status": "supported", "precise_gap": "支持限摘要可見之 NPC 設計、ORR 及 TRAE；不以此來源核 TNBC、ESCC 或完整論文。摘要未明列確切 data cutoff，保持未知。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "network_time_note": "checked_at 是本輪完成讀取後的核對記錄時間；工具未提供精確 HTTP 取得時間。", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0193", "status": "supported", "supported_scope": "F03 引用的 NPC 原始三期摘要線索；不代表此來源證實 F03 其他設計。", "gap": "", "language": "ZH", "line": 193, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0218", "status": "supported", "supported_scope": "Iza-bren 在中國 NPC 的隨機三期原始論文及化療對照。", "gap": "", "language": "ZH", "line": 218, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0225", "status": "supported", "supported_scope": "F04 中 Iza-bren NPC 三期摘要的證據層級。", "gap": "", "language": "ZH", "line": 225, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0227", "status": "supported", "supported_scope": "NPC 中國三期人群、化療對照、ORR 54.6%/27.0%、≥3 級 TRAE 80%/62%；同段 TNBC 資料由其他來源負責。", "gap": "", "language": "ZH", "line": 227, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0193", "status": "supported", "supported_scope": "F03 引用的 NPC 原始三期摘要線索；不代表此來源證實 F03 其他設計。", "gap": "", "language": "EN", "line": 193, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0218", "status": "supported", "supported_scope": "Iza-bren 在中國 NPC 的隨機三期原始論文及化療對照。", "gap": "", "language": "EN", "line": 218, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0225", "status": "supported", "supported_scope": "F04 中 Iza-bren NPC 三期摘要的證據層級。", "gap": "", "language": "EN", "line": 225, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0227", "status": "supported", "supported_scope": "NPC 中國三期人群、化療對照、ORR 54.6%/27.0%、≥3 級 TRAE 80%/62%；同段 TNBC 資料由其他來源負責。", "gap": "", "language": "EN", "line": 227, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "verbatim_word_count": 20, "evidence_materials": [ { "path": "evidence/C10.txt", "bytes": 2084, "sha256": "69859c2d324e531388fead78c619ed83bea723d6f47b9b1cb890b1a0afc6a258", "kind": "public_minimum_excerpt_and_extracted_values" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/C10.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0193", "language": "ZH", "line": 193, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？" }, { "claim_location_id": "ZH-L0218", "language": "ZH", "line": 218, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0225", "language": "ZH", "line": 225, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0227", "language": "ZH", "line": 227, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "EN-L0193", "language": "EN", "line": 193, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?" }, { "claim_location_id": "EN-L0218", "language": "EN", "line": 218, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0225", "language": "EN", "line": 225, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0227", "language": "EN", "line": 227, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "C10", "supports_zh": "支持中國復發／轉移鼻咽癌三期的人群、化療對照、ORR 及 ≥3 級治療相關不良事件；不支持同段 TNBC 數據。", "supports_en": "Supports the population, chemotherapy comparator, ORR and grade ≥3 treatment-related adverse events in the phase 3 NPC trial in China; it does not substantiate the adjacent TNBC results.", "access_scope_zh": "本輪取得 PubMed 公開摘要及書目，未讀期刊全文；摘要未明列確切資料截點。", "access_scope_en": "PubMed abstract and bibliographic information were retrieved; the journal full text was not read. The abstract does not state an exact data cutoff.", "locator_zh": "PMID 41125110，Abstract 的 Methods、Findings；本輪文字 L296–300。", "locator_en": "PMID 41125110, Abstract: Methods and Findings; retrieved-text lines 296–300.", "source_date": "2025-10-19", "data_date": "" } }, { "source_id": "C11", "original_url": "https://news.bms.com/news/details/2026/Izalontamab-Brengitecan-Iza-Bren-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvements-in-Overall-Survival-and-Progression-Free-Survival-in-Patients-with-Triple-Negative-Breast-Cancer-and-Esophageal-Squamous-Cell-Carcinoma/default.aspx", "title": "BMS/SystImmune: iza-bren TNBC與ESCC三期期中OS/PFS結果", "source_date": "2026-06-02", "data_date": "", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "BMS 原始公開公司公告；相關試驗設計、期中結果與合作段落，非期刊全文", "retrieval_mode": "public_url_web_tool", "access_result": "正常取得原 URL 公開正文", "locators": [ "公司公告 2026-06-02：L11、L14–16", "Results from the Interim Analysis of PANKU-Breast02，L25–33", "PANKU-Breast02 / PANKU-Esophagus01 及合作地域，L44；About iza-bren，L46–48" ], "numeric_support": [ { "locator": "PANKU-Breast02 L26–29", "trial": "PANKU-Breast02", "country": "China", "phase": 3, "analysis": "prespecified interim", "population": "不可切除局部晚期或轉移 TNBC；晚期疾病接受過 1–2 線全身治療且曾用 taxane", "comparator": "physician choice chemotherapy", "N_iza_bren": 207, "N_comparator": 211, "median_OS_iza_bren": 15.9, "median_OS_comparator": 12.5, "unit": "months", "OS_HR": 0.6, "OS_HR_95ci": [ 0.42, 0.85 ], "median_follow_up_months": 11 }, { "locator": "L14–16, L44, L47–48", "phase3_regions": "中國的 PANKU-Breast02 與 PANKU-Esophagus01", "China_sponsor": "Sichuan Biokin Pharmaceutical", "outside_China_co_developers": [ "SystImmune", "Bristol Myers Squibb" ], "targets": [ "EGFR", "HER3" ], "payload_class": "Topo1i" } ], "web_refs": [ "turn116view5", "turn133view2", "turn134view1", "turn134view2" ], "overall_status": "partially_supported", "precise_gap": "中國三期期中資料及中國以外 BMS/SystImmune 共同開發有直接支持；公司地圖把合作不分地域概括為「全球合作」過寬，建議精確化。未把公司公告提升成期刊證據。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "network_time_note": "checked_at 是本輪完成讀取後的核對記錄時間；工具未提供精確 HTTP 取得時間。", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0193", "status": "supported", "supported_scope": "F03 引用 Iza-bren EGFR×HER3 / Topo1i 的公司描述；不證明雙靶的獨立臨床增益。", "gap": "", "language": "ZH", "line": 193, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0218", "status": "supported", "supported_scope": "TNBC/ESCC 中國三期公司期中結果；EGFR×HER3 / Topo1i 身分與化療對照。", "gap": "", "language": "ZH", "line": 218, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0225", "status": "supported", "supported_scope": "F04 Iza-bren TNBC/ESCC 公司證據層級。", "gap": "", "language": "ZH", "line": 225, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0227", "status": "supported", "supported_scope": "TNBC 中國 PANKU-Breast02、前 1–2 線晚期治療、化療對照、OS 15.9/12.5 個月、HR 0.60（95% CI 0.42–0.85）；不覆蓋同段 NPC 或登錄排除條件。", "gap": "", "language": "ZH", "line": 227, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0578", "status": "partially_supported", "supported_scope": "中國由 Biokin 主辦、中國以外由 BMS 與 SystImmune 共同開發。", "gap": "原文限定中國以外共同開發；「全球合作與開發」未區分中國由 Biokin 主辦的範圍。", "language": "ZH", "line": 578, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [ "ZH-L0578" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "ZH-L0584", "status": "partially_supported", "supported_scope": "公司地圖的 BMS/SystImmune 合作有證，地域限中國以外；其他企業由各自來源負責。", "gap": "此來源可支持 BMS/SystImmune 中國以外合作，需隨公司地圖那列限定地域；不覆蓋其他公司。", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0193", "status": "supported", "supported_scope": "F03 引用 Iza-bren EGFR×HER3 / Topo1i 的公司描述；不證明雙靶的獨立臨床增益。", "gap": "", "language": "EN", "line": 193, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0218", "status": "supported", "supported_scope": "TNBC/ESCC 中國三期公司期中結果；EGFR×HER3 / Topo1i 身分與化療對照。", "gap": "", "language": "EN", "line": 218, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0225", "status": "supported", "supported_scope": "F04 Iza-bren TNBC/ESCC 公司證據層級。", "gap": "", "language": "EN", "line": 225, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0227", "status": "supported", "supported_scope": "TNBC 中國 PANKU-Breast02、前 1–2 線晚期治療、化療對照、OS 15.9/12.5 個月、HR 0.60（95% CI 0.42–0.85）；不覆蓋同段 NPC 或登錄排除條件。", "gap": "", "language": "EN", "line": 227, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0578", "status": "partially_supported", "supported_scope": "中國由 Biokin 主辦、中國以外由 BMS 與 SystImmune 共同開發。", "gap": "原文限定中國以外共同開發；「全球合作與開發」未區分中國由 Biokin 主辦的範圍。", "language": "EN", "line": 578, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [ "EN-L0578" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0584", "status": "partially_supported", "supported_scope": "公司地圖的 BMS/SystImmune 合作有證，地域限中國以外；其他企業由各自來源負責。", "gap": "此來源可支持 BMS/SystImmune 中國以外合作，需隨公司地圖那列限定地域；不覆蓋其他公司。", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "verbatim_word_count": 20, "evidence_materials": [ { "path": "evidence/C11.txt", "bytes": 2459, "sha256": "34d591dcb1ebd006ecdebc7e20e0be2da59019ba7111b74d4af81c8aea056f7f", "kind": "public_minimum_excerpt_and_extracted_values" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/C11.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0193", "language": "ZH", "line": 193, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？" }, { "claim_location_id": "ZH-L0218", "language": "ZH", "line": 218, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0225", "language": "ZH", "line": 225, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0227", "language": "ZH", "line": 227, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0578", "language": "ZH", "line": 578, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0193", "language": "EN", "line": 193, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?" }, { "claim_location_id": "EN-L0218", "language": "EN", "line": 218, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0225", "language": "EN", "line": 225, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0227", "language": "EN", "line": 227, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0578", "language": "EN", "line": 578, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [ "ZH-L0578", "EN-L0578" ], "current_disposition": "Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.", "reader_source_note": { "source_id": "C11", "supports_zh": "支持中國 PANKU-Breast02 期中 OS 原值及人群，以及 TNBC／ESCC 三期公司結果的證據層級；BMS／SystImmune 共同開發範圍限定中國以外。", "supports_en": "Supports the interim OS figures and population for PANKU-Breast02 in China and the company-reported evidence level for the TNBC/ESCC phase 3 results. BMS/SystImmune joint development applies outside China.", "access_scope_zh": "本輪讀公司公告的相關試驗、機制及合作段落；不是期刊全文或獨立療效確認。", "access_scope_en": "The relevant trial, mechanism and collaboration sections of the company announcement were read; this is not a journal full text or independent confirmation of efficacy.", "locator_zh": "PANKU-Breast02 段 L25–33；中國／中國以外分工 L44；About iza-bren L46–48。", "locator_en": "PANKU-Breast02 section, lines 25–33; territorial responsibilities, line 44; About iza-bren, lines 46–48.", "source_date": "2026-06-02", "data_date": "" } }, { "source_id": "C12", "original_url": "https://heidelberg-pharma.com/images/managed/HDP-101-01_IMS_poster.pdf", "title": "Raab et al. HDP-101 IMS 2026 poster PA-216", "source_date": "2026-09-24", "data_date": "2026-09-03", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "原 URL 單頁 IMS 2026 海報的 web 工具 PDF 文字；僅必要研究設計、進展及安全性/PK-PD 段，未在本輪核圖像", "retrieval_mode": "original_web_ref_same_url", "access_result": "直接 URL 首次工具報 not accessible；原已用 turn62view0 正常回讀同一 URL 單頁 PDF 文字（不是替代 URL）。", "locators": [ "PDF 第1頁：Design & Methodology L30–35；Study Progress L43–53", "PDF 第1頁：Results / Demographics L57–62；PK/PD L83–86；Conclusions L88–91；Data cutoff L128" ], "numeric_support": [ { "locator": "p1 L57–59, L128", "trial_data_cutoff": "2026-09-03", "phase": 1, "N_dosed": 53, "dose_escalation_cohorts": 10, "dose_range": [ 20, 218 ], "dose_unit": "µg/kg" }, { "locator": "p1 Study Progress L44–53", "RP2D": 175, "unit": "µg/kg", "schedule": "首劑分次並預先給藥；之後 Q3W", "phase2a_expansion": "已開始收案", "premedication_classes": [ "corticosteroids", "antihistamines" ], "risk_targets": [ "thrombocytopenia", "liver enzyme elevations" ] }, { "locator": "p1 L85–86", "evidence_level": "當時 PK/PD 模型支持首劑分次降低對血小板及肝功能的影響；非隨機獨立比較證實" } ], "web_refs": [ "turn116view2", "turn118view0", "turn133view0", "turn133view1" ], "overall_status": "supported", "precise_gap": "支持早期 RRMM 劑量/進展與給藥管理；未證明實體癌的 prior Topo-I ADC 療效，也未將模型或單臂資料作確認性治療窗比較。source_date 2026-09-24 按附件保留；本頁直接可核的是 2026-09-03 cutoff。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "network_time_note": "checked_at 是本輪完成讀取後的核對記錄時間；工具未提供精確 HTTP 取得時間。", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0193", "status": "supported", "supported_scope": "F03 的 amanitin 開發例子屬一期/二期a早期研究海報；不作新型負載人體優越性證明。", "gap": "", "language": "ZH", "line": 193, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0219", "status": "supported", "supported_scope": "HDP-101 BCMA/amanitin、一期 53 人已給藥、RP2D 175 µg/kg、二期a擴增已開始。", "gap": "", "language": "ZH", "line": 219, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0225", "status": "supported", "supported_scope": "F04 HDP-101 早期研究層級。", "gap": "", "language": "ZH", "line": 225, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0229", "status": "supported", "supported_scope": "早期 RRMM 的劑量、血小板與肝指數管理問題；該單一疾病研究沒有實體腫瘤在 Topo-I ADC 後治療的比較設計。RNA polymerase II 機制另由 R09 負責。", "gap": "", "language": "ZH", "line": 229, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0352", "status": "supported", "supported_scope": "首劑分次與預先給藥的早期毒性管理措施。", "gap": "", "language": "ZH", "line": 352, "section": "08　更好的治療窗，要看完整給藥過程", "subsection": "比較表 F06｜把「治療窗較好」拆成四份證據", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0356", "status": "supported", "supported_scope": "F06 HDP-101 給藥管理案例來源，非同列其他產品來源。", "gap": "", "language": "ZH", "line": 356, "section": "08　更好的治療窗，要看完整給藥過程", "subsection": "比較表 F06｜把「治療窗較好」拆成四份證據", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0360", "status": "supported", "supported_scope": "分次首劑及預先給藥旨在管理血小板/肝指數變化，並已選 RP2D 推進擴增；「若可維持暴露則有機會擴大可使用性」是附條件研究推論，非來源已證效果。", "gap": "", "language": "ZH", "line": 360, "section": "08　更好的治療窗，要看完整給藥過程", "subsection": "比較表 F06｜把「治療窗較好」拆成四份證據", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0193", "status": "supported", "supported_scope": "F03 的 amanitin 開發例子屬一期/二期a早期研究海報；不作新型負載人體優越性證明。", "gap": "", "language": "EN", "line": 193, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0219", "status": "supported", "supported_scope": "HDP-101 BCMA/amanitin、一期 53 人已給藥、RP2D 175 µg/kg、二期a擴增已開始。", "gap": "", "language": "EN", "line": 219, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0225", "status": "supported", "supported_scope": "F04 HDP-101 早期研究層級。", "gap": "", "language": "EN", "line": 225, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0229", "status": "supported", "supported_scope": "早期 RRMM 的劑量、血小板與肝指數管理問題；該單一疾病研究沒有實體腫瘤在 Topo-I ADC 後治療的比較設計。RNA polymerase II 機制另由 R09 負責。", "gap": "", "language": "EN", "line": 229, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0352", "status": "supported", "supported_scope": "首劑分次與預先給藥的早期毒性管理措施。", "gap": "", "language": "EN", "line": 352, "section": "08 A Better Therapeutic Window Requires the Full Dosing Picture", "subsection": "Table F06｜Four Types of Evidence Behind a Better Therapeutic Window", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0356", "status": "supported", "supported_scope": "F06 HDP-101 給藥管理案例來源，非同列其他產品來源。", "gap": "", "language": "EN", "line": 356, "section": "08 A Better Therapeutic Window Requires the Full Dosing Picture", "subsection": "Table F06｜Four Types of Evidence Behind a Better Therapeutic Window", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0360", "status": "supported", "supported_scope": "分次首劑及預先給藥旨在管理血小板/肝指數變化，並已選 RP2D 推進擴增；「若可維持暴露則有機會擴大可使用性」是附條件研究推論，非來源已證效果。", "gap": "", "language": "EN", "line": 360, "section": "08 A Better Therapeutic Window Requires the Full Dosing Picture", "subsection": "Table F06｜Four Types of Evidence Behind a Better Therapeutic Window", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "verbatim_word_count": 17, "evidence_materials": [ { "path": "evidence/C12.txt", "bytes": 2198, "sha256": "7751a2a72decd13156abd51bfefd035d1365d8230915155a31f8a51af5eb5077", "kind": "public_minimum_excerpt_and_extracted_values" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/C12.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0193", "language": "ZH", "line": 193, "section": "04　把工程名詞翻成可驗證的改善", "subsection": "比較表 F03｜技術路線應對準哪個失效環節？" }, { "claim_location_id": "ZH-L0219", "language": "ZH", "line": 219, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0225", "language": "ZH", "line": 225, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0229", "language": "ZH", "line": 229, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0352", "language": "ZH", "line": 352, "section": "08　更好的治療窗，要看完整給藥過程", "subsection": "比較表 F06｜把「治療窗較好」拆成四份證據" }, { "claim_location_id": "ZH-L0356", "language": "ZH", "line": 356, "section": "08　更好的治療窗，要看完整給藥過程", "subsection": "比較表 F06｜把「治療窗較好」拆成四份證據" }, { "claim_location_id": "ZH-L0360", "language": "ZH", "line": 360, "section": "08　更好的治療窗，要看完整給藥過程", "subsection": "比較表 F06｜把「治療窗較好」拆成四份證據" }, { "claim_location_id": "EN-L0193", "language": "EN", "line": 193, "section": "04 Translate Engineering Labels into Testable Improvements", "subsection": "Table F03｜Which Point of Failure Does Each Design Address?" }, { "claim_location_id": "EN-L0219", "language": "EN", "line": 219, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0225", "language": "EN", "line": 225, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0229", "language": "EN", "line": 229, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0352", "language": "EN", "line": 352, "section": "08 A Better Therapeutic Window Requires the Full Dosing Picture", "subsection": "Table F06｜Four Types of Evidence Behind a Better Therapeutic Window" }, { "claim_location_id": "EN-L0356", "language": "EN", "line": 356, "section": "08 A Better Therapeutic Window Requires the Full Dosing Picture", "subsection": "Table F06｜Four Types of Evidence Behind a Better Therapeutic Window" }, { "claim_location_id": "EN-L0360", "language": "EN", "line": 360, "section": "08 A Better Therapeutic Window Requires the Full Dosing Picture", "subsection": "Table F06｜Four Types of Evidence Behind a Better Therapeutic Window" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "C12", "supports_zh": "支持 HDP-101 一期 53 人已給藥、RP2D 175 µg/kg、二期a擴增開始，以及首劑分次與預先給藥的管理措施。", "supports_en": "Supports 53 patients dosed in phase 1, the 175 µg/kg RP2D, the start of phase 2a expansion, and split-first-dose/premedication measures for HDP-101.", "access_scope_zh": "本輪由原已用 ref 讀回同一原 URL 的單頁海報 PDF 文字，只核必要段落，未重新核海報圖像。", "access_scope_en": "The previously used reference returned the one-page poster text at the same original URL. Only the necessary sections were checked; the poster image was not rechecked.", "locator_zh": "第1頁 Study Progress L43–53、Results L57–62、PK/PD L83–86；資料截點 L128。", "locator_en": "Page 1: Study Progress, lines 43–53; Results, 57–62; PK/PD, 83–86; data cutoff, 128.", "source_date": "2026-09-24", "data_date": "2026-09-03" } }, { "source_id": "C16", "original_url": "https://www.astrazeneca.com/content/dam/az/PDF/2026/h1q2/H1-and-Q2-2026-results-clinical-trials-appendix.pdf", "title": "AstraZeneca H1 and Q2 2026 Clinical Trials Appendix", "source_date": "2026-07-27", "data_date": "2026-07-27", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "154頁公司公開 PDF，只核 ADC 必要試驗列：印刷第15–16頁（PDF index14–15）及日期；未分析全份", "retrieval_mode": "public_url_web_tool", "access_result": "正常取得原 URL PDF 文字；未保存或聲稱下載全 PDF", "locators": [ "封面 H1 2026 Results Update / 27 July 2026，L0–2", "印刷第15頁，TROPION-Breast03，L850–866", "印刷第16頁：AVANZAR L909–919；TROPION-Lung07 L921–936；Lung08 L938–952；Lung15 L989–1006" ], "numeric_support": [ { "trial": "AVANZAR", "locator": "印刷p16 L909–919", "date_guidance": "H2 2026", "kind": "company anticipated data", "population": "1L 局部晚期/轉移 NSCLC，無可作用基因改變" }, { "trial": "TROPION-Lung15", "locator": "印刷p16 L989–1006", "date_guidance": "H2 2026", "kind": "company anticipated data", "population": "2L EGFRm NSCLC，先前 Tagrisso 後進展" }, { "trial": "TROPION-Lung07", "locator": "印刷p16 L921–936", "date_guidance": "H1 2027", "kind": "company anticipated data", "population": "1L PD-L1 TC <50% NSCLC，無可作用基因改變" }, { "trial": "TROPION-Lung08", "locator": "印刷p16 L938–952", "date_guidance": "H1 2027", "kind": "company anticipated data", "population": "1L PD-L1 TC >=50% 非鱗狀 NSCLC，無可作用基因改變" }, { "trial": "TROPION-Breast03", "locator": "印刷p15 L850–866", "date_guidance": "H2 2027", "kind": "company anticipated data", "population": "術前治療後未達 pCR 的 I–III 期 TNBC" } ], "web_refs": [ "turn116view4", "turn118view2", "turn118view4", "turn133view3", "turn134view0" ], "overall_status": "partially_supported", "precise_gap": "現版直接支持五項 anticipated data 時窗；不能單憑本版證明 Lung07 曾從舊 H2 2026 改期。未查其他年份原始版本，建議僅刪舊版比較子句。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "network_time_note": "checked_at 是本輪完成讀取後的核對記錄時間；工具未提供精確 HTTP 取得時間。", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0513", "status": "supported", "supported_scope": "2026-07-27 公司版 AVANZAR 與 Lung15 anticipated data H2 2026。", "gap": "", "language": "ZH", "line": 513, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0516", "status": "supported", "supported_scope": "同公司版 Lung07 與 Lung08 anticipated data H1 2027。", "gap": "", "language": "ZH", "line": 516, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0517", "status": "supported", "supported_scope": "公司版 TROPION-Breast03 anticipated data H2 2027；精確主要完成日由 C24 負責。", "gap": "", "language": "ZH", "line": 517, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0521", "status": "supported", "supported_scope": "F11 中該五項 AZ 公司指引，非表中其他來源或登錄估計。", "gap": "", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0523", "status": "partially_supported", "supported_scope": "當前已列 Lung07/08 為 H1 2027；不直接支持其舊版時程歷史。", "gap": "缺舊版本原文，不能證明 Lung07 的舊 H2 2026 期待或改期；只可確認本版 H1 2027。", "language": "ZH", "line": 523, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [ "ZH-L0523" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0513", "status": "supported", "supported_scope": "2026-07-27 公司版 AVANZAR 與 Lung15 anticipated data H2 2026。", "gap": "", "language": "EN", "line": 513, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0516", "status": "supported", "supported_scope": "同公司版 Lung07 與 Lung08 anticipated data H1 2027。", "gap": "", "language": "EN", "line": 516, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0517", "status": "supported", "supported_scope": "公司版 TROPION-Breast03 anticipated data H2 2027；精確主要完成日由 C24 負責。", "gap": "", "language": "EN", "line": 517, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0521", "status": "supported", "supported_scope": "F11 中該五項 AZ 公司指引，非表中其他來源或登錄估計。", "gap": "", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0523", "status": "partially_supported", "supported_scope": "當前已列 Lung07/08 為 H1 2027；不直接支持其舊版時程歷史。", "gap": "缺舊版本原文，不能證明 Lung07 的舊 H2 2026 期待或改期；只可確認本版 H1 2027。", "language": "EN", "line": 523, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [ "EN-L0523" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" } ], "verbatim_word_count": 4, "evidence_materials": [ { "path": "evidence/C16.txt", "bytes": 2397, "sha256": "c2c628a303e2e468adb5a44aa9c702fe577595bc255831fc4fe09ed79800a7a2", "kind": "public_minimum_excerpt_and_extracted_values" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/C16.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0513", "language": "ZH", "line": 513, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0516", "language": "ZH", "line": 516, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0517", "language": "ZH", "line": 517, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0521", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0523", "language": "ZH", "line": 523, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "EN-L0513", "language": "EN", "line": 513, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0516", "language": "EN", "line": 516, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0517", "language": "EN", "line": 517, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0521", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0523", "language": "EN", "line": 523, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" } ], "applied_corrections": [ "ZH-L0523", "EN-L0523" ], "current_disposition": "Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.", "reader_source_note": { "source_id": "C16", "supports_zh": "支持 2026-07-27 版所列 AVANZAR／Lung15 為 H2 2026、Lung07／08 為 H1 2027、Breast03 為 H2 2027 的公司指引。本版不能證明 Lung07 舊 H2 2026 預期或改期歷史。", "supports_en": "Supports this 2026-07-27 edition’s anticipated-data windows: H2 2026 for AVANZAR/Lung15, H1 2027 for Lung07/08, and H2 2027 for Breast03. This edition cannot establish the earlier H2 2026 expectation or a historical timing change.", "access_scope_zh": "154頁公開 PDF 僅核必要 ADC 試驗列的文字與日期，未分析全文。", "access_scope_en": "Only the necessary ADC trial rows and dates in the 154-page public PDF were checked; the complete document was not analyzed.", "locator_zh": "印刷第15頁 Breast03；第16頁 AVANZAR、Lung07、Lung08、Lung15 的 Status 欄。", "locator_en": "Printed page 15: Breast03; page 16: the Status column for AVANZAR, Lung07, Lung08 and Lung15.", "source_date": "2026-07-27", "data_date": "2026-07-27" } }, { "source_id": "C17", "original_url": "https://clinicaltrials.gov/study/NCT06382142", "title": "ClinicalTrials.gov: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)", "source_date": "2024-04-24", "data_date": "2026-07-23", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "已存 ClinicalTrials.gov 官方公開 API 字段選錄；原始完整 HTTP JSON 未保存；本輪未網路重取", "retrieval_mode": "stored_excerpt_review", "access_result": "已實讀原先保存的登錄日期、設計及必要排除字段；沒有用作者 clinical_records 結論替代", "locators": [ "research/clinical.json#/registry_records[source_id=C17]", "原 API eligibilityCriteria 排除條件；本地 prior_adc_or_specific_exclusions[0]", "本地 status.lastUpdatePostDateStruct" ], "numeric_support": [ { "locator": "research/clinical.json#/registry_records[source_id=C17]/status.lastUpdatePostDateStruct", "date": "2026-07-23" }, { "locator": "research/clinical.json#/registry_records[source_id=C17]/design.enrollmentInfo", "N": 418, "type": "ACTUAL" }, { "locator": "research/clinical.json#/registry_records[source_id=C17]/prior_adc_or_specific_exclusions[0]", "excluded_prior_treatment": "含 TOPI 抑制負載的 ADC" } ], "web_refs": [], "overall_status": "supported", "precise_gap": "限原保存字段和該次登錄版本；不是結果論文、不是本輪刷新登錄。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "stored_original_locator": "research/clinical.json#/registry_records[source_id=C17]", "original_public_api_url": "https://clinicaltrials.gov/api/v2/studies/NCT06382142", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0218", "status": "supported", "supported_scope": "PANKU-Breast02 排除既往 TOPI ADC。", "gap": "", "language": "ZH", "line": 218, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0225", "status": "supported", "supported_scope": "F04 既往 TOPI ADC 的排除條件來源。", "gap": "", "language": "ZH", "line": 225, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0227", "status": "supported", "supported_scope": "同段最後的 TNBC 試驗既往 TOPI ADC 排除條件；不作 NPC 或 TNBC 結果數據來源。", "gap": "", "language": "ZH", "line": 227, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0249", "status": "supported", "supported_scope": "PANKU-Breast02 的 TOPI ADC 排除；無法由此回答 prior ADC 後療效，屬設計邊界。", "gap": "", "language": "ZH", "line": 249, "section": "06　最有價值的缺口：ADC 之後怎麼治？", "subsection": "比較表 F02｜接續治療的三個缺口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0253", "status": "supported", "supported_scope": "F02 中 PANKU-Breast02 排除條件。", "gap": "", "language": "ZH", "line": 253, "section": "06　最有價值的缺口：ADC 之後怎麼治？", "subsection": "比較表 F02｜接續治療的三個缺口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0547", "status": "supported", "supported_scope": "F12 情境以 prior TOPI ADC 尚未被本試驗檢驗為基線；不是未來情境預測已經發生。", "gap": "", "language": "ZH", "line": 547, "section": "15　把差異的價值，落在下一個決策", "subsection": "比較表 F12｜三種情境，如何改變研發與合作優先序？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0218", "status": "supported", "supported_scope": "PANKU-Breast02 排除既往 TOPI ADC。", "gap": "", "language": "EN", "line": 218, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0225", "status": "supported", "supported_scope": "F04 既往 TOPI ADC 的排除條件來源。", "gap": "", "language": "EN", "line": 225, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0227", "status": "supported", "supported_scope": "同段最後的 TNBC 試驗既往 TOPI ADC 排除條件；不作 NPC 或 TNBC 結果數據來源。", "gap": "", "language": "EN", "line": 227, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0249", "status": "supported", "supported_scope": "PANKU-Breast02 的 TOPI ADC 排除；無法由此回答 prior ADC 後療效，屬設計邊界。", "gap": "", "language": "EN", "line": 249, "section": "06 A Valuable Gap: What Comes after an ADC?", "subsection": "Table F02｜Three Evidence Gaps in ADC Sequencing", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0253", "status": "supported", "supported_scope": "F02 中 PANKU-Breast02 排除條件。", "gap": "", "language": "EN", "line": 253, "section": "06 A Valuable Gap: What Comes after an ADC?", "subsection": "Table F02｜Three Evidence Gaps in ADC Sequencing", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0547", "status": "supported", "supported_scope": "F12 情境以 prior TOPI ADC 尚未被本試驗檢驗為基線；不是未來情境預測已經發生。", "gap": "", "language": "EN", "line": 547, "section": "15 Connect the Value of a Difference to the Next Decision", "subsection": "Table F12｜Three Scenarios That Could Change R&D and Partnership Priorities", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "verbatim_word_count": 12, "evidence_materials": [ { "path": "evidence/C17.txt", "bytes": 1861, "sha256": "f9cc6c47dcd54796a327a14db9b9eeed4642891a363f547f3231ae98ad6ebb18", "kind": "public_minimum_excerpt_and_extracted_values" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/C17.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0218", "language": "ZH", "line": 218, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0225", "language": "ZH", "line": 225, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0227", "language": "ZH", "line": 227, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0249", "language": "ZH", "line": 249, "section": "06　最有價值的缺口：ADC 之後怎麼治？", "subsection": "比較表 F02｜接續治療的三個缺口" }, { "claim_location_id": "ZH-L0253", "language": "ZH", "line": 253, "section": "06　最有價值的缺口：ADC 之後怎麼治？", "subsection": "比較表 F02｜接續治療的三個缺口" }, { "claim_location_id": "ZH-L0547", "language": "ZH", "line": 547, "section": "15　把差異的價值，落在下一個決策", "subsection": "比較表 F12｜三種情境，如何改變研發與合作優先序？" }, { "claim_location_id": "EN-L0218", "language": "EN", "line": 218, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0225", "language": "EN", "line": 225, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0227", "language": "EN", "line": 227, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0249", "language": "EN", "line": 249, "section": "06 A Valuable Gap: What Comes after an ADC?", "subsection": "Table F02｜Three Evidence Gaps in ADC Sequencing" }, { "claim_location_id": "EN-L0253", "language": "EN", "line": 253, "section": "06 A Valuable Gap: What Comes after an ADC?", "subsection": "Table F02｜Three Evidence Gaps in ADC Sequencing" }, { "claim_location_id": "EN-L0547", "language": "EN", "line": 547, "section": "15 Connect the Value of a Difference to the Next Decision", "subsection": "Table F12｜Three Scenarios That Could Change R&D and Partnership Priorities" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "C17", "supports_zh": "支持 PANKU-Breast02 排除既往使用 TOPI 抑制負載 ADC 的納排條件；不作臨床結果的來源。", "supports_en": "Supports PANKU-Breast02’s exclusion of prior ADCs with a TOPI-inhibitor payload; it is not a source of trial outcomes.", "access_scope_zh": "本輪讀已存官方 API 字段選錄，未重新連線刷新登錄；完整原始 HTTP JSON 未保存。", "access_scope_en": "Previously saved official API field extracts were reviewed; the registry was not refreshed online. The complete original HTTP JSON was not saved.", "locator_zh": "NCT06382142；已存 eligibility 排除條件第1項、更新日期字段。", "locator_en": "NCT06382142: saved first eligibility exclusion and last-update field.", "source_date": "2024-04-24", "data_date": "2026-07-23" } }, { "source_id": "C21", "original_url": "https://clinicaltrials.gov/study/NCT04622319", "title": "ClinicalTrials.gov: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)", "source_date": "2020-11-09", "data_date": "2026-05-15", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "已存 ClinicalTrials.gov 官方公開 API 字段選錄；原始完整 HTTP JSON 未保存；本輪未網路重取", "retrieval_mode": "stored_excerpt_review", "access_result": "已實讀原先保存的登錄日期、設計及必要排除字段；沒有用作者 clinical_records 結論替代", "locators": [ "research/clinical.json#/registry_records[source_id=C21]", "原 API eligibilityCriteria 排除條件；本地 prior_adc_or_specific_exclusions[1]", "本地 official_title；primary_outcomes[0]；status.lastUpdatePostDateStruct" ], "numeric_support": [ { "locator": "research/clinical.json#/registry_records[source_id=C21]/status.lastUpdatePostDateStruct", "date": "2026-05-15" }, { "locator": "research/clinical.json#/registry_records[source_id=C21]/prior_adc_or_specific_exclusions[1]", "excluded_prior_treatment": [ "T-DXd", "T-DM1", "other anti-HER2 ADC" ] }, { "locator": "research/clinical.json#/registry_records[source_id=C21]/official_title", "comparison": [ "T-DXd", "T-DM1" ], "population": "新輔助治療後高風險 HER2+ 乳癌殘餘侵襲病灶", "endpoint": "iDFS" } ], "web_refs": [], "overall_status": "supported", "precise_gap": "限原保存字段和該次登錄版本；不是結果論文、不是本輪刷新登錄。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "stored_original_locator": "research/clinical.json#/registry_records[source_id=C21]", "original_public_api_url": "https://clinicaltrials.gov/api/v2/studies/NCT04622319", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0250", "status": "supported", "supported_scope": "DB05 排除既往 T-DXd、T-DM1 或其他 HER2 ADC。", "gap": "", "language": "ZH", "line": 250, "section": "06　最有價值的缺口：ADC 之後怎麼治？", "subsection": "比較表 F02｜接續治療的三個缺口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0253", "status": "supported", "supported_scope": "F02 的 DB05 排除條件。", "gap": "", "language": "ZH", "line": 253, "section": "06　最有價值的缺口：ADC 之後怎麼治？", "subsection": "比較表 F02｜接續治療的三個缺口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0255", "status": "supported", "supported_scope": "DB05 比較術後 T-DXd/T-DM1 且有 prior HER2 ADC 排除，限制與 DB11 拼成連續治療結論；pCR、iDFS 百分比由已驗 C02 負責，本次不再核。", "gap": "", "language": "ZH", "line": 255, "section": "06　最有價值的缺口：ADC 之後怎麼治？", "subsection": "比較表 F02｜接續治療的三個缺口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0250", "status": "supported", "supported_scope": "DB05 排除既往 T-DXd、T-DM1 或其他 HER2 ADC。", "gap": "", "language": "EN", "line": 250, "section": "06 A Valuable Gap: What Comes after an ADC?", "subsection": "Table F02｜Three Evidence Gaps in ADC Sequencing", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0253", "status": "supported", "supported_scope": "F02 的 DB05 排除條件。", "gap": "", "language": "EN", "line": 253, "section": "06 A Valuable Gap: What Comes after an ADC?", "subsection": "Table F02｜Three Evidence Gaps in ADC Sequencing", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0255", "status": "supported", "supported_scope": "DB05 比較術後 T-DXd/T-DM1 且有 prior HER2 ADC 排除，限制與 DB11 拼成連續治療結論；pCR、iDFS 百分比由已驗 C02 負責，本次不再核。", "gap": "", "language": "EN", "line": 255, "section": "06 A Valuable Gap: What Comes after an ADC?", "subsection": "Table F02｜Three Evidence Gaps in ADC Sequencing", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "verbatim_word_count": 11, "evidence_materials": [ { "path": "evidence/C21.txt", "bytes": 2077, "sha256": "a1434e7e5724639d9a56a2cb70720239f982f05b9bf4927c9ae480ed30bc0301", "kind": "public_minimum_excerpt_and_extracted_values" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/C21.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0250", "language": "ZH", "line": 250, "section": "06　最有價值的缺口：ADC 之後怎麼治？", "subsection": "比較表 F02｜接續治療的三個缺口" }, { "claim_location_id": "ZH-L0253", "language": "ZH", "line": 253, "section": "06　最有價值的缺口：ADC 之後怎麼治？", "subsection": "比較表 F02｜接續治療的三個缺口" }, { "claim_location_id": "ZH-L0255", "language": "ZH", "line": 255, "section": "06　最有價值的缺口：ADC 之後怎麼治？", "subsection": "比較表 F02｜接續治療的三個缺口" }, { "claim_location_id": "EN-L0250", "language": "EN", "line": 250, "section": "06 A Valuable Gap: What Comes after an ADC?", "subsection": "Table F02｜Three Evidence Gaps in ADC Sequencing" }, { "claim_location_id": "EN-L0253", "language": "EN", "line": 253, "section": "06 A Valuable Gap: What Comes after an ADC?", "subsection": "Table F02｜Three Evidence Gaps in ADC Sequencing" }, { "claim_location_id": "EN-L0255", "language": "EN", "line": 255, "section": "06 A Valuable Gap: What Comes after an ADC?", "subsection": "Table F02｜Three Evidence Gaps in ADC Sequencing" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "C21", "supports_zh": "支持 DB05 排除既往 T-DXd、T-DM1 或其他 HER2 ADC，以及術後比較設計；同段 DB11／DB05 結果百分比另由 C02 支持。", "supports_en": "Supports DB05’s exclusion of prior T-DXd, T-DM1 or other HER2 ADCs and its postoperative comparison. C02 is the source for the adjacent DB11/DB05 outcome percentages.", "access_scope_zh": "本輪讀已存官方 API 字段選錄，未重新連線刷新登錄；不是結果論文。", "access_scope_en": "Previously saved official API field extracts were reviewed without an online registry refresh; this is not a results paper.", "locator_zh": "NCT04622319；已存 prior_adc_or_specific_exclusions[1]、試驗正式題名與主要終點字段。", "locator_en": "NCT04622319: saved prior_adc_or_specific_exclusions[1], official trial title and primary-outcome fields.", "source_date": "2020-11-09", "data_date": "2026-05-15" } }, { "source_id": "C22", "original_url": "https://clinicaltrials.gov/study/NCT04784715", "title": "ClinicalTrials.gov: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)", "source_date": "2021-03-05", "data_date": "2026-07-30", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "已存 ClinicalTrials.gov 官方公開 API 字段選錄；原始完整 HTTP JSON 未保存；本輪未網路重取", "retrieval_mode": "stored_excerpt_review", "access_result": "已實讀原先保存的登錄日期、設計及必要排除字段；沒有用作者 clinical_records 結論替代", "locators": [ "research/clinical.json#/registry_records[source_id=C22]", "本地 status.primaryCompletionDateStruct；status.lastUpdatePostDateStruct；official_title/design/primary_outcomes" ], "numeric_support": [ { "locator": "research/clinical.json#/registry_records[source_id=C22]/status.primaryCompletionDateStruct", "date": "2026-11-11", "type": "ESTIMATED", "meaning": "primary completion，非數據發表或監管決策日" }, { "locator": "research/clinical.json#/registry_records[source_id=C22]/status.lastUpdatePostDateStruct", "date": "2026-07-30" }, { "locator": "research/clinical.json#/registry_records[source_id=C22]/design.designInfo.interventionModelDescription", "arms": [ "T-DXd + pertuzumab-matching placebo", "T-DXd + pertuzumab", "taxane + trastuzumab + pertuzumab" ], "number_of_arms": 3 } ], "web_refs": [], "overall_status": "supported", "precise_gap": "限原保存字段和該次登錄版本；不是結果論文、不是本輪刷新登錄。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "stored_original_locator": "research/clinical.json#/registry_records[source_id=C22]", "original_public_api_url": "https://clinicaltrials.gov/api/v2/studies/NCT04784715", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0514", "status": "supported", "supported_scope": "已存 DB09 版本的主要完成日 2026-11-11/ESTIMATED、更新日 2026-07-30 及三臂設計；讀出內容為待觀察問題，不能由登錄保證發表。", "gap": "", "language": "ZH", "line": 514, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0521", "status": "supported", "supported_scope": "F11 DB09 日期/估計類別。", "gap": "", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0514", "status": "supported", "supported_scope": "已存 DB09 版本的主要完成日 2026-11-11/ESTIMATED、更新日 2026-07-30 及三臂設計；讀出內容為待觀察問題，不能由登錄保證發表。", "gap": "", "language": "EN", "line": 514, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0521", "status": "supported", "supported_scope": "F11 DB09 日期/估計類別。", "gap": "", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "verbatim_word_count": 5, "evidence_materials": [ { "path": "evidence/C22.txt", "bytes": 2079, "sha256": "b81862f525b6cda99e28167d9bec2434b6b1957893e3953d46a7891183bbc90b", "kind": "public_minimum_excerpt_and_extracted_values" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/C22.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0514", "language": "ZH", "line": 514, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0521", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "EN-L0514", "language": "EN", "line": 514, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0521", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "C22", "supports_zh": "支持 DB09 主要完成日 2026-11-11 為登錄估計、2026-07-30 更新日及三臂設計；這不是預定發表日。", "supports_en": "Supports DB09’s estimated primary completion on 2026-11-11, its 2026-07-30 update date and three-arm design; it does not establish a publication date.", "access_scope_zh": "本輪讀已存官方 API 日期／設計字段，未重新連線刷新登錄。", "access_scope_en": "Previously saved official API date and design fields were reviewed; no online registry refresh was performed.", "locator_zh": "NCT04784715；status.primaryCompletionDateStruct、lastUpdatePostDateStruct 及三臂設計字段。", "locator_en": "NCT04784715: status.primaryCompletionDateStruct, lastUpdatePostDateStruct and the three-arm design field.", "source_date": "2021-03-05", "data_date": "2026-07-30" } }, { "source_id": "C23", "original_url": "https://clinicaltrials.gov/study/NCT06203210", "title": "ClinicalTrials.gov: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer", "source_date": "2024-01-12", "data_date": "2026-08-06", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "已存 ClinicalTrials.gov 官方公開 API 字段選錄；原始完整 HTTP JSON 未保存；本輪未網路重取", "retrieval_mode": "stored_excerpt_review", "access_result": "已實讀原先保存的登錄日期、設計及必要排除字段；沒有用作者 clinical_records 結論替代", "locators": [ "research/clinical.json#/registry_records[source_id=C23]", "本地 status.primaryCompletionDateStruct；status.lastUpdatePostDateStruct；official_title/design/primary_outcomes" ], "numeric_support": [ { "locator": "research/clinical.json#/registry_records[source_id=C23]/status.primaryCompletionDateStruct", "date": "2028-01-30", "type": "ESTIMATED", "meaning": "primary completion，非數據發表或監管決策日" }, { "locator": "research/clinical.json#/registry_records[source_id=C23]/status.lastUpdatePostDateStruct", "date": "2026-08-06" } ], "web_refs": [], "overall_status": "supported", "precise_gap": "限原保存字段和該次登錄版本；不是結果論文、不是本輪刷新登錄。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "stored_original_locator": "research/clinical.json#/registry_records[source_id=C23]", "original_public_api_url": "https://clinicaltrials.gov/api/v2/studies/NCT06203210", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0523", "status": "supported", "supported_scope": "IDeate-Lung02 主要完成日 2028-01-30/ESTIMATED，晚於十二個月窗口；其他撤件/PDUFA 由 C13 負責，本次不再核。", "gap": "", "language": "ZH", "line": 523, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0523", "status": "supported", "supported_scope": "IDeate-Lung02 主要完成日 2028-01-30/ESTIMATED，晚於十二個月窗口；其他撤件/PDUFA 由 C13 負責，本次不再核。", "gap": "", "language": "EN", "line": 523, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "verbatim_word_count": 5, "evidence_materials": [ { "path": "evidence/C23.txt", "bytes": 1789, "sha256": "4e4c76f10710da83775a6123ed0b4799ea880e17b7b523e4e0f519fd1642ee2b", "kind": "public_minimum_excerpt_and_extracted_values" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/C23.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0523", "language": "ZH", "line": 523, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "EN-L0523", "language": "EN", "line": 523, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "C23", "supports_zh": "支持 IDeate-Lung02 主要完成日估 2028-01-30，位於本報十二個月窗口以外；撤件及 PDUFA 由 C13 負責。", "supports_en": "Supports IDeate-Lung02’s estimated primary completion on 2028-01-30, outside the report’s twelve-month window. C13 is responsible for the withdrawal and PDUFA statements.", "access_scope_zh": "本輪讀已存官方 API 日期字段，未重新連線刷新登錄。", "access_scope_en": "Previously saved official API date fields were reviewed; no online registry refresh was performed.", "locator_zh": "NCT06203210；status.primaryCompletionDateStruct 與 lastUpdatePostDateStruct。", "locator_en": "NCT06203210: status.primaryCompletionDateStruct and lastUpdatePostDateStruct.", "source_date": "2024-01-12", "data_date": "2026-08-06" } }, { "source_id": "C24", "original_url": "https://clinicaltrials.gov/study/NCT05629585", "title": "ClinicalTrials.gov: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)", "source_date": "2022-11-29", "data_date": "2026-06-15", "checked_at": "2026-10-07T18:42:25+08:00", "timezone": "Asia/Taipei", "original_artifact_sha256": null, "read_level": "已存 ClinicalTrials.gov 官方公開 API 字段選錄；原始完整 HTTP JSON 未保存；本輪未網路重取", "retrieval_mode": "stored_excerpt_review", "access_result": "已實讀原先保存的登錄日期、設計及必要排除字段；沒有用作者 clinical_records 結論替代", "locators": [ "research/clinical.json#/registry_records[source_id=C24]", "本地 status.primaryCompletionDateStruct；status.lastUpdatePostDateStruct；official_title/design/primary_outcomes" ], "numeric_support": [ { "locator": "research/clinical.json#/registry_records[source_id=C24]/status.primaryCompletionDateStruct", "date": "2027-09-20", "type": "ESTIMATED", "meaning": "primary completion，非數據發表或監管決策日" }, { "locator": "research/clinical.json#/registry_records[source_id=C24]/status.lastUpdatePostDateStruct", "date": "2026-06-15" }, { "locator": "research/clinical.json#/registry_records[source_id=C24]/official_title, primary_outcomes[0]", "population": "I–III 期 TNBC，新輔助治療後有殘餘侵襲病灶", "primary_comparison": "Dato-DXd + durvalumab vs ICT", "endpoint": "iDFS" } ], "web_refs": [], "overall_status": "supported", "precise_gap": "限原保存字段和該次登錄版本；不是結果論文、不是本輪刷新登錄。", "original_network_read_time": null, "original_network_read_date": "2026-10-07", "stored_original_locator": "research/clinical.json#/registry_records[source_id=C24]", "original_public_api_url": "https://clinicaltrials.gov/api/v2/studies/NCT05629585", "assessment_unit": "每項狀態只評該來源在原句被用來支持的子句；其他來源負責部分在 supported_scope 明示，不藉單來源替整句背書。", "claim_assessments": [ { "claim_location_id": "ZH-L0517", "status": "supported", "supported_scope": "TROPION-Breast03 主要完成日 2027-09-20/ESTIMATED 及新輔助治療後 TNBC 殘餘病灶/iDFS 設計；公司 H2 2027 指引由 C16 負責。", "gap": "", "language": "ZH", "line": 517, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0521", "status": "supported", "supported_scope": "F11 Breast03 登錄估計日期。", "gap": "", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0517", "status": "supported", "supported_scope": "TROPION-Breast03 主要完成日 2027-09-20/ESTIMATED 及新輔助治療後 TNBC 殘餘病灶/iDFS 設計；公司 H2 2027 指引由 C16 負責。", "gap": "", "language": "EN", "line": 517, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0521", "status": "supported", "supported_scope": "F11 Breast03 登錄估計日期。", "gap": "", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "verbatim_word_count": 5, "evidence_materials": [ { "path": "evidence/C24.txt", "bytes": 2069, "sha256": "44d2d3fbe838c9763b805b017447a24be526bba24c98105958c462153a4fbdb3", "kind": "public_minimum_excerpt_and_extracted_values" } ], "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/C24.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0517", "language": "ZH", "line": 517, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0521", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "EN-L0517", "language": "EN", "line": 517, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0521", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "C24", "supports_zh": "支持 Breast03 主要完成日估 2027-09-20，及新輔助治療後 TNBC 殘餘病灶／iDFS 設計；公司 H2 2027 指引另見 C16。", "supports_en": "Supports Breast03’s estimated primary completion on 2027-09-20 and its residual-disease TNBC/iDFS design after neoadjuvant treatment. The H2 2027 company guidance comes from C16.", "access_scope_zh": "本輪讀已存官方 API 日期及研究設計字段，未重新連線刷新登錄。", "access_scope_en": "Previously saved official API date and study-design fields were reviewed; no online registry refresh was performed.", "locator_zh": "NCT05629585；status.primaryCompletionDateStruct、official_title 及 primary_outcomes[0]。", "locator_en": "NCT05629585: status.primaryCompletionDateStruct, official_title and primary_outcomes[0].", "source_date": "2022-11-29", "data_date": "2026-06-15" } }, { "source_id": "D04", "original_url": "https://www.merck.com/news/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer/", "title": "Patritumab Deruxtecan BLA Receives Complete Response Letter Due to Third-Party Manufacturer Inspection", "source_date": "2024-06-26", "data_date": "2024-06-26", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "Company announcement opening; retrieved lines 94–110, especially 104–105.", "evidence_materials": [ { "path": "evidence/D04.txt", "bytes": 2393, "sha256": "7f61595de1f670087fe4160e4aa28e3aeae1ed67026841fe4618610720c2d5f2", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "Company announcement opening; retrieved lines 94–110, especially 104–105.", "web_ref": "turn110view0" } ], "minimum_excerpt_total_english_words": 9, "numeric_support": [ { "field": "announcement_date", "original_value": "June 26, 2024", "unit_or_role": "calendar date", "locator": "L94" }, { "field": "CRL_basis", "original_value": "third-party manufacturing inspection", "unit_or_role": "company-reported status", "locator": "L104" }, { "field": "submitted_efficacy_safety_issues", "original_value": "none identified in the CRL, according to the companies", "unit_or_role": "company-reported status", "locator": "L105" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0376", "status": "supported", "supported_scope": "Company reported a June 2024 HER3-DXd CRL arising from third-party manufacturing inspection findings and reported no efficacy/safety-data issues. This is the company’s account, not an FDA CRL.", "gap": null, "language": "ZH", "line": 376, "section": "09　平台成熟之後，監管仍逐項檢驗", "subsection": "HER3-DXd：同一產品，曾遇到不同層次的障礙", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0376", "status": "supported", "supported_scope": "Company reported a June 2024 HER3-DXd CRL arising from third-party manufacturing inspection findings and reported no efficacy/safety-data issues. This is the company’s account, not an FDA CRL.", "gap": null, "language": "EN", "line": 376, "section": "09 A Mature Platform Still Faces Product-Specific Regulatory Tests", "subsection": "HER3-DXd: the same product has faced distinct types of obstacles", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn35view5", "turn110view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D04.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0376", "language": "ZH", "line": 376, "section": "09　平台成熟之後，監管仍逐項檢驗", "subsection": "HER3-DXd：同一產品，曾遇到不同層次的障礙" }, { "claim_location_id": "EN-L0376", "language": "EN", "line": 376, "section": "09 A Mature Platform Still Faces Product-Specific Regulatory Tests", "subsection": "HER3-DXd: the same product has faced distinct types of obstacles" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D04", "supports_zh": "支持公司對 2024 年 patritumab deruxtecan CRL 的說明：涉及第三方製造商查廠，公告稱未指出療效或安全資料問題。", "supports_en": "Supports the companies’ account of the 2024 patritumab deruxtecan CRL: third-party manufacturer inspection findings, with no efficacy or safety data issues identified in that announcement.", "access_scope_zh": "讀取公司公告開頭的相關段落；未取得 FDA 的 CRL 原函。", "access_scope_en": "Relevant opening paragraphs of the company announcement were read; the FDA CRL itself was not obtained.", "locator_zh": "公告開頭，第 94–110 行，重點為第 104–105 行。", "locator_en": "Opening announcement paragraphs, lines 94–110, especially 104–105." } }, { "source_id": "D05", "original_url": "https://www.merck.com/news/patritumab-deruxtecan-biologics-license-application-for-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-voluntarily-withdrawn/", "title": "Patritumab Deruxtecan BLA Voluntarily Withdrawn", "source_date": "2025-05-29", "data_date": "2025-05-29", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "Opening withdrawal paragraphs; retrieved lines 94–105, especially 96–98.", "evidence_materials": [ { "path": "evidence/D05.txt", "bytes": 2359, "sha256": "fca885f7295785f179235933a038cc344cddf08b79b6284157c18b71dd7d787c", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "Opening withdrawal paragraphs; retrieved lines 94–105, especially 96–98.", "web_ref": "turn112view0" } ], "minimum_excerpt_total_english_words": 6, "numeric_support": [ { "field": "announcement_date", "original_value": "May 29, 2025", "unit_or_role": "calendar date", "locator": "L94–95" }, { "field": "OS_status", "original_value": "did not meet statistical significance", "unit_or_role": "categorical trial result; no new numeric estimate extracted", "locator": "L97" }, { "field": "withdrawal_status", "original_value": "voluntarily withdrawn", "unit_or_role": "regulatory application status described by companies", "locator": "L96" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0378", "status": "supported", "supported_scope": "Company announced HER3-DXd BLA withdrawal after non-significant HERTHENA-Lung02 OS and FDA discussions; announcement explicitly separates this from the June 2024 manufacturing CRL.", "gap": null, "language": "ZH", "line": 378, "section": "09　平台成熟之後，監管仍逐項檢驗", "subsection": "HER3-DXd：同一產品，曾遇到不同層次的障礙", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0571", "status": "partially_supported", "supported_scope": "Company announced HER3-DXd BLA withdrawal after non-significant HERTHENA-Lung02 OS and FDA discussions; announcement explicitly separates this from the June 2024 manufacturing CRL.", "gap": "This source supports the HER3-DXd regulatory evidence issue; three-asset scope/payment/amendment details remain attributed to D01/D02, not established by this withdrawal paragraph.", "language": "ZH", "line": 571, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0378", "status": "supported", "supported_scope": "Company announced HER3-DXd BLA withdrawal after non-significant HERTHENA-Lung02 OS and FDA discussions; announcement explicitly separates this from the June 2024 manufacturing CRL.", "gap": null, "language": "EN", "line": 378, "section": "09 A Mature Platform Still Faces Product-Specific Regulatory Tests", "subsection": "HER3-DXd: the same product has faced distinct types of obstacles", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0571", "status": "partially_supported", "supported_scope": "Company announced HER3-DXd BLA withdrawal after non-significant HERTHENA-Lung02 OS and FDA discussions; announcement explicitly separates this from the June 2024 manufacturing CRL.", "gap": "This source supports the HER3-DXd regulatory evidence issue; three-asset scope/payment/amendment details remain attributed to D01/D02, not established by this withdrawal paragraph.", "language": "EN", "line": 571, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn35view6", "turn112view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D05.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0378", "language": "ZH", "line": 378, "section": "09　平台成熟之後，監管仍逐項檢驗", "subsection": "HER3-DXd：同一產品，曾遇到不同層次的障礙" }, { "claim_location_id": "ZH-L0571", "language": "ZH", "line": 571, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0378", "language": "EN", "line": 378, "section": "09 A Mature Platform Still Faces Product-Specific Regulatory Tests", "subsection": "HER3-DXd: the same product has faced distinct types of obstacles" }, { "claim_location_id": "EN-L0571", "language": "EN", "line": 571, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D05", "supports_zh": "支持 2025 年自願撤回 BLA，以及公告所述確認試驗 OS 未達統計顯著的原因；公告明確區別於 2024 年製造查廠事件。", "supports_en": "Supports the 2025 voluntary BLA withdrawal and the stated reason involving non-significant OS in the confirmatory trial; the release explicitly separates it from the 2024 manufacturing inspection issue.", "access_scope_zh": "讀取撤件原因與共同開發段落；此公告不驗證原合作的付款或修約條件。", "access_scope_en": "The withdrawal rationale and joint-development paragraphs were read; this release does not verify the original collaboration’s payments or amendments.", "locator_zh": "公告開頭，第 94–105 行，重點為第 96–98 行。", "locator_en": "Opening paragraphs, lines 94–105, especially 96–98." } }, { "source_id": "D07", "original_url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen", "title": "Pfizer Completes Acquisition of Seagen", "source_date": "2023-12-14", "data_date": "2023-12-14", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "Acquisition completion release; retrieved lines 101–112, especially 107.", "evidence_materials": [ { "path": "evidence/D07.txt", "bytes": 2148, "sha256": "76f9c02cfaceee003c23044ee5a88cfc7d73e8a275e3d653445c42d71afada2e", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "Acquisition completion release; retrieved lines 101–112, especially 107.", "web_ref": "turn112view1" } ], "minimum_excerpt_total_english_words": 11, "numeric_support": [ { "field": "completion_announcement_date", "original_value": "December 14, 2023", "unit_or_role": "calendar date", "locator": "L101" }, { "field": "equity_scope", "original_value": "all outstanding common stock of Seagen", "unit_or_role": "acquired equity scope", "locator": "L107" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0572", "status": "partially_supported", "supported_scope": "Directly establishes completed acquisition of all Seagen outstanding common stock on the release date and the acquired oncology portfolio. An exchange delisting notice was not obtained from this page.", "gap": "The phrase no longer independently listed is not stated as an exchange delisting fact in the retrieved release. Full ownership is directly supported; a narrower ownership statement is proposed.", "language": "ZH", "line": 572, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [ "ZH-L0572" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0572", "status": "partially_supported", "supported_scope": "Directly establishes completed acquisition of all Seagen outstanding common stock on the release date and the acquired oncology portfolio. An exchange delisting notice was not obtained from this page.", "gap": "The phrase no longer independently listed is not stated as an exchange delisting fact in the retrieved release. Full ownership is directly supported; a narrower ownership statement is proposed.", "language": "EN", "line": 572, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [ "EN-L0572" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "partially_supported", "precise_gap": "The phrase no longer independently listed is not stated as an exchange delisting fact in the retrieved release. Full ownership is directly supported; a narrower ownership statement is proposed.", "web_refs": [ "turn26view1", "turn112view1" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D07.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0572", "language": "ZH", "line": 572, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0572", "language": "EN", "line": 572, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [ "ZH-L0572", "EN-L0572" ], "current_disposition": "Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.", "reader_source_note": { "source_id": "D07", "supports_zh": "支持 Pfizer 於 2023 年 12 月完成取得 Seagen 全部普通股，以及納入其 ADC 與其他腫瘤資產。", "supports_en": "Supports Pfizer’s December 2023 completion of the acquisition of all outstanding Seagen common stock and incorporation of its ADC and other oncology assets.", "access_scope_zh": "讀取公司完成收購公告；沒有另外核對交易所的下市文件。", "access_scope_en": "The company’s acquisition-completion release was read; exchange delisting documentation was not separately checked.", "locator_zh": "完成收購段落，第 101–112 行，全部普通股文字在第 107 行。", "locator_en": "Acquisition-completion section, lines 101–112; all outstanding common stock at line 107." } }, { "source_id": "D10", "original_url": "https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen", "title": "AbbVie Completes Acquisition of ImmunoGen", "source_date": "2024-02-12", "data_date": "2024-02-12", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "Company release title/date, bullets and opening paragraphs; retrieved lines 9–27, especially 15–16, 20 and 25.", "evidence_materials": [ { "path": "evidence/D10.txt", "bytes": 2186, "sha256": "d4da7a5aafff7842871f3d859e463a22400b7ab2b16c122f4730443a6a870faa", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "Company release title/date, bullets and opening paragraphs; retrieved lines 9–27, especially 15–16, 20 and 25.", "web_ref": "turn112view3" } ], "minimum_excerpt_total_english_words": 12, "numeric_support": [ { "field": "completion_announcement_date", "original_value": "February 12, 2024", "unit_or_role": "calendar date", "locator": "L9, L20" }, { "field": "acquired_organization", "original_value": "ImmunoGen is now part of AbbVie", "unit_or_role": "ownership status", "locator": "L20" }, { "field": "portfolio_assets", "original_value": "ELAHERE; follow-on pipeline of ADCs", "unit_or_role": "asset scope", "locator": "L15–16, L25" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0574", "status": "supported", "supported_scope": "Completion of the ImmunoGen acquisition and addition of ELAHERE and the ADC pipeline to AbbVie are directly stated.", "gap": null, "language": "ZH", "line": 574, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0574", "status": "supported", "supported_scope": "Completion of the ImmunoGen acquisition and addition of ELAHERE and the ADC pipeline to AbbVie are directly stated.", "gap": null, "language": "EN", "line": 574, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn12view6", "turn112view3" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D10.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0574", "language": "ZH", "line": 574, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0574", "language": "EN", "line": 574, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D10", "supports_zh": "支持 AbbVie 於 2024 年 2 月完成收購 ImmunoGen，並取得 ELAHERE 與其 ADC 研發組合。", "supports_en": "Supports AbbVie’s February 2024 completion of the ImmunoGen acquisition, including ELAHERE and the ADC pipeline.", "access_scope_zh": "讀取公告標題、日期及收購與產品組合段落；未以當時產品描述更新後續監管狀態。", "access_scope_en": "The title, date, acquisition and portfolio paragraphs were read; historical product descriptions were not used to update subsequent regulatory status.", "locator_zh": "日期第 9 行；產品組合與完成收購第 15–27 行，重點為第 15–16、20、25 行。", "locator_en": "Date at line 9; portfolio and completion paragraphs at lines 15–27, especially 15–16, 20 and 25." } }, { "source_id": "D12", "original_url": "https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html", "title": "BioNTech and DualityBio Form Global Strategic Partnership", "source_date": "2023-04-03", "data_date": "2023-04-03", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "License announcement; retrieved lines 36–51, especially 39–40 and 49–51.", "evidence_materials": [ { "path": "evidence/D12.txt", "bytes": 2538, "sha256": "50806558ed8ab8aed70905c1831ebad13754e0f4a9d04f5d264313d511f508c2", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "License announcement; retrieved lines 36–51, especially 39–40 and 49–51.", "web_ref": "turn119view0" } ], "minimum_excerpt_total_english_words": 6, "numeric_support": [ { "field": "announcement_date", "original_value": "April 3, 2023", "unit_or_role": "calendar date", "locator": "L39" }, { "field": "licensed_assets", "original_value": [ "DB-1303", "DB-1311" ], "unit_or_role": "asset identifiers", "locator": "L36, L43–45" }, { "field": "excluded_territories", "original_value": [ "Mainland China", "Hong Kong SAR", "Macau SAR" ], "unit_or_role": "territory", "locator": "L40, L50" }, { "field": "DB1311_US_option", "original_value": "co-development cost and profit/loss sharing; co-promotion option", "unit_or_role": "contractual option, not exercise", "locator": "L50–51" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0154", "status": "partially_supported", "supported_scope": "BioNTech and Duality entered two-asset development/manufacture/commercialization licenses; the original DB-1311 US cost/profit-loss option is specified. This 2023 source does not establish exercise in May 2026.", "gap": "Supports only the Duality/BioNTech relationship and original option structure; Daiichi/AZ/Merck relationships use their already cited sources.", "language": "ZH", "line": 154, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0576", "status": "partially_supported", "supported_scope": "BioNTech and Duality entered two-asset development/manufacture/commercialization licenses; the original DB-1311 US cost/profit-loss option is specified. This 2023 source does not establish exercise in May 2026.", "gap": "Supports original DB-1303/DB-1311 licensing and the US option right, not 2026 exercise or the later BNT aliases; D13/D26 cover those components.", "language": "ZH", "line": 576, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0154", "status": "partially_supported", "supported_scope": "BioNTech and Duality entered two-asset development/manufacture/commercialization licenses; the original DB-1311 US cost/profit-loss option is specified. This 2023 source does not establish exercise in May 2026.", "gap": "Supports only the Duality/BioNTech relationship and original option structure; Daiichi/AZ/Merck relationships use their already cited sources.", "language": "EN", "line": 154, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0576", "status": "partially_supported", "supported_scope": "BioNTech and Duality entered two-asset development/manufacture/commercialization licenses; the original DB-1311 US cost/profit-loss option is specified. This 2023 source does not establish exercise in May 2026.", "gap": "Supports original DB-1303/DB-1311 licensing and the US option right, not 2026 exercise or the later BNT aliases; D13/D26 cover those components.", "language": "EN", "line": 576, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn12view5", "turn119view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D12.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0154", "language": "ZH", "line": 154, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0160", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0576", "language": "ZH", "line": 576, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0154", "language": "EN", "line": 154, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0160", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0576", "language": "EN", "line": 576, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D12", "supports_zh": "支持 2023 年 BioNTech–DualityBio 兩項 ADC 合作的地域權利與分工，以及 DB-1311 美國成本／損益分攤選擇權的設置。", "supports_en": "Supports the territories and responsibilities in the 2023 BioNTech–DualityBio two-ADC collaboration and establishment of the US DB-1311 cost/profit-and-loss-sharing option.", "access_scope_zh": "讀取原始合作公告條款；此 2023 年公告不證明 2026 年已行使選擇權，後者由 D13 支持。", "access_scope_en": "The original collaboration terms were read; this 2023 release does not establish exercise of the option in 2026, which is supported by D13.", "locator_zh": "合作及權利第 36–51 行，重點為第 39–40、49–51 行。", "locator_en": "Collaboration and rights terms, lines 36–51, especially 39–40 and 49–51." } }, { "source_id": "D13", "original_url": "https://en.dualitybiologics.com/news/615.html", "title": "DualityBio Announces 2026 Interim Results and Corporate Updates", "source_date": "2026-08-28", "data_date": "2026-06-30", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "Interim release title/date and partnership section; retrieved lines 30, 36–43, 148–155 and 171–175.", "evidence_materials": [ { "path": "evidence/D13.txt", "bytes": 2594, "sha256": "815b6a526390527bd3f419e99ac9b879052c3e8442d4d3a432c081566864f5d3", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "Interim release title/date and partnership section; retrieved lines 30, 36–43, 148–155 and 171–175.", "web_ref": "turn121view0" } ], "minimum_excerpt_total_english_words": 11, "numeric_support": [ { "field": "release_date", "original_value": "August 28, 2026", "unit_or_role": "calendar date", "locator": "L30" }, { "field": "reporting_period_end", "original_value": "June 30, 2026", "unit_or_role": "calendar date", "locator": "L43" }, { "field": "exercise_notice_month", "original_value": "May 2026", "unit_or_role": "calendar month; no day asserted", "locator": "L154" }, { "field": "option_asset_aliases", "original_value": [ "DB-1311", "BNT324", "elfe-D" ], "unit_or_role": "asset aliases", "locator": "L36–37, L52, L175" }, { "field": "other_partnered_asset_aliases", "original_value": [ "DB-1303", "BNT323" ], "unit_or_role": "asset aliases", "locator": "L36, L69–74" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0154", "status": "partially_supported", "supported_scope": "Company reports written exercise notice in May 2026 for DB-1311/BNT324/elfe-D US cost/profit-loss option. Asset aliases and the BioNTech relationship are explicit; strategic implications remain author inference.", "gap": "Supports Duality/BioNTech role and exercised US option, not the other partnerships in this mixed row.", "language": "ZH", "line": 154, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0168", "status": "supported", "supported_scope": "Company reports written exercise notice in May 2026 for DB-1311/BNT324/elfe-D US cost/profit-loss option. Asset aliases and the BioNTech relationship are explicit; strategic implications remain author inference.", "gap": null, "language": "ZH", "line": 168, "section": "03　企業如何把平台接成可交付的產品", "subsection": "2026年10月的組合合作，把競爭單位推向完整療程", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0576", "status": "supported", "supported_scope": "Company reports written exercise notice in May 2026 for DB-1311/BNT324/elfe-D US cost/profit-loss option. Asset aliases and the BioNTech relationship are explicit; strategic implications remain author inference.", "gap": null, "language": "ZH", "line": 576, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0154", "status": "partially_supported", "supported_scope": "Company reports written exercise notice in May 2026 for DB-1311/BNT324/elfe-D US cost/profit-loss option. Asset aliases and the BioNTech relationship are explicit; strategic implications remain author inference.", "gap": "Supports Duality/BioNTech role and exercised US option, not the other partnerships in this mixed row.", "language": "EN", "line": 154, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0168", "status": "supported", "supported_scope": "Company reports written exercise notice in May 2026 for DB-1311/BNT324/elfe-D US cost/profit-loss option. Asset aliases and the BioNTech relationship are explicit; strategic implications remain author inference.", "gap": null, "language": "EN", "line": 168, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "The October 2026 Combination Collaboration Extends Competition to the Regimen", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0576", "status": "supported", "supported_scope": "Company reports written exercise notice in May 2026 for DB-1311/BNT324/elfe-D US cost/profit-loss option. Asset aliases and the BioNTech relationship are explicit; strategic implications remain author inference.", "gap": null, "language": "EN", "line": 576, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn29view1", "turn121view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D13.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0154", "language": "ZH", "line": 154, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0160", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0168", "language": "ZH", "line": 168, "section": "03　企業如何把平台接成可交付的產品", "subsection": "2026年10月的組合合作，把競爭單位推向完整療程" }, { "claim_location_id": "ZH-L0576", "language": "ZH", "line": 576, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0154", "language": "EN", "line": 154, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0160", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0168", "language": "EN", "line": 168, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "The October 2026 Combination Collaboration Extends Competition to the Regimen" }, { "claim_location_id": "EN-L0576", "language": "EN", "line": 576, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D13", "supports_zh": "支持公司所述 2026 年 5 月已通知行使 DB-1311/BNT324/elfe-D 美國成本與損益分攤選擇權，並支持相關產品別名。", "supports_en": "Supports the company’s statement that it notified BioNTech in May 2026 of exercise of the US DB-1311/BNT324/elfe-D cost-and-profit/loss-sharing option, and supports the relevant asset aliases.", "access_scope_zh": "讀取 2026 年中期公告的合作及相關財務段落；這是公司披露，不能據此證明平台臨床優越性。", "access_scope_en": "The partnership and related financial sections of the 2026 interim release were read; these company disclosures do not establish clinical superiority of the platform.", "locator_zh": "日期與期間第 30、43 行；產品別名第 36–43 行；行權第 148–155 行，重點第 154 行。", "locator_en": "Date and reporting period at lines 30 and 43; aliases at 36–43; option exercise at 148–155, especially 154." } }, { "source_id": "D14", "original_url": "https://investors.gilead.com/news/news-details/2024/Gilead-and-Tubulis-Enter-Into-Exclusive-Option-and-License-Agreement-to-Develop-ADC-Candidate-for-Select-Solid-Tumor-Target/default.aspx", "title": "Gilead and Tubulis Enter Exclusive Option and License Agreement", "source_date": "2024-12-03", "data_date": "2024-12-03", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "Single-asset option release; retrieved lines 29, 31–40; monetary terms in line 39.", "evidence_materials": [ { "path": "evidence/D14.txt", "bytes": 3049, "sha256": "3981cd1b14c407586a6fb7d4e311367d7ccbee36feb684162bb7b8715de3f41b", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "Single-asset option release; retrieved lines 29, 31–40; monetary terms in line 39.", "web_ref": "turn122view0" } ], "minimum_excerpt_total_english_words": 12, "numeric_support": [ { "field": "announcement_date", "original_value": "December 3, 2024", "unit_or_role": "calendar date", "locator": "L29" }, { "field": "upfront", "original_value": 20, "unit_or_role": "USD million; agreed, not proved received", "locator": "L39" }, { "field": "conditional_option_exercise_fee", "original_value": 30, "unit_or_role": "USD million", "locator": "L39" }, { "field": "milestones_upper_bound", "original_value": 415, "unit_or_role": "USD million; development and commercialization, conditional", "locator": "L39" }, { "field": "nominal_fee_plus_milestone_sum", "original_value": 465, "unit_or_role": "USD million; calculated 20 + 30 + 415, excluding sales royalties", "locator": "derived only from L39" }, { "field": "additional_royalties", "original_value": "mid-single to low double-digit tiered royalties", "unit_or_role": "separate future sales-based payments; no exact rate invented", "locator": "L39" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0156", "status": "partially_supported", "supported_scope": "Original agreement supports one solid-tumor-target ADC program, upfront/conditional option/milestone amounts and downstream responsibility after option exercise. A nominal USD 465 million sum excludes separately stated sales royalties; receipt or exercise after announcement is not established.", "gap": "Supports the 2024 antecedent collaboration only; 2026 completed acquisition remains attributed to D16.", "language": "ZH", "line": 156, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0433", "status": "partially_supported", "supported_scope": "Original agreement supports one solid-tumor-target ADC program, upfront/conditional option/milestone amounts and downstream responsibility after option exercise. A nominal USD 465 million sum excludes separately stated sales royalties; receipt or exercise after announcement is not established.", "gap": "The 465 total is the computed maximum of specified fees plus milestones; royalties are additional. Subsequent exercise/receipt is explicitly unknown in the row.", "language": "ZH", "line": 433, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾", "exact_correction_ids": [ "ZH-L0433" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "ZH-L0439", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 439, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0634", "status": "partially_supported", "supported_scope": "Original agreement supports one solid-tumor-target ADC program, upfront/conditional option/milestone amounts and downstream responsibility after option exercise. A nominal USD 465 million sum excludes separately stated sales royalties; receipt or exercise after announcement is not established.", "gap": "Arithmetic 20+30+415=465 is reproducible. Sales royalties are outside this nominal sum.", "language": "ZH", "line": 634, "section": "附錄 C　公式、來源範圍與更新方法", "subsection": "比較表 F15｜可重算數據：公式與單位一起保留", "exact_correction_ids": [ "ZH-L0634" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "ZH-L0638", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 638, "section": "附錄 C　公式、來源範圍與更新方法", "subsection": "比較表 F15｜可重算數據：公式與單位一起保留", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0156", "status": "partially_supported", "supported_scope": "Original agreement supports one solid-tumor-target ADC program, upfront/conditional option/milestone amounts and downstream responsibility after option exercise. A nominal USD 465 million sum excludes separately stated sales royalties; receipt or exercise after announcement is not established.", "gap": "Supports the 2024 antecedent collaboration only; 2026 completed acquisition remains attributed to D16.", "language": "EN", "line": 156, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0433", "status": "partially_supported", "supported_scope": "Original agreement supports one solid-tumor-target ADC program, upfront/conditional option/milestone amounts and downstream responsibility after option exercise. A nominal USD 465 million sum excludes separately stated sales royalties; receipt or exercise after announcement is not established.", "gap": "The 465 total is the computed maximum of specified fees plus milestones; royalties are additional. Subsequent exercise/receipt is explicitly unknown in the row.", "language": "EN", "line": 433, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments", "exact_correction_ids": [ "EN-L0433" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0439", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 439, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0634", "status": "partially_supported", "supported_scope": "Original agreement supports one solid-tumor-target ADC program, upfront/conditional option/milestone amounts and downstream responsibility after option exercise. A nominal USD 465 million sum excludes separately stated sales royalties; receipt or exercise after announcement is not established.", "gap": "Arithmetic 20+30+415=465 is reproducible. Sales royalties are outside this nominal sum.", "language": "EN", "line": 634, "section": "Appendix C Formulas, Source Scope and Update Method", "subsection": "Table F15｜Reproducible Data: Retaining Both Formulas and Units", "exact_correction_ids": [ "EN-L0634" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0638", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 638, "section": "Appendix C Formulas, Source Scope and Update Method", "subsection": "Table F15｜Reproducible Data: Retaining Both Formulas and Units", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "partially_supported", "precise_gap": "No evidence of later option exercise/payment is claimed. The computed 465 figure needs an explicit royalties-excluded scope if described as a maximum.", "web_refs": [ "turn26view2", "turn122view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D14.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0156", "language": "ZH", "line": 156, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0160", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0433", "language": "ZH", "line": 433, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾" }, { "claim_location_id": "ZH-L0439", "language": "ZH", "line": 439, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾" }, { "claim_location_id": "ZH-L0634", "language": "ZH", "line": 634, "section": "附錄 C　公式、來源範圍與更新方法", "subsection": "比較表 F15｜可重算數據：公式與單位一起保留" }, { "claim_location_id": "ZH-L0638", "language": "ZH", "line": 638, "section": "附錄 C　公式、來源範圍與更新方法", "subsection": "比較表 F15｜可重算數據：公式與單位一起保留" }, { "claim_location_id": "EN-L0156", "language": "EN", "line": 156, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0160", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0433", "language": "EN", "line": 433, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments" }, { "claim_location_id": "EN-L0439", "language": "EN", "line": 439, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments" }, { "claim_location_id": "EN-L0634", "language": "EN", "line": 634, "section": "Appendix C Formulas, Source Scope and Update Method", "subsection": "Table F15｜Reproducible Data: Retaining Both Formulas and Units" }, { "claim_location_id": "EN-L0638", "language": "EN", "line": 638, "section": "Appendix C Formulas, Source Scope and Update Method", "subsection": "Table F15｜Reproducible Data: Retaining Both Formulas and Units" } ], "applied_corrections": [ "ZH-L0433", "ZH-L0634", "EN-L0433", "EN-L0634" ], "current_disposition": "Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.", "reader_source_note": { "source_id": "D14", "supports_zh": "支持 Gilead–Tubulis 單一資產選擇權合作：20 百萬美元首付款、30 百萬美元條件行權款及最高 415 百萬美元里程碑，合計最高 465 百萬美元，銷售權利金另計。", "supports_en": "Supports the Gilead–Tubulis single-asset option agreement: USD 20 million upfront, a conditional USD 30 million option fee and up to USD 415 million in milestones, totaling up to USD 465 million, with sales royalties additional.", "access_scope_zh": "讀取原始選擇權及授權條款；465 百萬美元是所列款項的加總，並非實收，也未由此驗證後續行權。", "access_scope_en": "The original option and license terms were read; USD 465 million is the sum of the specified fees and milestones, not receipts, and subsequent exercise was not verified here.", "locator_zh": "單一資產及分工第 31–40 行；金額與權利金第 39 行。", "locator_en": "Single-asset scope and responsibilities at lines 31–40; financial terms and royalties at line 39." } }, { "source_id": "D15", "original_url": "https://www.gilead.com/news/news-details/2026/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline", "title": "Gilead to Acquire Tubulis", "source_date": "2026-04-07", "data_date": "2026-04-07", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "Acquisition agreement announcement; retrieved lines 304–314 and 319. Agreement, planned organizational integration and terms are at 304, 311 and 314.", "evidence_materials": [ { "path": "evidence/D15.txt", "bytes": 2928, "sha256": "9e3be0f2c3e317daa208c5f64ecb1ff8c403b3fa6f60c37d50ec63327ebf4165", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "Acquisition agreement announcement; retrieved lines 304–314 and 319. Agreement, planned organizational integration and terms are at 304, 311 and 314.", "web_ref": "turn120view0" } ], "minimum_excerpt_total_english_words": 11, "numeric_support": [ { "field": "closing_cash_consideration", "original_value": 3.15, "unit_or_role": "USD billion; cash-free/debt-free, customary adjustments, payable at closing", "locator": "L314" }, { "field": "conditional_milestone_cap", "original_value": 1.85, "unit_or_role": "USD billion", "locator": "L314" }, { "field": "expected_closing", "original_value": "second quarter of 2026", "unit_or_role": "company expectation as of original announcement", "locator": "L314" }, { "field": "announcement_call_date_text", "original_value": "Tuesday, April 7", "unit_or_role": "calendar wording returned in body; year from supplied source metadata/URL, not a newly returned date header", "locator": "L319" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0156", "status": "partially_supported", "supported_scope": "Supports signed agreement for all Tubulis equity and promised closing consideration plus conditional milestones; not the subsequent completion or SEC purchase-accounting figures, which remain attributed to D16/D17 in the original row.", "gap": "Supports the acquisition agreement and prior collaboration, not completed closing; completion remains attributed to D16.", "language": "ZH", "line": 156, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0434", "status": "partially_supported", "supported_scope": "Supports signed agreement for all Tubulis equity and promised closing consideration plus conditional milestones; not the subsequent completion or SEC purchase-accounting figures, which remain attributed to D16/D17 in the original row.", "gap": "Supports original cash-free/debt-free closing consideration and conditional milestones; does not establish 2026-05-21 closing or SEC net-of-cash accounting. D16/D17 remain their assigned sources.", "language": "ZH", "line": 434, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0439", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 439, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0156", "status": "partially_supported", "supported_scope": "Supports signed agreement for all Tubulis equity and promised closing consideration plus conditional milestones; not the subsequent completion or SEC purchase-accounting figures, which remain attributed to D16/D17 in the original row.", "gap": "Supports the acquisition agreement and prior collaboration, not completed closing; completion remains attributed to D16.", "language": "EN", "line": 156, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0434", "status": "partially_supported", "supported_scope": "Supports signed agreement for all Tubulis equity and promised closing consideration plus conditional milestones; not the subsequent completion or SEC purchase-accounting figures, which remain attributed to D16/D17 in the original row.", "gap": "Supports original cash-free/debt-free closing consideration and conditional milestones; does not establish 2026-05-21 closing or SEC net-of-cash accounting. D16/D17 remain their assigned sources.", "language": "EN", "line": 434, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0439", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 439, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "partially_supported", "precise_gap": "The returned extraction did not expose a separate publication date header. Source/data date 2026-04-07 is retained verbatim from the supplied attachment, not relabeled as newly confirmed by a header. Completion and net acquired-cash amounts require the already-cited D16/D17 and are not supported by this pre-close announcement alone.", "web_refs": [ "turn17view0", "turn120view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D15.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0156", "language": "ZH", "line": 156, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0160", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0434", "language": "ZH", "line": 434, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾" }, { "claim_location_id": "ZH-L0439", "language": "ZH", "line": 439, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾" }, { "claim_location_id": "EN-L0156", "language": "EN", "line": 156, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0160", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0434", "language": "EN", "line": 434, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments" }, { "claim_location_id": "EN-L0439", "language": "EN", "line": 439, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments" } ], "applied_corrections": [], "current_disposition": "Agreement terms retained. Original publication date retained with explicit unverified-header qualification; closing and accounting stay with D16/D17.", "reader_source_note": { "source_id": "D15", "supports_zh": "支持 Gilead 收購 Tubulis 的協議條件：交割時支付 31.5 億美元首付款（依公告基準及調整），另有最高 18.5 億美元里程碑。", "supports_en": "Supports the agreed terms for Gilead’s acquisition of Tubulis: USD 3.15 billion upfront payable at closing, on the stated basis and subject to adjustments, plus up to USD 1.85 billion in milestones.", "access_scope_zh": "讀取協議、預計整合及條件段落；附件發布日 2026-04-07 沿用，未另讀回日期標頭，亦不挪用 D16 的完成收購或 D17 的會計範圍。", "access_scope_en": "The agreement, planned integration and terms were read; the supplied publication date of 2026-04-07 is retained without a separately retrieved date header, and the closing scope of D16 and accounting scope of D17 are not imported.", "locator_zh": "協議第 304 行；整合第 311 行；條件第 314 行；電話會議日期文字第 319 行。", "locator_en": "Agreement at line 304; integration at 311; terms at 314; conference-call date wording at 319." } }, { "source_id": "D18", "original_url": "https://en.dualitybiologics.com/news/614.html", "title": "DualityBio Enters Global Collaboration and License with Genentech for DUPAC", "source_date": "2026-08-28", "data_date": "2026-08-28", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "DUPAC release; retrieved lines 28–38 and About DUPAC lines 46–48.", "evidence_materials": [ { "path": "evidence/D18.txt", "bytes": 2559, "sha256": "b54158189f634cbc8ad2edaa5502039c851bd188077f1e41776b9d3096049de9", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "DUPAC release; retrieved lines 28–38 and About DUPAC lines 46–48.", "web_ref": "turn126view0" } ], "minimum_excerpt_total_english_words": 8, "numeric_support": [ { "field": "announcement_date", "original_value": "August 28, 2026", "unit_or_role": "calendar date", "locator": "L32" }, { "field": "upfront", "original_value": 45, "unit_or_role": "USD million; agreed, receipt not verified", "locator": "L31, L37" }, { "field": "milestone_threshold", "original_value": 1, "unit_or_role": "USD billion; over, not exact upper ceiling", "locator": "L31, L37" }, { "field": "handoff", "original_value": "after Phase 1a", "unit_or_role": "development stage", "locator": "L36" }, { "field": "public_evidence_stage", "original_value": "preclinical DUP5/DUP9 data", "unit_or_role": "company-reported research stage", "locator": "L48" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0221", "status": "supported", "supported_scope": "Supports Genentech worldwide collaboration licenses, Duality discovery/early clinical role and handoff after Phase 1a; USD45m upfront and over USD1bn conditional aggregate milestones. Resistance claims are design/preclinical claims, not demonstrated clinical benefit.", "gap": null, "language": "ZH", "line": 221, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0225", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 225, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0435", "status": "supported", "supported_scope": "Supports Genentech worldwide collaboration licenses, Duality discovery/early clinical role and handoff after Phase 1a; USD45m upfront and over USD1bn conditional aggregate milestones. Resistance claims are design/preclinical claims, not demonstrated clinical benefit.", "gap": null, "language": "ZH", "line": 435, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0439", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 439, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0443", "status": "supported", "supported_scope": "Supports Genentech worldwide collaboration licenses, Duality discovery/early clinical role and handoff after Phase 1a; USD45m upfront and over USD1bn conditional aggregate milestones. Resistance claims are design/preclinical claims, not demonstrated clinical benefit.", "gap": null, "language": "ZH", "line": 443, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0577", "status": "supported", "supported_scope": "Supports Genentech worldwide collaboration licenses, Duality discovery/early clinical role and handoff after Phase 1a; USD45m upfront and over USD1bn conditional aggregate milestones. Resistance claims are design/preclinical claims, not demonstrated clinical benefit.", "gap": null, "language": "ZH", "line": 577, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0221", "status": "supported", "supported_scope": "Supports Genentech worldwide collaboration licenses, Duality discovery/early clinical role and handoff after Phase 1a; USD45m upfront and over USD1bn conditional aggregate milestones. Resistance claims are design/preclinical claims, not demonstrated clinical benefit.", "gap": null, "language": "EN", "line": 221, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0225", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 225, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0435", "status": "supported", "supported_scope": "Supports Genentech worldwide collaboration licenses, Duality discovery/early clinical role and handoff after Phase 1a; USD45m upfront and over USD1bn conditional aggregate milestones. Resistance claims are design/preclinical claims, not demonstrated clinical benefit.", "gap": null, "language": "EN", "line": 435, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0439", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 439, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0443", "status": "supported", "supported_scope": "Supports Genentech worldwide collaboration licenses, Duality discovery/early clinical role and handoff after Phase 1a; USD45m upfront and over USD1bn conditional aggregate milestones. Resistance claims are design/preclinical claims, not demonstrated clinical benefit.", "gap": null, "language": "EN", "line": 443, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0577", "status": "supported", "supported_scope": "Supports Genentech worldwide collaboration licenses, Duality discovery/early clinical role and handoff after Phase 1a; USD45m upfront and over USD1bn conditional aggregate milestones. Resistance claims are design/preclinical claims, not demonstrated clinical benefit.", "gap": null, "language": "EN", "line": 577, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn29view0", "turn126view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D18.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0221", "language": "ZH", "line": 221, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0225", "language": "ZH", "line": 225, "section": "05　「新一代」之外，證據走到哪裡？", "subsection": "比較表 F04｜新設計的證據成熟度，並不整齊" }, { "claim_location_id": "ZH-L0435", "language": "ZH", "line": 435, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾" }, { "claim_location_id": "ZH-L0439", "language": "ZH", "line": 439, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾" }, { "claim_location_id": "ZH-L0443", "language": "ZH", "line": 443, "section": "11　最高總額，沒有告訴你的買單內容", "subsection": "比較表 F08｜五種交易，五種不同的承諾" }, { "claim_location_id": "ZH-L0577", "language": "ZH", "line": 577, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0221", "language": "EN", "line": 221, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0225", "language": "EN", "line": 225, "section": "05 Beyond “Next Generation”: How Mature Is the Evidence?", "subsection": "Table F04｜Evidence Maturity Varies Across New Designs" }, { "claim_location_id": "EN-L0435", "language": "EN", "line": 435, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments" }, { "claim_location_id": "EN-L0439", "language": "EN", "line": 439, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments" }, { "claim_location_id": "EN-L0443", "language": "EN", "line": 443, "section": "11 What the Headline Deal Value Does Not Tell You", "subsection": "Table F08｜Five Transaction Types, Five Different Commitments" }, { "claim_location_id": "EN-L0577", "language": "EN", "line": 577, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D18", "supports_zh": "支持 DualityBio–Genentech 的 DUPAC 合作及第 1a 期後的開發分工，並支持 4,500 萬美元首付款、超過 10 億美元條件里程碑與另計權利金。", "supports_en": "Supports the DualityBio–Genentech DUPAC collaboration and the development handoff after Phase 1a, with USD 45 million upfront, over USD 1 billion in conditional milestones and additional royalties.", "access_scope_zh": "讀取合作條款及 DUPAC 介紹；公告的前臨床設計主張不代表人體增益，亦未核實收款。", "access_scope_en": "The collaboration terms and DUPAC description were read; preclinical design claims do not establish human benefit, and receipt of the stated payments was not verified.", "locator_zh": "合作與金額第 28–38 行；分工第 36 行；平台介紹第 46–48 行。", "locator_en": "Collaboration and financial terms at lines 28–38; responsibilities at 36; platform description at 46–48." } }, { "source_id": "D21", "original_url": "https://www.lonza.com/news/2026-06-30-07-00", "title": "Lonza Expands HPAPI Capacity in Visp, Supporting Payload-Linker Manufacturing", "source_date": "2026-06-30", "data_date": "2026-06-30", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "Lonza expansion release; retrieved lines 16–26, especially 24–26.", "evidence_materials": [ { "path": "evidence/D21.txt", "bytes": 2315, "sha256": "0d98d4e2811a9ff40340c455d380392aaf45d122147157f36e2640f43272bf08", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "Lonza expansion release; retrieved lines 16–26, especially 24–26.", "web_ref": "turn125view0" } ], "minimum_excerpt_total_english_words": 9, "numeric_support": [ { "field": "release_date", "original_value": "30 Jun 2026", "unit_or_role": "calendar date", "locator": "L16" }, { "field": "expected_operational_year", "original_value": 2028, "unit_or_role": "calendar year; future company expectation", "locator": "L26" }, { "field": "role", "original_value": "payload-linker production/purification, analytical/process development; connected antibody/conjugation/drug-product network", "unit_or_role": "company capability/investment description", "locator": "L24–25" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0407", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 407, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "比較表 F07｜ADC 製造的價值，在四個交接點", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0415", "status": "partially_supported", "supported_scope": "Announced Visp payload-linker production/purification capacity and analytical/process development laboratories with expected 2028 operation. Supply flexibility is a proposed design; not proof of product-specific orders or performance.", "gap": "Supports the Lonza expected-2028 portion only; AZ and WuXi portions have their own citations.", "language": "ZH", "line": 415, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "第一三共的教訓，是供應計畫也要隨證據更新", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0579", "status": "partially_supported", "supported_scope": "Announced Visp payload-linker production/purification capacity and analytical/process development laboratories with expected 2028 operation. Supply flexibility is a proposed design; not proof of product-specific orders or performance.", "gap": "Supports manufacturing/analytical capacity, not Synaffix integration or Oss prototyping; D22 supplies those elements.", "language": "ZH", "line": 579, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0407", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 407, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Table F07｜Four Handoffs Define Value in ADC Manufacturing", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0415", "status": "partially_supported", "supported_scope": "Announced Visp payload-linker production/purification capacity and analytical/process development laboratories with expected 2028 operation. Supply flexibility is a proposed design; not proof of product-specific orders or performance.", "gap": "Supports the Lonza expected-2028 portion only; AZ and WuXi portions have their own citations.", "language": "EN", "line": 415, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Daiichi Sankyo’s lesson: supply plans also need to evolve with the evidence", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0579", "status": "partially_supported", "supported_scope": "Announced Visp payload-linker production/purification capacity and analytical/process development laboratories with expected 2028 operation. Supply flexibility is a proposed design; not proof of product-specific orders or performance.", "gap": "Supports manufacturing/analytical capacity, not Synaffix integration or Oss prototyping; D22 supplies those elements.", "language": "EN", "line": 579, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn35view1", "turn125view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D21.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0407", "language": "ZH", "line": 407, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "比較表 F07｜ADC 製造的價值，在四個交接點" }, { "claim_location_id": "ZH-L0415", "language": "ZH", "line": 415, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "第一三共的教訓，是供應計畫也要隨證據更新" }, { "claim_location_id": "ZH-L0579", "language": "ZH", "line": 579, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0407", "language": "EN", "line": 407, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Table F07｜Four Handoffs Define Value in ADC Manufacturing" }, { "claim_location_id": "EN-L0415", "language": "EN", "line": 415, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Daiichi Sankyo’s lesson: supply plans also need to evolve with the evidence" }, { "claim_location_id": "EN-L0579", "language": "EN", "line": 579, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D21", "supports_zh": "支持 Lonza 在 Visp 增加高效價原料藥及負載－連接子能力的建置計畫，預計 2028 年營運。", "supports_en": "Supports Lonza’s plan to expand HPAPI and payload-linker capabilities in Visp, with operations expected in 2028.", "access_scope_zh": "讀取建置範圍及時程段落；這是公司未來產能計畫，並非已投產或已接訂單的證據。", "access_scope_en": "The expansion scope and schedule were read; this is a company plan for future capacity, not evidence of current operation or customer orders.", "locator_zh": "擴產公告第 16–26 行；設施與整合能力第 24–25 行，預定營運第 26 行。", "locator_en": "Expansion release, lines 16–26; facilities and integrated capabilities at 24–25, expected operations at 26." } }, { "source_id": "D22", "original_url": "https://www.lonza.com/media-advisories/2026-02-19-09-00", "title": "Lonza Strengthens Advanced Synthesis Capabilities", "source_date": "2026-02-19", "data_date": "2026-02-19", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "Lonza Advanced Synthesis advisory; retrieved lines 16–27, especially 19, 22–27.", "evidence_materials": [ { "path": "evidence/D22.txt", "bytes": 2581, "sha256": "46ff02ce813bc5244d554e5b089b5f2d9dc3dd29a00f79c0fb1519fe76df4ef0", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "Lonza Advanced Synthesis advisory; retrieved lines 16–27, especially 19, 22–27.", "web_ref": "turn127view0" } ], "minimum_excerpt_total_english_words": 11, "numeric_support": [ { "field": "release_date", "original_value": "19 Feb 2026", "unit_or_role": "calendar date", "locator": "L16" }, { "field": "Synaffix_acquisition_year", "original_value": 2023, "unit_or_role": "calendar year, as cited in this release", "locator": "L23" }, { "field": "integrated_technologies", "original_value": [ "GlycoConnect", "HydraSpace", "toxSYN" ], "unit_or_role": "named technology components", "locator": "L22" }, { "field": "service_handoffs", "original_value": [ "small-scale prototyping", "pilot toxicology material", "process development", "analytical development" ], "unit_or_role": "company-described services", "locator": "L27" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0157", "status": "partially_supported", "supported_scope": "Directly supports Synaffix-derived technology integration, named conjugation/linker technologies, prototyping, pilot toxicology material and process/analytical development at Oss. General clinical-superiority language is not adopted.", "gap": "Supports Lonza/Synaffix integration only; WuXi Singapore component is supported by D23.", "language": "ZH", "line": 157, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0407", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 407, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "比較表 F07｜ADC 製造的價值，在四個交接點", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0579", "status": "supported", "supported_scope": "Directly supports Synaffix-derived technology integration, named conjugation/linker technologies, prototyping, pilot toxicology material and process/analytical development at Oss. General clinical-superiority language is not adopted.", "gap": null, "language": "ZH", "line": 579, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0157", "status": "partially_supported", "supported_scope": "Directly supports Synaffix-derived technology integration, named conjugation/linker technologies, prototyping, pilot toxicology material and process/analytical development at Oss. General clinical-superiority language is not adopted.", "gap": "Supports Lonza/Synaffix integration only; WuXi Singapore component is supported by D23.", "language": "EN", "line": 157, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0407", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 407, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Table F07｜Four Handoffs Define Value in ADC Manufacturing", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0579", "status": "supported", "supported_scope": "Directly supports Synaffix-derived technology integration, named conjugation/linker technologies, prototyping, pilot toxicology material and process/analytical development at Oss. General clinical-superiority language is not adopted.", "gap": null, "language": "EN", "line": 579, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn35view2", "turn127view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D22.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0157", "language": "ZH", "line": 157, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0160", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0407", "language": "ZH", "line": 407, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "比較表 F07｜ADC 製造的價值，在四個交接點" }, { "claim_location_id": "ZH-L0579", "language": "ZH", "line": 579, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0157", "language": "EN", "line": 157, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0160", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0407", "language": "EN", "line": 407, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Table F07｜Four Handoffs Define Value in ADC Manufacturing" }, { "claim_location_id": "EN-L0579", "language": "EN", "line": 579, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D22", "supports_zh": "支持 Lonza 整合 Synaffix 平台與 Oss 原型、毒理材料及製程／分析開發能力的分工。", "supports_en": "Supports Lonza’s integration of the Synaffix platform and the role of Oss in prototyping, toxicology materials, and process/analytical development.", "access_scope_zh": "讀取 Advanced Synthesis 能力及 Oss 分工段落；能力說明不等於每項候選藥的人體優勢或商業訂單。", "access_scope_en": "The Advanced Synthesis capabilities and Oss responsibilities were read; descriptions of capabilities do not establish human advantages for each candidate or commercial orders.", "locator_zh": "能力公告第 16–27 行；平台第 19、22–24 行；Oss 分工第 27 行。", "locator_en": "Capabilities advisory, lines 16–27; platform at 19 and 22–24; Oss role at 27." } }, { "source_id": "D23", "original_url": "https://wuxixdc.com/wuxi-xdc-celebrates-gmp-release-of-singapore-site-ushering-in-a-new-era-of-global-expansion/", "title": "WuXi XDC Celebrates GMP Release of Singapore Site", "source_date": "2026-09-22", "data_date": "2026-09-21", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "WuXi XDC Singapore release; retrieved lines 111–117 and 161–164.", "evidence_materials": [ { "path": "evidence/D23.txt", "bytes": 2340, "sha256": "f993f13e6171830bbf99228ee3e26a8899a43e23ca1449fcd7ef3531f22c645a", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "WuXi XDC Singapore release; retrieved lines 111–117 and 161–164.", "web_ref": "turn128view0" } ], "minimum_excerpt_total_english_words": 6, "numeric_support": [ { "field": "page_publication_date", "original_value": "Sep. 22, 2026", "unit_or_role": "calendar date", "locator": "L111" }, { "field": "ceremony_date", "original_value": "September 21, 2026", "unit_or_role": "calendar date", "locator": "L116" }, { "field": "BCM3_DP4_GMP_release_month", "original_value": "August 2026", "unit_or_role": "calendar month; company report, no day invented", "locator": "L117" }, { "field": "BCM4_expected_GMP_release", "original_value": "by the end of 2026", "unit_or_role": "company forecast", "locator": "L163" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0157", "status": "partially_supported", "supported_scope": "Company explicitly reports GMP release for BCM3 and DP4 and a further BCM4 plan. This is a company operational milestone, not a verified product authorization or order.", "gap": "Supports the WuXi Singapore services/expansion portion only; Lonza/Synaffix component is supported by D22.", "language": "ZH", "line": 157, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0415", "status": "partially_supported", "supported_scope": "Company explicitly reports GMP release for BCM3 and DP4 and a further BCM4 plan. This is a company operational milestone, not a verified product authorization or order.", "gap": "Supports the 2026 company GMP-release operating milestone only; Lonza/AZ future plans have D21/D24.", "language": "ZH", "line": 415, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "第一三共的教訓，是供應計畫也要隨證據更新", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0580", "status": "supported", "supported_scope": "Company explicitly reports GMP release for BCM3 and DP4 and a further BCM4 plan. This is a company operational milestone, not a verified product authorization or order.", "gap": null, "language": "ZH", "line": 580, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0157", "status": "partially_supported", "supported_scope": "Company explicitly reports GMP release for BCM3 and DP4 and a further BCM4 plan. This is a company operational milestone, not a verified product authorization or order.", "gap": "Supports the WuXi Singapore services/expansion portion only; Lonza/Synaffix component is supported by D22.", "language": "EN", "line": 157, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0160", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0415", "status": "partially_supported", "supported_scope": "Company explicitly reports GMP release for BCM3 and DP4 and a further BCM4 plan. This is a company operational milestone, not a verified product authorization or order.", "gap": "Supports the 2026 company GMP-release operating milestone only; Lonza/AZ future plans have D21/D24.", "language": "EN", "line": 415, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Daiichi Sankyo’s lesson: supply plans also need to evolve with the evidence", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0580", "status": "supported", "supported_scope": "Company explicitly reports GMP release for BCM3 and DP4 and a further BCM4 plan. This is a company operational milestone, not a verified product authorization or order.", "gap": null, "language": "EN", "line": 580, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn36view0", "turn128view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D23.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0157", "language": "ZH", "line": 157, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0160", "language": "ZH", "line": 160, "section": "03　企業如何把平台接成可交付的產品", "subsection": "比較表 F09｜全球合作的四個接口" }, { "claim_location_id": "ZH-L0415", "language": "ZH", "line": 415, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "第一三共的教訓，是供應計畫也要隨證據更新" }, { "claim_location_id": "ZH-L0580", "language": "ZH", "line": 580, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0157", "language": "EN", "line": 157, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0160", "language": "EN", "line": 160, "section": "03 How Companies Turn Platforms into Deliverable Products", "subsection": "Table F09｜Four Interfaces in Global Collaboration" }, { "claim_location_id": "EN-L0415", "language": "EN", "line": 415, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Daiichi Sankyo’s lesson: supply plans also need to evolve with the evidence" }, { "claim_location_id": "EN-L0580", "language": "EN", "line": 580, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D23", "supports_zh": "支持 WuXi XDC 新加坡 BCM3 與 DP4 於 2026 年 8 月完成 GMP 放行，以及 BCM4 預計 2026 年底的時程。", "supports_en": "Supports the August 2026 GMP release of WuXi XDC’s Singapore BCM3 and DP4 facilities and the expected end-2026 timing for BCM4.", "access_scope_zh": "讀取公司設施公告；9 月 22 日為頁面發布日、9 月 21 日為典禮日期，GMP 放行不等同個別產品核准或客戶訂單。", "access_scope_en": "The company’s facility announcement was read; September 22 is the page date and September 21 the ceremony date, while GMP release does not establish individual product approval or customer orders.", "locator_zh": "日期與事件第 111–117 行；設施放行及 BCM4 時程第 161–164 行。", "locator_en": "Dates and events at lines 111–117; facility releases and BCM4 timing at 161–164." } }, { "source_id": "D24", "original_url": "https://www.astrazeneca.com/country-sites/singapore/press-releases/astrazeneca-to-hire-over-800-employees-to-produce-cancer-medicines-at-adc-manufacturing-facility-in-singapore.html", "title": "AstraZeneca breaks ground on Singapore ADC facility", "source_date": "2024-11-07", "data_date": "2024-11-07", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "AstraZeneca Singapore construction release; retrieved lines 182–200, especially 195 and 200.", "evidence_materials": [ { "path": "evidence/D24.txt", "bytes": 2625, "sha256": "96cae73930e89fb8ba06472253562148a3c55d915b142993a98321e15b312aa0", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "AstraZeneca Singapore construction release; retrieved lines 182–200, especially 195 and 200.", "web_ref": "turn132view0" } ], "minimum_excerpt_total_english_words": 8, "numeric_support": [ { "field": "release_date", "original_value": "7 November 2024", "unit_or_role": "calendar date", "locator": "L182" }, { "field": "planned_investment", "original_value": 1.5, "unit_or_role": "USD billion", "locator": "L195" }, { "field": "target_operational_year", "original_value": 2029, "unit_or_role": "calendar year; target, not achieved operation", "locator": "L184, L195" }, { "field": "manufacturing_stages", "original_value": [ "antibody production", "chemotherapy drug and linker synthesis", "conjugation", "vial filling" ], "unit_or_role": "planned facility scope", "locator": "L200" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0415", "status": "partially_supported", "supported_scope": "Construction investment and 2029 target are explicit. The planned site covers antibody production, drug/linker synthesis, conjugation and vial filling; future capacity is not current delivered supply. Old ticker boilerplate is not reused as current listing evidence.", "gap": "Supports AZ’s 2029 Singapore target only; Lonza/WuXi components have D21/D23.", "language": "ZH", "line": 415, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "第一三共的教訓，是供應計畫也要隨證據更新", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0570", "status": "partially_supported", "supported_scope": "Construction investment and 2029 target are explicit. The planned site covers antibody production, drug/linker synthesis, conjugation and vial filling; future capacity is not current delivered supply. Old ticker boilerplate is not reused as current listing evidence.", "gap": "Supports AZ manufacturing investment only, not every DXd product or co-development relationship in the row.", "language": "ZH", "line": 570, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0415", "status": "partially_supported", "supported_scope": "Construction investment and 2029 target are explicit. The planned site covers antibody production, drug/linker synthesis, conjugation and vial filling; future capacity is not current delivered supply. Old ticker boilerplate is not reused as current listing evidence.", "gap": "Supports AZ’s 2029 Singapore target only; Lonza/WuXi components have D21/D23.", "language": "EN", "line": 415, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Daiichi Sankyo’s lesson: supply plans also need to evolve with the evidence", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0570", "status": "partially_supported", "supported_scope": "Construction investment and 2029 target are explicit. The planned site covers antibody production, drug/linker synthesis, conjugation and vial filling; future capacity is not current delivered supply. Old ticker boilerplate is not reused as current listing evidence.", "gap": "Supports AZ manufacturing investment only, not every DXd product or co-development relationship in the row.", "language": "EN", "line": 570, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn35view4", "turn132view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D24.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0415", "language": "ZH", "line": 415, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "第一三共的教訓，是供應計畫也要隨證據更新" }, { "claim_location_id": "ZH-L0570", "language": "ZH", "line": 570, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0415", "language": "EN", "line": 415, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Daiichi Sankyo’s lesson: supply plans also need to evolve with the evidence" }, { "claim_location_id": "EN-L0570", "language": "EN", "line": 570, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D24", "supports_zh": "支持 AstraZeneca 新加坡 15 億美元 ADC 廠的全流程設計與預計 2029 年營運時程。", "supports_en": "Supports the planned end-to-end scope of AstraZeneca’s USD 1.5 billion Singapore ADC facility and expected operations in 2029.", "access_scope_zh": "讀取 2024 年動工公告的投資與流程段落；這是未來建置計畫，未以舊頁面股票代號更新上市身分。", "access_scope_en": "The investment and process sections of the 2024 groundbreaking release were read; this is a future construction plan, and historical ticker boilerplate was not used to update listing status.", "locator_zh": "日期第 182 行；金額與時程第 195 行；抗體、藥物／連接子、偶聯及充填第 200 行。", "locator_en": "Date at line 182; amount and timing at 195; antibody, drug/linker, conjugation and filling scope at 200." } }, { "source_id": "D26", "original_url": "https://www.sec.gov/Archives/edgar/data/1776985/000177698526000054/a991bntx_q22026pressreleas.htm", "title": "BioNTech Q2 2026 financial results, SEC exhibit", "source_date": "2026-08-04", "data_date": "2026-06-30", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "SEC exhibit company earnings release; retrieved lines 24 and ADC section 264–279.", "evidence_materials": [ { "path": "evidence/D26.txt", "bytes": 2619, "sha256": "27b0db7d70af32bb7ce641581a48812a64cbb249963c3cf4bf25b0f38691a3ce", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "SEC exhibit company earnings release; retrieved lines 24 and ADC section 264–279.", "web_ref": "turn130view0" } ], "minimum_excerpt_total_english_words": 10, "numeric_support": [ { "field": "release_date", "original_value": "August 4, 2026", "unit_or_role": "calendar date", "locator": "L24" }, { "field": "reporting_period_end", "original_value": "June 30, 2026", "unit_or_role": "calendar date", "locator": "L24" }, { "field": "DYNASTY_Breast02_primary_analysis_expectation", "original_value": "fourth quarter 2026", "unit_or_role": "event-accrual-based company expectation", "locator": "L276" }, { "field": "BNT323_alias", "original_value": "DB-1303 / trastuzumab pamirtecan", "unit_or_role": "asset alias", "locator": "L265" }, { "field": "BNT324_alias", "original_value": "DB-1311 / elfetabart drozuntecan", "unit_or_role": "asset alias", "locator": "L278" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0515", "status": "supported", "supported_scope": "SEC-hosted company release specifies event-accrual-dependent Q4 2026 DYNASTY-Breast02 primary-analysis expectation and identifies BNT323/DB-1303 and BNT324/DB-1311 collaborations with Duality. This does not establish option exercise or that a readout occurred.", "gap": null, "language": "ZH", "line": 515, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0521", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0576", "status": "partially_supported", "supported_scope": "SEC-hosted company release specifies event-accrual-dependent Q4 2026 DYNASTY-Breast02 primary-analysis expectation and identifies BNT323/DB-1303 and BNT324/DB-1311 collaborations with Duality. This does not establish option exercise or that a readout occurred.", "gap": "Supports BNT323/BNT324 asset aliases and development with Duality, not exercise of the profit/loss option; D13 supports exercise.", "language": "ZH", "line": 576, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0515", "status": "supported", "supported_scope": "SEC-hosted company release specifies event-accrual-dependent Q4 2026 DYNASTY-Breast02 primary-analysis expectation and identifies BNT323/DB-1303 and BNT324/DB-1311 collaborations with Duality. This does not establish option exercise or that a readout occurred.", "gap": null, "language": "EN", "line": 515, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0521", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0576", "status": "partially_supported", "supported_scope": "SEC-hosted company release specifies event-accrual-dependent Q4 2026 DYNASTY-Breast02 primary-analysis expectation and identifies BNT323/DB-1303 and BNT324/DB-1311 collaborations with Duality. This does not establish option exercise or that a readout occurred.", "gap": "Supports BNT323/BNT324 asset aliases and development with Duality, not exercise of the profit/loss option; D13 supports exercise.", "language": "EN", "line": 576, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn52view2", "turn130view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D26.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0515", "language": "ZH", "line": 515, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0521", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0576", "language": "ZH", "line": 576, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0515", "language": "EN", "line": 515, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0521", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0576", "language": "EN", "line": 576, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D26", "supports_zh": "支持 BioNTech 的 BNT323/DB-1303 與 BNT324/DB-1311 別名，以及依事件累積推估 DYNASTY-Breast02 主要分析於 2026 年第 4 季的預期。", "supports_en": "Supports BioNTech’s BNT323/DB-1303 and BNT324/DB-1311 aliases and its event-accrual-based expectation for the DYNASTY-Breast02 primary analysis in Q4 2026.", "access_scope_zh": "讀取 SEC 存檔財報公告中的 ADC 管線段落；預期讀出並非已公布結果，此段也不驗證美國損益分攤行權。", "access_scope_en": "The ADC pipeline section of the SEC-filed earnings release was read; an expected analysis is not a reported result, and this section does not verify exercise of US profit/loss sharing.", "locator_zh": "發布日及期間第 24 行；ADC 段第 264–279 行，別名第 265、278 行，預期分析第 276 行。", "locator_en": "Date and reporting period at line 24; ADC section at 264–279, aliases at 265 and 278, expected analysis at 276." } }, { "source_id": "D27", "original_url": "https://newsroom.astellas.com/2026-09-18-padcev-in-combination-with-keytruda-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-resectable-mibc", "title": "Astellas: PADCEV plus Keytruda CHMP positive opinion for resectable MIBC", "source_date": "2026-09-18", "data_date": "2026-09-18", "checked_at": "2026-10-07T18:42:41+08:00", "timezone": "Asia/Taipei", "retrieval_mode": "public_web_tool_readback_prior_ref", "original_network_read_time": null, "checked_at_meaning": "Review time of current returned public web extraction; not the earlier network access time.", "read_level": "web_extracted_relevant_primary_source_sections", "access_result": "specified original public URL returned the necessary text; no access-control block encountered", "actual_returned_scope": "Astellas announcement; retrieved lines 265–276, 281–282 and 291–292.", "evidence_materials": [ { "path": "evidence/D27.txt", "bytes": 2727, "sha256": "bb4c46aaa33960cb1acb3d6662d20aa9f3495e5935384b4bf8d72dda36c6f134", "kind": "bounded_original_excerpt_and_factual_extraction" } ], "original_artifact_sha256": null, "locators": [ { "section": "Astellas announcement; retrieved lines 265–276, 281–282 and 291–292.", "web_ref": "turn129view0" } ], "minimum_excerpt_total_english_words": 10, "numeric_support": [ { "field": "release_date", "original_value": "September 18, 2026", "unit_or_role": "calendar date", "locator": "L265" }, { "field": "EU_regulatory_status", "original_value": "positive CHMP opinion; final EC decision expected", "unit_or_role": "regulatory stage as reported by company", "locator": "L266, L276" }, { "field": "regimen", "original_value": "neoadjuvant EV + pembrolizumab, continued after radical cystectomy as adjuvant treatment", "unit_or_role": "treatment sequence", "locator": "L266" }, { "field": "US_MIBC_scope", "original_value": "regardless of cisplatin eligibility", "unit_or_role": "company-described label scope, not substitute for C08", "locator": "L281" } ], "claim_assessments": [ { "claim_location_id": "ZH-L0573", "status": "supported", "supported_scope": "Supports positive CHMP opinion for perioperative EV+pembrolizumab in resectable MIBC, distinction from final EC decision, and the Astellas/Pfizer collaboration. US status is also described as regardless of cisplatin eligibility in this company release; C08 remains the original regulatory source and was not re-read here.", "gap": null, "language": "ZH", "line": 573, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0573", "status": "supported", "supported_scope": "Supports positive CHMP opinion for perioperative EV+pembrolizumab in resectable MIBC, distinction from final EC decision, and the Astellas/Pfizer collaboration. US status is also described as regardless of cisplatin eligibility in this company release; C08 remains the original regulatory source and was not re-read here.", "gap": null, "language": "EN", "line": 573, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0584", "status": "supported", "supported_scope": "Citation/date-provenance line: this source has been read back at its specified original URL; this assessment covers its own metadata and support contribution only.", "gap": "Not a blanket validation of every other source or claim in the figure.", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": null, "web_refs": [ "turn47view3", "turn129view0" ], "status_scope": "Overall status concerns this source’s assigned factual contribution; per-location mixed-source limits are separately listed.", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/D27.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0573", "language": "ZH", "line": 573, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "ZH-L0584", "language": "ZH", "line": 584, "section": "附錄 A　全球公司與合作地圖", "subsection": "比較表 F13｜全球公司地圖：依競爭角色選列" }, { "claim_location_id": "EN-L0573", "language": "EN", "line": 573, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" }, { "claim_location_id": "EN-L0584", "language": "EN", "line": 584, "section": "Appendix A Global Company and Collaboration Map", "subsection": "Table F13｜Global Company Map: Selected by Competitive Role" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "D27", "supports_zh": "支持 2026 年 9 月 CHMP 對 PADCEV＋KEYTRUDA 用於可切除 MIBC 的正面意見，並區別順鉑適用人群與既有歐盟適應症。", "supports_en": "Supports the September 2026 positive CHMP opinion for PADCEV plus KEYTRUDA in resectable MIBC, distinguishing the cisplatin-eligible population from the existing EU indication.", "access_scope_zh": "讀取 Astellas 公告的監管、人群及合作段落；CHMP 意見不等同歐盟執委會最終核准，未以此取代原 FDA 來源。", "access_scope_en": "The regulatory, population and collaboration paragraphs of Astellas’s release were read; a CHMP opinion is not a final European Commission approval and does not replace the original FDA source.", "locator_zh": "日期及監管第 265–276 行；人群第 267、275 行；合作關係第 291–292 行。", "locator_en": "Date and regulatory status at lines 265–276; populations at 267 and 275; collaboration relationships at 291–292." } }, { "source_id": "T01", "original_url": "https://www.obipharma.com/what-we-do/pipeline-overview/", "title": "OBI Pharma — Pipeline", "source_date": "", "data_date": "", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T01.txt", "bytes": 1551, "sha256": "5b6e93a4bebcc787d9bed9482f6936236074b4c77c7a1b14d1effafdf779f034", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "OBI-992", "position": "web lines 116–138; mechanism at line 133; study status at line 137" }, { "section": "OBI-902", "position": "web lines 145–169; mechanism at lines 163–164; study status at line 168" } ], "numeric_support": [], "supported_summary": "公司管線頁區分OBI-902的TROP2／GlycOBI醣位點設計與OBI-992的半胱胺酸偶聯，並述人體研究；產品差異仍須人體資料支持。", "claim_assessments": [ { "claim_location_id": "ZH-L0453", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司管線頁區分OBI-902的TROP2／GlycOBI醣位點設計與OBI-992的半胱胺酸偶聯，並述人體研究；產品差異仍須人體資料支持。", "gap": null, "language": "ZH", "line": 453, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "浩鼎與醣聯：都談「醣」，改動的位置不同", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0601", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司管線頁區分OBI-902的TROP2／GlycOBI醣位點設計與OBI-992的半胱胺酸偶聯，並述人體研究；產品差異仍須人體資料支持。", "gap": null, "language": "ZH", "line": 601, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0453", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司管線頁區分OBI-902的TROP2／GlycOBI醣位點設計與OBI-992的半胱胺酸偶聯，並述人體研究；產品差異仍須人體資料支持。", "gap": null, "language": "EN", "line": 453, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "OBI Pharma and GlycoNex: Both Work with Glycans, at Different Points in the ADC", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0601", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司管線頁區分OBI-902的TROP2／GlycOBI醣位點設計與OBI-992的半胱胺酸偶聯，並述人體研究；產品差異仍須人體資料支持。", "gap": null, "language": "EN", "line": 601, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "原頁未標發布或更新日；這是本輪公開頁讀取，不是具日期的歷史快照。公司工程優勢不當成人體優效。", "web_refs": [ "turn113view0" ], "observed_publication_date": null, "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T01.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0453", "language": "ZH", "line": 453, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "浩鼎與醣聯：都談「醣」，改動的位置不同" }, { "claim_location_id": "ZH-L0601", "language": "ZH", "line": 601, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0453", "language": "EN", "line": 453, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "OBI Pharma and GlycoNex: Both Work with Glycans, at Different Points in the ADC" }, { "claim_location_id": "EN-L0601", "language": "EN", "line": 601, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T01", "supports_zh": "公司管線頁區分OBI-902的TROP2／GlycOBI醣位點偶聯與OBI-992的半胱胺酸偶聯，並描述各自的人體研究。", "supports_en": "The company pipeline distinguishes OBI-902’s TROP2/GlycOBI glycan-site design from OBI-992’s cysteine conjugation and describes their human studies.", "access_scope_zh": "已讀公開管線的必要段落；頁面未標更新日期，工程特性與人體比較效益分開解讀。", "access_scope_en": "Relevant public pipeline passages were read. The page is undated; engineering features do not establish comparative benefit in humans.", "locator_zh": "OBI-992與OBI-902段；本輪擷取文字第133、137、163–168行。", "locator_en": "OBI-992 and OBI-902 sections; retrieved-text lines 133, 137 and 163–168.", "source_date": "", "data_date": "" } }, { "source_id": "T02", "original_url": "https://clinicaltrials.gov/study/NCT06480240", "title": "ClinicalTrials.gov — NCT06480240 / OBI-992", "source_date": "2024-06-28", "data_date": "2025-08-08", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_official_registry_API_fields", "retrieval_mode": "live_public_registry_api", "access_result": "HTTP 200, official API JSON read", "evidence_materials": [ { "path": "evidence/T02.txt", "bytes": 2401, "sha256": "d015dae8ba3ee2fca7206f1adc66dc16e2289fbab632a41f565f76f959b4dca1", "kind": "authored_minimum_excerpt_and_numeric_support_record" }, { "path": "evidence/T02.api.json", "bytes": 16026, "sha256": "d2232fdb45048b0be3158963f5c7a2f9193ab8cb834908c2f07054c589bcbf7e", "kind": "original_live_official_registry_API_response_bytes" } ], "original_artifact_sha256": "d2232fdb45048b0be3158963f5c7a2f9193ab8cb834908c2f07054c589bcbf7e", "original_network_read_time": null, "network_time_note": "HTTP200 read in this task. network_request_started_at is the recorded request initiation time; checked_at is subsequent field review. No earlier API capture time is asserted.", "locators": [ { "section": "Official ClinicalTrials.gov API", "position": "$.protocolSection.identificationModule.nctId; $.protocolSection.statusModule.overallStatus; $.protocolSection.designModule.phases; $.protocolSection.designModule.enrollmentInfo" }, { "section": "Dates/results", "position": "$.protocolSection.statusModule.studyFirstPostDateStruct; lastUpdatePostDateStruct; primaryCompletionDateStruct; $.hasResults" } ], "numeric_support": [ { "field": "nct_id", "value": "NCT06480240", "unit": "identifier", "locator": "$.protocolSection.identificationModule.nctId" }, { "field": "phase", "value": [ "PHASE1", "PHASE2" ], "unit": "phase", "locator": "$.protocolSection.designModule.phases" }, { "field": "enrollment", "value": 117, "unit": "persons", "locator": "$.protocolSection.designModule.enrollmentInfo", "basis": "ESTIMATED" }, { "field": "primary_completion", "value": "2027-06", "unit": "date", "locator": "$.protocolSection.statusModule.primaryCompletionDateStruct", "basis": "ESTIMATED" }, { "field": "hasResults", "value": false, "unit": "boolean", "locator": "$.hasResults" }, { "field": "study_first_posted", "value": "2024-06-28", "unit": "date", "locator": "$.protocolSection.statusModule.studyFirstPostDateStruct" }, { "field": "last_update_posted", "value": "2025-08-08", "unit": "date", "locator": "$.protocolSection.statusModule.lastUpdatePostDateStruct" } ], "supported_summary": "OBI-992官方登錄為一期／二期、進行中不再收案；估計完成日不是確定公告日，無已張貼結果。", "claim_assessments": [ { "claim_location_id": "ZH-L0453", "status": "supported", "supported_scope": "僅支持本來源所對應子句：OBI-992官方登錄為一期／二期、進行中不再收案；估計完成日不是確定公告日，無已張貼結果。", "gap": null, "language": "ZH", "line": 453, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "浩鼎與醣聯：都談「醣」，改動的位置不同", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0518", "status": "supported", "supported_scope": "支持該候選藥已披露的研究／監管狀態作條件監看；未來讀出時間未承諾。", "gap": null, "language": "ZH", "line": 518, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0521", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0453", "status": "supported", "supported_scope": "僅支持本來源所對應子句：OBI-992官方登錄為一期／二期、進行中不再收案；估計完成日不是確定公告日，無已張貼結果。", "gap": null, "language": "EN", "line": 453, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "OBI Pharma and GlycoNex: Both Work with Glycans, at Different Points in the ADC", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0518", "status": "supported", "supported_scope": "支持該候選藥已披露的研究／監管狀態作條件監看；未來讀出時間未承諾。", "gap": null, "language": "EN", "line": 518, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0521", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "此登錄不支持偶聯技術比較或人體療效結論；它僅支持OBI-992的登錄狀態與条件監看。", "web_refs": [], "observed_publication_date": "2024-06-28", "api_url": "https://clinicaltrials.gov/api/v2/studies/NCT06480240", "network_request_started_at": "2026-10-07T10:38:42.519045+00:00", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T02.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0453", "language": "ZH", "line": 453, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "浩鼎與醣聯：都談「醣」，改動的位置不同" }, { "claim_location_id": "ZH-L0518", "language": "ZH", "line": 518, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0521", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "EN-L0453", "language": "EN", "line": 453, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "OBI Pharma and GlycoNex: Both Work with Glycans, at Different Points in the ADC" }, { "claim_location_id": "EN-L0518", "language": "EN", "line": 518, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0521", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T02", "supports_zh": "OBI-992官方登錄列一期／二期、進行中不再收案及估計收案117人；沒有已張貼的結果。", "supports_en": "The OBI-992 registry lists Phase 1/2, active but not recruiting, estimated enrollment of 117, and no posted results.", "access_scope_zh": "本輪直接讀取並保存官方公開API原始JSON；完成日期為估計，不是確定讀出日。", "access_scope_en": "The official public API was read directly and its response JSON retained. Completion dates are estimates, not confirmed readout dates.", "locator_zh": "API的protocolSection.statusModule、protocolSection.designModule及hasResults欄位。", "locator_en": "API fields protocolSection.statusModule, protocolSection.designModule and hasResults.", "source_date": "2024-06-28", "data_date": "2025-08-08" } }, { "source_id": "T03", "original_url": "https://clinicaltrials.gov/study/NCT07124117", "title": "ClinicalTrials.gov — NCT07124117 / OBI-902", "source_date": "2025-08-15", "data_date": "2026-01-05", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_official_registry_API_fields", "retrieval_mode": "live_public_registry_api", "access_result": "HTTP 200, official API JSON read", "evidence_materials": [ { "path": "evidence/T03.txt", "bytes": 2580, "sha256": "e79dc1523202e58131b727f00d6ccd5766f358f577e4305014a231d252cecfa0", "kind": "authored_minimum_excerpt_and_numeric_support_record" }, { "path": "evidence/T03.api.json", "bytes": 16023, "sha256": "b2a5d632906a37123b46e5ed37f556afae76edd1e02eb6dbe0c58a3b073a5bb3", "kind": "original_live_official_registry_API_response_bytes" } ], "original_artifact_sha256": "b2a5d632906a37123b46e5ed37f556afae76edd1e02eb6dbe0c58a3b073a5bb3", "original_network_read_time": null, "network_time_note": "HTTP200 read in this task. network_request_started_at is the recorded request initiation time; checked_at is subsequent field review. No earlier API capture time is asserted.", "locators": [ { "section": "Official ClinicalTrials.gov API", "position": "$.protocolSection.identificationModule.nctId; $.protocolSection.statusModule.overallStatus; $.protocolSection.designModule.phases; $.protocolSection.designModule.enrollmentInfo" }, { "section": "Dates/results", "position": "$.protocolSection.statusModule.studyFirstPostDateStruct; lastUpdatePostDateStruct; startDateStruct; primaryCompletionDateStruct; $.hasResults" } ], "numeric_support": [ { "field": "nct_id", "value": "NCT07124117", "unit": "identifier", "locator": "$.protocolSection.identificationModule.nctId" }, { "field": "phase", "value": [ "PHASE1", "PHASE2" ], "unit": "phase", "locator": "$.protocolSection.designModule.phases" }, { "field": "enrollment", "value": 147, "unit": "persons", "locator": "$.protocolSection.designModule.enrollmentInfo", "basis": "ESTIMATED" }, { "field": "study_start", "value": "2025-08-04", "unit": "date", "locator": "$.protocolSection.statusModule.startDateStruct", "basis": "ACTUAL" }, { "field": "primary_completion", "value": "2029-02-08", "unit": "date", "locator": "$.protocolSection.statusModule.primaryCompletionDateStruct", "basis": "ESTIMATED" }, { "field": "hasResults", "value": false, "unit": "boolean", "locator": "$.hasResults" }, { "field": "study_first_posted", "value": "2025-08-15", "unit": "date", "locator": "$.protocolSection.statusModule.studyFirstPostDateStruct" }, { "field": "last_update_posted", "value": "2026-01-05", "unit": "date", "locator": "$.protocolSection.statusModule.lastUpdatePostDateStruct" } ], "supported_summary": "OBI-902官方登錄支持已進入人體研究且收案中；一期／二期，估計收案與完成日期，不是療效結果。", "claim_assessments": [ { "claim_location_id": "ZH-L0453", "status": "supported", "supported_scope": "僅支持本來源所對應子句：OBI-902官方登錄支持已進入人體研究且收案中；一期／二期，估計收案與完成日期，不是療效結果。", "gap": null, "language": "ZH", "line": 453, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "浩鼎與醣聯：都談「醣」，改動的位置不同", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0518", "status": "supported", "supported_scope": "支持該候選藥已披露的研究／監管狀態作條件監看；未來讀出時間未承諾。", "gap": null, "language": "ZH", "line": 518, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0521", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0601", "status": "supported", "supported_scope": "僅支持本來源所對應子句：OBI-902官方登錄支持已進入人體研究且收案中；一期／二期，估計收案與完成日期，不是療效結果。", "gap": null, "language": "ZH", "line": 601, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0453", "status": "supported", "supported_scope": "僅支持本來源所對應子句：OBI-902官方登錄支持已進入人體研究且收案中；一期／二期，估計收案與完成日期，不是療效結果。", "gap": null, "language": "EN", "line": 453, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "OBI Pharma and GlycoNex: Both Work with Glycans, at Different Points in the ADC", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0518", "status": "supported", "supported_scope": "支持該候選藥已披露的研究／監管狀態作條件監看；未來讀出時間未承諾。", "gap": null, "language": "EN", "line": 518, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0521", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0601", "status": "supported", "supported_scope": "僅支持本來源所對應子句：OBI-902官方登錄支持已進入人體研究且收案中；一期／二期，估計收案與完成日期，不是療效結果。", "gap": null, "language": "EN", "line": 601, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "此登錄不單獨支持GlycOBI工程差異；T01支持技術設計。沒有把尚未公布的PK、劑量或活性寫成已證實。", "web_refs": [], "observed_publication_date": "2025-08-15", "api_url": "https://clinicaltrials.gov/api/v2/studies/NCT07124117", "network_request_started_at": "2026-10-07T10:38:42.519821+00:00", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T03.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0453", "language": "ZH", "line": 453, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "浩鼎與醣聯：都談「醣」，改動的位置不同" }, { "claim_location_id": "ZH-L0518", "language": "ZH", "line": 518, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0521", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0601", "language": "ZH", "line": 601, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0453", "language": "EN", "line": 453, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "OBI Pharma and GlycoNex: Both Work with Glycans, at Different Points in the ADC" }, { "claim_location_id": "EN-L0518", "language": "EN", "line": 518, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0521", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0601", "language": "EN", "line": 601, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T03", "supports_zh": "OBI-902官方登錄支持已進入人體研究且收案中，列一期／二期及估計收案147人。", "supports_en": "The OBI-902 registry supports entry into human studies and recruiting status, with Phase 1/2 and estimated enrollment of 147.", "access_scope_zh": "本輪直接讀取並保存官方公開API原始JSON；登錄未張貼結果，不單獨支持工程優勢。", "access_scope_en": "The official public API was read directly and its response JSON retained. No results are posted; the registry alone does not establish engineering advantages.", "locator_zh": "API的protocolSection.statusModule、protocolSection.designModule及hasResults欄位。", "locator_en": "API fields protocolSection.statusModule, protocolSection.designModule and hasResults.", "source_date": "2025-08-15", "data_date": "2026-01-05" } }, { "source_id": "T04", "original_url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/obi-pharma-and-tegmine-therapeutics-sign-exclusive-global-license-agr-1126261", "title": "OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC", "source_date": "2026-01-12", "data_date": "2026-01-12", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T04.txt", "bytes": 2180, "sha256": "0d5a7806d012b194f58aaf334e18c6926423fd8d320414e06b080fba004cff4a", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "Publication date / issuer", "position": "web lines 12, 19, 56" }, { "section": "Agreement terms / licensed candidate", "position": "web lines 20–22; services-to-license transition at line 24" } ], "numeric_support": [ { "field": "public_release_date", "value": "2026-01-12", "unit": "date", "locator": "web lines 12 and 19" }, { "field": "upfront_amount", "value": null, "unit": "not disclosed", "locator": "web line 20" }, { "field": "milestone_amount", "value": null, "unit": "not disclosed", "locator": "web line 20" }, { "field": "cash_received", "value": null, "unit": "not confirmed by release", "locator": "web line 20" } ], "supported_summary": "ACCESS具名OBI公司發稿直接支持TegMine提供抗醣抗體、OBI偶聯／連接子與全球開發商業授權；公布付款種類，未披露金額或確認實收。", "claim_assessments": [ { "claim_location_id": "ZH-L0455", "status": "partially_supported", "supported_scope": "僅支持本來源所對應子句：ACCESS具名OBI公司發稿直接支持TegMine提供抗醣抗體、OBI偶聯／連接子與全球開發商業授權；公布付款種類，未披露金額或確認實收。", "gap": "這份ACCESS發稿沒有寫2025年12月初始公告或兩次公告屬同一交易；舊研究摘要的該說法沒有存下真原文。本輪依指示未探讀OBI受保護旧公告，故日期／同一交易對應尚未驗。", "language": "ZH", "line": 455, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "浩鼎與醣聯：都談「醣」，改動的位置不同", "exact_correction_ids": [ "ZH-L0455" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "ZH-L0601", "status": "supported", "supported_scope": "僅支持本來源所對應子句：ACCESS具名OBI公司發稿直接支持TegMine提供抗醣抗體、OBI偶聯／連接子與全球開發商業授權；公布付款種類，未披露金額或確認實收。", "gap": null, "language": "ZH", "line": 601, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0455", "status": "partially_supported", "supported_scope": "僅支持本來源所對應子句：ACCESS具名OBI公司發稿直接支持TegMine提供抗醣抗體、OBI偶聯／連接子與全球開發商業授權；公布付款種類，未披露金額或確認實收。", "gap": "這份ACCESS發稿沒有寫2025年12月初始公告或兩次公告屬同一交易；舊研究摘要的該說法沒有存下真原文。本輪依指示未探讀OBI受保護旧公告，故日期／同一交易對應尚未驗。", "language": "EN", "line": 455, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "OBI Pharma and GlycoNex: Both Work with Glycans, at Different Points in the ADC", "exact_correction_ids": [ "EN-L0455" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0601", "status": "supported", "supported_scope": "僅支持本來源所對應子句：ACCESS具名OBI公司發稿直接支持TegMine提供抗醣抗體、OBI偶聯／連接子與全球開發商業授權；公布付款種類，未披露金額或確認實收。", "gap": null, "language": "EN", "line": 601, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "partially_supported", "precise_gap": "這份ACCESS發稿沒有寫2025年12月初始公告或兩次公告屬同一交易；舊研究摘要的該說法沒有存下真原文。本輪依指示未探讀OBI受保護旧公告，故日期／同一交易對應尚未驗。", "web_refs": [ "turn113view1" ], "observed_publication_date": "2026-01-12", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T04.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0455", "language": "ZH", "line": 455, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "浩鼎與醣聯：都談「醣」，改動的位置不同" }, { "claim_location_id": "ZH-L0601", "language": "ZH", "line": 601, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0455", "language": "EN", "line": 455, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "OBI Pharma and GlycoNex: Both Work with Glycans, at Different Points in the ADC" }, { "claim_location_id": "EN-L0601", "language": "EN", "line": 601, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [ "ZH-L0455", "EN-L0455" ], "current_disposition": "Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.", "reader_source_note": { "source_id": "T04", "supports_zh": "公司2026-01-12公開發稿支持TegMine提供抗醣抗體、浩鼎提供偶聯／連接子技術與全球授權；詳細財務條款未披露。", "supports_en": "The company’s 2026-01-12 release supports TegMine’s glycan-targeting antibody, OBI’s conjugation/linker technologies and a global license; detailed financial terms are undisclosed.", "access_scope_zh": "已讀公司經ACCESS公開的必要發稿段落；未讀受保護舊公告，這份稿未交代2025年12月公告對應，也未確認實收現金。", "access_scope_en": "Relevant company-issued ACCESS passages were read, without accessing the protected earlier announcement. This release neither establishes the December 2025 linkage nor confirms cash received.", "locator_zh": "發稿日期及授權條款；本輪擷取文字第12、19–24、56行。", "locator_en": "Release date, license terms and issuer; retrieved-text lines 12, 19–24 and 56.", "source_date": "2026-01-12", "data_date": "2026-01-12" } }, { "source_id": "T05", "original_url": "https://glyconex.com.tw/news/2026/2026-08-03-gnx1021-first-patient-dosed", "title": "GlycoNex Doses First Patient in Phase 1 Trial of GNX1021", "source_date": "2026-08-03", "data_date": "2026-08-03", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T05.txt", "bytes": 1824, "sha256": "4baf5ff415b8c074ea8ccb3f3df09f96c89afa2c74c72e838227fea8d34149a2", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "Dateline / first patient", "position": "web lines 14–18" }, { "section": "Target / trial", "position": "web lines 20–23" } ], "numeric_support": [ { "field": "announcement_date", "value": "2026-08-03", "unit": "date", "locator": "web lines 14 and 18" }, { "field": "trial_phase", "value": 1, "unit": "phase", "locator": "web lines 18 and 22" }, { "field": "first_patient_dosed_country", "value": "Japan", "unit": "geography", "locator": "web lines 17–18" } ], "supported_summary": "公司公告直接支持GNX1021標的bLeB/Y、在日本一期首次人體研究首位給藥；後續安全性、PK與活性仍為試驗評估目標。", "claim_assessments": [ { "claim_location_id": "ZH-L0457", "status": "partially_supported", "supported_scope": "僅支持本來源所對應子句：公司公告直接支持GNX1021標的bLeB/Y、在日本一期首次人體研究首位給藥；後續安全性、PK與活性仍為試驗評估目標。", "gap": "本公告未提GNX102或其裸抗體身份，不能以這份來源直接證明該舊分子的種類；GNX1021一期節點與bLeB/Y標的不受此缺口影響。未另核監管或登錄。", "language": "ZH", "line": 457, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "浩鼎與醣聯：都談「醣」，改動的位置不同", "exact_correction_ids": [ "ZH-L0457" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "ZH-L0518", "status": "supported", "supported_scope": "支持該候選藥已披露的研究／監管狀態作條件監看；未來讀出時間未承諾。", "gap": null, "language": "ZH", "line": 518, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0521", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0602", "status": "partially_supported", "supported_scope": "僅支持本來源所對應子句：公司公告直接支持GNX1021標的bLeB/Y、在日本一期首次人體研究首位給藥；後續安全性、PK與活性仍為試驗評估目標。", "gap": "本公告未提GNX102或其裸抗體身份，不能以這份來源直接證明該舊分子的種類；GNX1021一期節點與bLeB/Y標的不受此缺口影響。未另核監管或登錄。", "language": "ZH", "line": 602, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [ "ZH-L0602" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0457", "status": "partially_supported", "supported_scope": "僅支持本來源所對應子句：公司公告直接支持GNX1021標的bLeB/Y、在日本一期首次人體研究首位給藥；後續安全性、PK與活性仍為試驗評估目標。", "gap": "本公告未提GNX102或其裸抗體身份，不能以這份來源直接證明該舊分子的種類；GNX1021一期節點與bLeB/Y標的不受此缺口影響。未另核監管或登錄。", "language": "EN", "line": 457, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "OBI Pharma and GlycoNex: Both Work with Glycans, at Different Points in the ADC", "exact_correction_ids": [ "EN-L0457" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0518", "status": "supported", "supported_scope": "支持該候選藥已披露的研究／監管狀態作條件監看；未來讀出時間未承諾。", "gap": null, "language": "EN", "line": 518, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0521", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0602", "status": "partially_supported", "supported_scope": "僅支持本來源所對應子句：公司公告直接支持GNX1021標的bLeB/Y、在日本一期首次人體研究首位給藥；後續安全性、PK與活性仍為試驗評估目標。", "gap": "本公告未提GNX102或其裸抗體身份，不能以這份來源直接證明該舊分子的種類；GNX1021一期節點與bLeB/Y標的不受此缺口影響。未另核監管或登錄。", "language": "EN", "line": 602, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [ "EN-L0602" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "partially_supported", "precise_gap": "本公告未提GNX102或其裸抗體身份，不能以這份來源直接證明該舊分子的種類；GNX1021一期節點與bLeB/Y標的不受此缺口影響。未另核監管或登錄。", "web_refs": [ "turn115view0" ], "observed_publication_date": "2026-08-03", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T05.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0457", "language": "ZH", "line": 457, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "浩鼎與醣聯：都談「醣」，改動的位置不同" }, { "claim_location_id": "ZH-L0518", "language": "ZH", "line": 518, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0521", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0602", "language": "ZH", "line": 602, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0457", "language": "EN", "line": 457, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "OBI Pharma and GlycoNex: Both Work with Glycans, at Different Points in the ADC" }, { "claim_location_id": "EN-L0518", "language": "EN", "line": 518, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0521", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0602", "language": "EN", "line": 602, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [ "ZH-L0457", "ZH-L0602", "EN-L0457", "EN-L0602" ], "current_disposition": "Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.", "reader_source_note": { "source_id": "T05", "supports_zh": "公司公告GNX1021靶向bLeB/Y醣抗原，並於2026-08-03宣布一期研究首位病人在日本給藥。", "supports_en": "The company identifies bLeB/Y as GNX1021’s glycan target and announced first-patient dosing in Japan in its Phase 1 study on 2026-08-03.", "access_scope_zh": "已讀公開公告必要段落；未另核試驗登錄，該稿也沒有交代GNX102或其裸抗體身分。", "access_scope_en": "Relevant public announcement passages were read; the trial registry was not separately checked. The release does not identify GNX102 or its unconjugated-antibody status.", "locator_zh": "日期、首位給藥、標的及研究設計；本輪擷取文字第14–23行。", "locator_en": "Date, first-patient dosing, target and trial design; retrieved-text lines 14–23.", "source_date": "2026-08-03", "data_date": "2026-08-03" } }, { "source_id": "T06", "original_url": "https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/", "title": "Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers", "source_date": "2026-08-28", "data_date": "2026-08-28", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T06.txt", "bytes": 2055, "sha256": "77f67fc8dbd5904497de84894c06051af832abcc0522b55e2c0d63d659c14542", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "Dateline / CTA / trial scope", "position": "web lines 90–91" }, { "section": "About TSY-110", "position": "web lines 94–96; EirGenix profile lines 104–106" } ], "numeric_support": [ { "field": "announcement_date", "value": "2026-08-28", "unit": "date", "locator": "web line 90" }, { "field": "candidate_alias", "value": "EG12043", "unit": "identifier", "locator": "web line 95" }, { "field": "reference_product", "value": "Kadcyla / ado-trastuzumab emtansine", "unit": "product identity", "locator": "web line 90" } ], "supported_summary": "2026-08-28公司公告歐洲CTA已遞交；TSY-110亦稱EG12043，台新藥／台康共同開發，參照Kadcyla。試驗擬比較PK、安全性與免疫原性。", "claim_assessments": [ { "claim_location_id": "ZH-L0465", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2026-08-28公司公告歐洲CTA已遞交；TSY-110亦稱EG12043，台新藥／台康共同開發，參照Kadcyla。試驗擬比較PK、安全性與免疫原性。", "gap": null, "language": "ZH", "line": 465, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "台新藥／台康：相似性是另一種產品價值", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0518", "status": "supported", "supported_scope": "支持該候選藥已披露的研究／監管狀態作條件監看；未來讀出時間未承諾。", "gap": null, "language": "ZH", "line": 518, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0521", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0603", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2026-08-28公司公告歐洲CTA已遞交；TSY-110亦稱EG12043，台新藥／台康共同開發，參照Kadcyla。試驗擬比較PK、安全性與免疫原性。", "gap": null, "language": "ZH", "line": 603, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0604", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2026-08-28公司公告歐洲CTA已遞交；TSY-110亦稱EG12043，台新藥／台康共同開發，參照Kadcyla。試驗擬比較PK、安全性與免疫原性。", "gap": null, "language": "ZH", "line": 604, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0465", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2026-08-28公司公告歐洲CTA已遞交；TSY-110亦稱EG12043，台新藥／台康共同開發，參照Kadcyla。試驗擬比較PK、安全性與免疫原性。", "gap": null, "language": "EN", "line": 465, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "Formosa Pharmaceuticals / EirGenix: Similarity Offers a Different Kind of Product Value", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0518", "status": "supported", "supported_scope": "支持該候選藥已披露的研究／監管狀態作條件監看；未來讀出時間未承諾。", "gap": null, "language": "EN", "line": 518, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0521", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0603", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2026-08-28公司公告歐洲CTA已遞交；TSY-110亦稱EG12043，台新藥／台康共同開發，參照Kadcyla。試驗擬比較PK、安全性與免疫原性。", "gap": null, "language": "EN", "line": 603, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0604", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2026-08-28公司公告歐洲CTA已遞交；TSY-110亦稱EG12043，台新藥／台康共同開發，參照Kadcyla。試驗擬比較PK、安全性與免疫原性。", "gap": null, "language": "EN", "line": 604, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "支持CTA遞交與公司描述的臨床前相似性，不支持CTA已獲准、已給藥或相似藥已核准。未以頁面市场數字扩充本次範圍。", "web_refs": [ "turn115view1" ], "observed_publication_date": "2026-08-28", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T06.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0465", "language": "ZH", "line": 465, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "台新藥／台康：相似性是另一種產品價值" }, { "claim_location_id": "ZH-L0518", "language": "ZH", "line": 518, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0521", "language": "ZH", "line": 521, "section": "14　未來十二個月，什麼事件會改變判斷？", "subsection": "比較表 F11｜未來十二個月：哪些事件值得改判？" }, { "claim_location_id": "ZH-L0603", "language": "ZH", "line": 603, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0604", "language": "ZH", "line": 604, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0465", "language": "EN", "line": 465, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "Formosa Pharmaceuticals / EirGenix: Similarity Offers a Different Kind of Product Value" }, { "claim_location_id": "EN-L0518", "language": "EN", "line": 518, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0521", "language": "EN", "line": 521, "section": "14 Which Events Could Change the Assessment over Twelve Months?", "subsection": "Table F11｜The Next Twelve Months: Which Events Could Change the Assessment?" }, { "claim_location_id": "EN-L0603", "language": "EN", "line": 603, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0604", "language": "EN", "line": 604, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T06", "supports_zh": "2026-08-28公告TSY-110／EG12043歐洲CTA已遞交，由台新藥與台康共同開發並參照Kadcyla；試驗擬評估PK、安全性與免疫原性。", "supports_en": "The 2026-08-28 release reports a European CTA submission for TSY-110/EG12043, co-developed with EirGenix and referencing Kadcyla, with planned PK, safety and immunogenicity assessments.", "access_scope_zh": "已讀公司公開公告必要段落；CTA遞交與公司臨床前相似性敘述，不等於核准、給藥或已核准生物相似藥。", "access_scope_en": "Relevant company announcement passages were read. CTA submission and company-reported preclinical similarity do not establish authorization, dosing or biosimilar approval.", "locator_zh": "CTA正文與About TSY-110；本輪擷取文字第90–96行。", "locator_en": "CTA announcement and About TSY-110; retrieved-text lines 90–96.", "source_date": "2026-08-28", "data_date": "2026-08-28" } }, { "source_id": "T07", "original_url": "https://www.formosapharma.com/formosa-pharmaceuticals-announces-presentation-of-tsy-310-at-the-2026-asco-annual-meeting/", "title": "Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting", "source_date": "2026-05-22", "data_date": "2026-05-22", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T07.txt", "bytes": 1708, "sha256": "d9e33f30283bba10c7fa4dec0f35d14d8fb7d41f718e37ef03e3a347490e8aa9", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "Dated announcement", "position": "web line 88" }, { "section": "ASCO details / preclinical design", "position": "web lines 94–105; programme description line 112" } ], "numeric_support": [ { "field": "announcement_date", "value": "2026-05-22", "unit": "date", "locator": "web line 88" }, { "field": "abstract_number", "value": 3086, "unit": "abstract identifier", "locator": "web line 97" } ], "supported_summary": "2026-05-22公告所呈現的TSY-310為EGFR×ROR1雙特異ADC臨床前資料，不能因ASCO發表視為人體證據。", "claim_assessments": [ { "claim_location_id": "ZH-L0465", "status": "partially_supported", "supported_scope": "僅支持本來源所對應子句：2026-05-22公告所呈現的TSY-310為EGFR×ROR1雙特異ADC臨床前資料，不能因ASCO發表視為人體證據。", "gap": "該舊公告支持已呈現資料屬臨床前，但未獨立證明截至2026-10-07仍未進入人體；建議把持續階段敘述限定為公告的資料層級。", "language": "ZH", "line": 465, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "台新藥／台康：相似性是另一種產品價值", "exact_correction_ids": [ "ZH-L0465" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "ZH-L0603", "status": "partially_supported", "supported_scope": "僅支持本來源所對應子句：2026-05-22公告所呈現的TSY-310為EGFR×ROR1雙特異ADC臨床前資料，不能因ASCO發表視為人體證據。", "gap": "該舊公告支持已呈現資料屬臨床前，但未獨立證明截至2026-10-07仍未進入人體；建議把持續階段敘述限定為公告的資料層級。", "language": "ZH", "line": 603, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [ "ZH-L0603" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0465", "status": "partially_supported", "supported_scope": "僅支持本來源所對應子句：2026-05-22公告所呈現的TSY-310為EGFR×ROR1雙特異ADC臨床前資料，不能因ASCO發表視為人體證據。", "gap": "該舊公告支持已呈現資料屬臨床前，但未獨立證明截至2026-10-07仍未進入人體；建議把持續階段敘述限定為公告的資料層級。", "language": "EN", "line": 465, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "Formosa Pharmaceuticals / EirGenix: Similarity Offers a Different Kind of Product Value", "exact_correction_ids": [ "EN-L0465" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0603", "status": "partially_supported", "supported_scope": "僅支持本來源所對應子句：2026-05-22公告所呈現的TSY-310為EGFR×ROR1雙特異ADC臨床前資料，不能因ASCO發表視為人體證據。", "gap": "該舊公告支持已呈現資料屬臨床前，但未獨立證明截至2026-10-07仍未進入人體；建議把持續階段敘述限定為公告的資料層級。", "language": "EN", "line": 603, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [ "EN-L0603" ], "current_disposition": "specified_clause_corrected_or_removed; see changes.json" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "partially_supported", "precise_gap": "該舊公告支持已呈現資料屬臨床前，但未獨立證明截至2026-10-07仍未進入人體；建議把持續階段敘述限定為公告的資料層級。", "web_refs": [ "turn115view2" ], "observed_publication_date": "2026-05-22", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T07.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0465", "language": "ZH", "line": 465, "section": "12　台灣創新：不同技術位置，需要不同證據", "subsection": "台新藥／台康：相似性是另一種產品價值" }, { "claim_location_id": "ZH-L0603", "language": "ZH", "line": 603, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0465", "language": "EN", "line": 465, "section": "12 Taiwan’s Innovation: Different Technical Roles Need Different Evidence", "subsection": "Formosa Pharmaceuticals / EirGenix: Similarity Offers a Different Kind of Product Value" }, { "claim_location_id": "EN-L0603", "language": "EN", "line": 603, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [ "ZH-L0465", "ZH-L0603", "EN-L0465", "EN-L0603" ], "current_disposition": "Exact wording narrowed or clarified; see applied_corrections and changes.json. Earlier proposed/needs language records the before-correction assessment.", "reader_source_note": { "source_id": "T07", "supports_zh": "2026-05-22公告呈現TSY-310的EGFR×ROR1雙特異設計與臨床前資料。", "supports_en": "The 2026-05-22 announcement presents TSY-310’s EGFR×ROR1 bispecific design and preclinical data.", "access_scope_zh": "已讀公司公告的設計及ASCO發表資訊；支持當次資料層級，未另證截至10月7日仍未入人體。", "access_scope_en": "Design and ASCO presentation details were read. They establish the announced evidence stage, without separately verifying the absence of human development through October 7.", "locator_zh": "公告首段及Details／Highlights；本輪擷取文字第88、94–105行。", "locator_en": "Opening announcement and Details/Highlights; retrieved-text lines 88 and 94–105.", "source_date": "2026-05-22", "data_date": "2026-05-22" } }, { "source_id": "T09", "original_url": "https://www.eirgenix.com/antibody-drug-conjugate", "title": "EirGenix — ADC & Bioconjugates", "source_date": "", "data_date": "", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T09.txt", "bytes": 1547, "sha256": "f3e2b0bd5ff82cc7369ea2c4594ac9cdd64255ab970c958092b6722916efc26d", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "ADC & Bioconjugates / partner", "position": "web lines 87–95" }, { "section": "Monoclonal Antibody Development and Production / High Potency Chemicals / Linkers", "position": "web lines 109–125" } ], "numeric_support": [], "supported_summary": "台康公開頁列台耀為策略夥伴，描述抗體、分析／品質、GMP製造與偶聯相關整合服務；支持對外能力與合作配置。", "claim_assessments": [ { "claim_location_id": "ZH-L0407", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 407, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "比較表 F07｜ADC 製造的價值，在四個交接點", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0473", "status": "supported", "supported_scope": "僅支持本來源所對應子句：台康公開頁列台耀為策略夥伴，描述抗體、分析／品質、GMP製造與偶聯相關整合服務；支持對外能力與合作配置。", "gap": null, "language": "ZH", "line": 473, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0484", "status": "supported", "supported_scope": "僅支持本來源所對應子句：台康公開頁列台耀為策略夥伴，描述抗體、分析／品質、GMP製造與偶聯相關整合服務；支持對外能力與合作配置。", "gap": null, "language": "ZH", "line": 484, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0490", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 490, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0492", "status": "supported", "supported_scope": "僅支持本來源所對應子句：台康公開頁列台耀為策略夥伴，描述抗體、分析／品質、GMP製造與偶聯相關整合服務；支持對外能力與合作配置。", "gap": null, "language": "ZH", "line": 492, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0604", "status": "supported", "supported_scope": "僅支持本來源所對應子句：台康公開頁列台耀為策略夥伴，描述抗體、分析／品質、GMP製造與偶聯相關整合服務；支持對外能力與合作配置。", "gap": null, "language": "ZH", "line": 604, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0407", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 407, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Table F07｜Four Handoffs Define Value in ADC Manufacturing", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0473", "status": "supported", "supported_scope": "僅支持本來源所對應子句：台康公開頁列台耀為策略夥伴，描述抗體、分析／品質、GMP製造與偶聯相關整合服務；支持對外能力與合作配置。", "gap": null, "language": "EN", "line": 473, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0484", "status": "supported", "supported_scope": "僅支持本來源所對應子句：台康公開頁列台耀為策略夥伴，描述抗體、分析／品質、GMP製造與偶聯相關整合服務；支持對外能力與合作配置。", "gap": null, "language": "EN", "line": 484, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0490", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 490, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0492", "status": "supported", "supported_scope": "僅支持本來源所對應子句：台康公開頁列台耀為策略夥伴，描述抗體、分析／品質、GMP製造與偶聯相關整合服務；支持對外能力與合作配置。", "gap": null, "language": "EN", "line": 492, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0604", "status": "supported", "supported_scope": "僅支持本來源所對應子句：台康公開頁列台耀為策略夥伴，描述抗體、分析／品質、GMP製造與偶聯相關整合服務；支持對外能力與合作配置。", "gap": null, "language": "EN", "line": 604, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "頁面未標資料日；不能由服務頁推定特定ADC商業訂單、客戶批次已放行或收入。未採過時的ADC核准總數或其他槽體尺度。", "web_refs": [ "turn115view3" ], "observed_publication_date": null, "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T09.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0407", "language": "ZH", "line": 407, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "比較表 F07｜ADC 製造的價值，在四個交接點" }, { "claim_location_id": "ZH-L0473", "language": "ZH", "line": 473, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "" }, { "claim_location_id": "ZH-L0484", "language": "ZH", "line": 484, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0490", "language": "ZH", "line": 490, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0492", "language": "ZH", "line": 492, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0604", "language": "ZH", "line": 604, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0407", "language": "EN", "line": 407, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Table F07｜Four Handoffs Define Value in ADC Manufacturing" }, { "claim_location_id": "EN-L0473", "language": "EN", "line": 473, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "" }, { "claim_location_id": "EN-L0484", "language": "EN", "line": 484, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0490", "language": "EN", "line": 490, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0492", "language": "EN", "line": 492, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0604", "language": "EN", "line": 604, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T09", "supports_zh": "台康列台耀為策略夥伴，描述抗體、分析、GMP製造與偶聯相關整合服務。", "supports_en": "EirGenix names Formosa Laboratories as a strategic partner and describes integrated antibody, analytical, GMP-manufacturing and conjugation services.", "access_scope_zh": "已讀公開服務頁必要段落；未標更新日，支持對外能力範圍而非特定產品的商業訂單或放行。", "access_scope_en": "Relevant public service passages were read. The undated page supports offered capabilities, not product-specific commercial orders or batch release.", "locator_zh": "ADC & Bioconjugates、Monoclonal Antibody Development and Production；本輪擷取文字第87–95、109–125行。", "locator_en": "ADC & Bioconjugates and Monoclonal Antibody Development and Production; retrieved-text lines 87–95 and 109–125.", "source_date": "", "data_date": "" } }, { "source_id": "T10", "original_url": "https://www.formosalab.com/tw/bioconjugation-adc", "title": "台耀化學 — 抗體藥物複合體", "source_date": "", "data_date": "", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T10.txt", "bytes": 1456, "sha256": "c8aed6eac16a16403927a58067cf775ae3ae476d95d5a5af85614f290ba9af24", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "一站式方案", "position": "web lines 296–305" }, { "section": "經驗和專業", "position": "web line 320 (company claim only)" } ], "numeric_support": [], "supported_summary": "公司公開服務列高效價化學、偶聯、TFF／管柱純化、劑型、液體充填與凍乾；公司另稱臨床供藥經驗。", "claim_assessments": [ { "claim_location_id": "ZH-L0407", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 407, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "比較表 F07｜ADC 製造的價值，在四個交接點", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0473", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司公開服務列高效價化學、偶聯、TFF／管柱純化、劑型、液體充填與凍乾；公司另稱臨床供藥經驗。", "gap": null, "language": "ZH", "line": 473, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0484", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司公開服務列高效價化學、偶聯、TFF／管柱純化、劑型、液體充填與凍乾；公司另稱臨床供藥經驗。", "gap": null, "language": "ZH", "line": 484, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0490", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 490, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0492", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司公開服務列高效價化學、偶聯、TFF／管柱純化、劑型、液體充填與凍乾；公司另稱臨床供藥經驗。", "gap": null, "language": "ZH", "line": 492, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0605", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司公開服務列高效價化學、偶聯、TFF／管柱純化、劑型、液體充填與凍乾；公司另稱臨床供藥經驗。", "gap": null, "language": "ZH", "line": 605, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0407", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 407, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Table F07｜Four Handoffs Define Value in ADC Manufacturing", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0473", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司公開服務列高效價化學、偶聯、TFF／管柱純化、劑型、液體充填與凍乾；公司另稱臨床供藥經驗。", "gap": null, "language": "EN", "line": 473, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0484", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司公開服務列高效價化學、偶聯、TFF／管柱純化、劑型、液體充填與凍乾；公司另稱臨床供藥經驗。", "gap": null, "language": "EN", "line": 484, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0490", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 490, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0492", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司公開服務列高效價化學、偶聯、TFF／管柱純化、劑型、液體充填與凍乾；公司另稱臨床供藥經驗。", "gap": null, "language": "EN", "line": 492, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0605", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司公開服務列高效價化學、偶聯、TFF／管柱純化、劑型、液體充填與凍乾；公司另稱臨床供藥經驗。", "gap": null, "language": "EN", "line": 605, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "未標資料日；能力／供藥經驗為公司說法。15件專案與50Kg願景未作當期訂單或產能採用，也不以本頁證實產品別放行。", "web_refs": [ "turn124view0" ], "observed_publication_date": null, "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T10.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0407", "language": "ZH", "line": 407, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "比較表 F07｜ADC 製造的價值，在四個交接點" }, { "claim_location_id": "ZH-L0473", "language": "ZH", "line": 473, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "" }, { "claim_location_id": "ZH-L0484", "language": "ZH", "line": 484, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0490", "language": "ZH", "line": 490, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0492", "language": "ZH", "line": 492, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0605", "language": "ZH", "line": 605, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0407", "language": "EN", "line": 407, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Table F07｜Four Handoffs Define Value in ADC Manufacturing" }, { "claim_location_id": "EN-L0473", "language": "EN", "line": 473, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "" }, { "claim_location_id": "EN-L0484", "language": "EN", "line": 484, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0490", "language": "EN", "line": 490, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0492", "language": "EN", "line": 492, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0605", "language": "EN", "line": 605, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T10", "supports_zh": "台耀公開服務含高效價化學、偶聯、TFF／管柱純化、劑型及液體充填／凍乾；臨床供藥經驗為公司說法。", "supports_en": "Formosa Laboratories lists highly potent chemistry, conjugation, TFF/chromatographic purification, formulation and liquid filling/lyophilization; clinical-supply experience is company-reported.", "access_scope_zh": "已讀公開服務頁必要段落；頁面未標資料日，未以專案數或產能願景推算當期訂單。", "access_scope_en": "Relevant public service passages were read. The page is undated; project counts and capacity aspirations were not used to infer current orders.", "locator_zh": "一站式方案及經驗和專業；本輪擷取文字第296–305、320行。", "locator_en": "One-stop solution and experience sections; retrieved-text lines 296–305 and 320.", "source_date": "", "data_date": "" } }, { "source_id": "T11", "original_url": "https://www.formosalab.com/tw/adc", "title": "台耀化學 — 抗體藥物複合體廠房", "source_date": "", "data_date": "", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T11.txt", "bytes": 1633, "sha256": "a95514ecde411cb49886f7dc1559c85ad7ebd50b0336c71c831d2db06ea9467a", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "ADC 實驗室", "position": "web lines 301–308" }, { "section": "ADC 生產製造", "position": "web lines 312–319; listed manufacturing equipment" } ], "numeric_support": [ { "field": "bioconjugation_reactor_volume_min", "value": 30, "unit": "L", "locator": "web line 317", "basis": "company-listed nominal reactor volume" }, { "field": "bioconjugation_reactor_volume_max", "value": 200, "unit": "L", "locator": "web line 317", "basis": "company-listed nominal reactor volume" } ], "supported_summary": "公司設施頁明列30–200 L偶聯反應器、ÄKTA、TFF與層析；只支持設備規格和所述服務範圍。", "claim_assessments": [ { "claim_location_id": "ZH-L0407", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 407, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "比較表 F07｜ADC 製造的價值，在四個交接點", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0485", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司設施頁明列30–200 L偶聯反應器、ÄKTA、TFF與層析；只支持設備規格和所述服務範圍。", "gap": null, "language": "ZH", "line": 485, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0490", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 490, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0492", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司設施頁明列30–200 L偶聯反應器、ÄKTA、TFF與層析；只支持設備規格和所述服務範圍。", "gap": null, "language": "ZH", "line": 492, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0494", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司設施頁明列30–200 L偶聯反應器、ÄKTA、TFF與層析；只支持設備規格和所述服務範圍。", "gap": null, "language": "ZH", "line": 494, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0605", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司設施頁明列30–200 L偶聯反應器、ÄKTA、TFF與層析；只支持設備規格和所述服務範圍。", "gap": null, "language": "ZH", "line": 605, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0407", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 407, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Table F07｜Four Handoffs Define Value in ADC Manufacturing", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0485", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司設施頁明列30–200 L偶聯反應器、ÄKTA、TFF與層析；只支持設備規格和所述服務範圍。", "gap": null, "language": "EN", "line": 485, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0490", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 490, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0492", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司設施頁明列30–200 L偶聯反應器、ÄKTA、TFF與層析；只支持設備規格和所述服務範圍。", "gap": null, "language": "EN", "line": 492, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0494", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司設施頁明列30–200 L偶聯反應器、ÄKTA、TFF與層析；只支持設備規格和所述服務範圍。", "gap": null, "language": "EN", "line": 494, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0605", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司設施頁明列30–200 L偶聯反應器、ÄKTA、TFF與層析；只支持設備規格和所述服務範圍。", "gap": null, "language": "EN", "line": 605, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "原頁未標更新日；容積不是每批合格ADC公斤數、年產量、稼動率、商業銷量或營收。", "web_refs": [ "turn124view1" ], "observed_publication_date": null, "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T11.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0407", "language": "ZH", "line": 407, "section": "10　製造競爭：合格批次之外，還有承諾彈性", "subsection": "比較表 F07｜ADC 製造的價值，在四個交接點" }, { "claim_location_id": "ZH-L0485", "language": "ZH", "line": 485, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0490", "language": "ZH", "line": 490, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0492", "language": "ZH", "line": 492, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0494", "language": "ZH", "line": 494, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0605", "language": "ZH", "line": 605, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0407", "language": "EN", "line": 407, "section": "10 Manufacturing: Qualified Batches and Flexible Commitments", "subsection": "Table F07｜Four Handoffs Define Value in ADC Manufacturing" }, { "claim_location_id": "EN-L0485", "language": "EN", "line": 485, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0490", "language": "EN", "line": 490, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0492", "language": "EN", "line": 492, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0494", "language": "EN", "line": 494, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0605", "language": "EN", "line": 605, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T11", "supports_zh": "台耀公司設施頁列30–200 L偶聯反應器、ÄKTA、TFF及層析配置。", "supports_en": "The company facility page lists 30–200 L conjugation reactors, ÄKTA, TFF and chromatography equipment.", "access_scope_zh": "已讀公開設施規格；未標更新日，反應器容積不代表合格產品年產量或商業銷售。", "access_scope_en": "Public facility specifications were read. The undated reactor volumes do not establish qualified annual product output or commercial sales.", "locator_zh": "ADC生產製造設備清單；本輪擷取文字第312–319行。", "locator_en": "ADC manufacturing equipment list; retrieved-text lines 312–319.", "source_date": "", "data_date": "" } }, { "source_id": "T12", "original_url": "https://www.mycenax.com/news-detail.php?id=122&lang=en", "title": "Mycenax and RIN Sign License Agreement to Advance ADC Development Using RIN’s Proprietary Linker Technology", "source_date": "2025-10-31", "data_date": "2025-10-31", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T12.txt", "bytes": 1645, "sha256": "56593e73e3d872bbf1d838719d753ff4c6c621a2577e3d8715b678709b1f7366", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "Release date / agreement", "position": "web lines 118, 124, 128" }, { "section": "About RIN / About Mycenax", "position": "web lines 139–149; anti-TMEM180 study at line 141, KriSan/Spera at line 149" } ], "numeric_support": [ { "field": "license_announcement_date", "value": "2025-10-31", "unit": "date", "locator": "web lines 118 and 124" } ], "supported_summary": "2025-10-31公告授予永昕將RIN之VLK連接子用於全球CDMO服務的權利；並描述KriSan／Spera合作與另一anti-TMEM180抗體一期項目。", "claim_assessments": [ { "claim_location_id": "ZH-L0473", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2025-10-31公告授予永昕將RIN之VLK連接子用於全球CDMO服務的權利；並描述KriSan／Spera合作與另一anti-TMEM180抗體一期項目。", "gap": null, "language": "ZH", "line": 473, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0486", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2025-10-31公告授予永昕將RIN之VLK連接子用於全球CDMO服務的權利；並描述KriSan／Spera合作與另一anti-TMEM180抗體一期項目。", "gap": null, "language": "ZH", "line": 486, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0490", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 490, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0492", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2025-10-31公告授予永昕將RIN之VLK連接子用於全球CDMO服務的權利；並描述KriSan／Spera合作與另一anti-TMEM180抗體一期項目。", "gap": null, "language": "ZH", "line": 492, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0606", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2025-10-31公告授予永昕將RIN之VLK連接子用於全球CDMO服務的權利；並描述KriSan／Spera合作與另一anti-TMEM180抗體一期項目。", "gap": null, "language": "ZH", "line": 606, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0473", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2025-10-31公告授予永昕將RIN之VLK連接子用於全球CDMO服務的權利；並描述KriSan／Spera合作與另一anti-TMEM180抗體一期項目。", "gap": null, "language": "EN", "line": 473, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0486", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2025-10-31公告授予永昕將RIN之VLK連接子用於全球CDMO服務的權利；並描述KriSan／Spera合作與另一anti-TMEM180抗體一期項目。", "gap": null, "language": "EN", "line": 486, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0490", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 490, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0492", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2025-10-31公告授予永昕將RIN之VLK連接子用於全球CDMO服務的權利；並描述KriSan／Spera合作與另一anti-TMEM180抗體一期項目。", "gap": null, "language": "EN", "line": 492, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0606", "status": "supported", "supported_scope": "僅支持本來源所對應子句：2025-10-31公告授予永昕將RIN之VLK連接子用於全球CDMO服務的權利；並描述KriSan／Spera合作與另一anti-TMEM180抗體一期項目。", "gap": null, "language": "EN", "line": 606, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "不是全部產品／全部用途的全球專屬權利；公告未提供具名ADC商業批次或訂單收入，抗體一期不移植為ADC一期。", "web_refs": [ "turn117view0" ], "observed_publication_date": "2025-10-31", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T12.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0473", "language": "ZH", "line": 473, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "" }, { "claim_location_id": "ZH-L0486", "language": "ZH", "line": 486, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0490", "language": "ZH", "line": 490, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0492", "language": "ZH", "line": 492, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0606", "language": "ZH", "line": 606, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0473", "language": "EN", "line": 473, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "" }, { "claim_location_id": "EN-L0486", "language": "EN", "line": 486, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0490", "language": "EN", "line": 490, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0492", "language": "EN", "line": 492, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0606", "language": "EN", "line": 606, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T12", "supports_zh": "2025-10-31公告永昕獲全球CDMO服務使用RIN VLK連接子技術的權利，並描述KriSan／Spera合作。", "supports_en": "The 2025-10-31 release grants Mycenax rights to use RIN’s VLK linker in CDMO services worldwide and describes KriSan/Spera partnerships.", "access_scope_zh": "已讀公開授權及合作段落；未擴張成所有用途專屬權利，抗體一期案例也未當作ADC一期。", "access_scope_en": "Public license and partnership passages were read. The rights were not expanded to all-use exclusivity, nor an antibody Phase 1 example treated as an ADC trial.", "locator_zh": "日期與授權正文、About RIN／Mycenax；本輪擷取文字第118、124、128、141、149行。", "locator_en": "Date, license paragraph and About RIN/Mycenax; retrieved-text lines 118, 124, 128, 141 and 149.", "source_date": "2025-10-31", "data_date": "2025-10-31" } }, { "source_id": "T13", "original_url": "https://www.mycenax.com/cdmo.php?id=56", "title": "Mycenax — Antibody-Drug Conjugate", "source_date": "", "data_date": "", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T13.txt", "bytes": 1612, "sha256": "0de6f4d88575780d2d7e99c6e76dc4d3f1d2fe1d9022f52346dab8a7fd941b36", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "ConjuMX Toolbox", "position": "web lines 134–136" }, { "section": "VLK Linker / Strategic ADC Partners", "position": "web lines 147–149, 158–164; page repeats these at 197–216" } ], "numeric_support": [ { "field": "company_reported_GMP_production_scale", "value": 50, "unit": "L", "locator": "web line 136", "basis": "company capability statement, not independently audited commercial capacity" } ], "supported_summary": "公司服務頁列GMP級50 L生產尺度；分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備，另列合作鏈。", "claim_assessments": [ { "claim_location_id": "ZH-L0473", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司服務頁列GMP級50 L生產尺度；分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備，另列合作鏈。", "gap": null, "language": "ZH", "line": 473, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0486", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司服務頁列GMP級50 L生產尺度；分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備，另列合作鏈。", "gap": null, "language": "ZH", "line": 486, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0490", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 490, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0492", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司服務頁列GMP級50 L生產尺度；分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備，另列合作鏈。", "gap": null, "language": "ZH", "line": 492, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0494", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司服務頁列GMP級50 L生產尺度；分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備，另列合作鏈。", "gap": null, "language": "ZH", "line": 494, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0606", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司服務頁列GMP級50 L生產尺度；分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備，另列合作鏈。", "gap": null, "language": "ZH", "line": 606, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0473", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司服務頁列GMP級50 L生產尺度；分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備，另列合作鏈。", "gap": null, "language": "EN", "line": 473, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0486", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司服務頁列GMP級50 L生產尺度；分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備，另列合作鏈。", "gap": null, "language": "EN", "line": 486, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0490", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 490, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0492", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司服務頁列GMP級50 L生產尺度；分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備，另列合作鏈。", "gap": null, "language": "EN", "line": 492, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0494", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司服務頁列GMP級50 L生產尺度；分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備，另列合作鏈。", "gap": null, "language": "EN", "line": 494, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0606", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司服務頁列GMP級50 L生產尺度；分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備，另列合作鏈。", "gap": null, "language": "EN", "line": 606, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "未標資料日；50 L並非產品別放行量、年產量、訂單或營收；未宣稱anti-IF ADC已進入一期。", "web_refs": [ "turn117view1" ], "observed_publication_date": null, "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T13.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0473", "language": "ZH", "line": 473, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "" }, { "claim_location_id": "ZH-L0486", "language": "ZH", "line": 486, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0490", "language": "ZH", "line": 490, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0492", "language": "ZH", "line": 492, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0494", "language": "ZH", "line": 494, "section": "13　台灣交付：可用能力如何接成供應", "subsection": "比較表 F10｜台灣製造能力，應如何讓買方核驗？" }, { "claim_location_id": "ZH-L0606", "language": "ZH", "line": 606, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0473", "language": "EN", "line": 473, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "" }, { "claim_location_id": "EN-L0486", "language": "EN", "line": 486, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0490", "language": "EN", "line": 490, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0492", "language": "EN", "line": 492, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0494", "language": "EN", "line": 494, "section": "13 Delivery in Taiwan: Connecting Capabilities into Supply", "subsection": "Table F10｜Taiwan's Manufacturing Capabilities: What Can a Buyer Verify?" }, { "claim_location_id": "EN-L0606", "language": "EN", "line": 606, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T13", "supports_zh": "永昕公司服務頁列GMP級50 L尺度，並分開描述anti-TMEM180抗體一期供藥與後續anti-IF ADC製備。", "supports_en": "Mycenax’s service page lists GMP-grade 50 L production and distinguishes anti-TMEM180 antibody Phase 1 supply from subsequent anti-IF ADC production.", "access_scope_zh": "已讀ConjuMX、VLK及合作段落；頁面未標資料日，50 L為公司能力口徑，不是產品別商業放行或訂單。", "access_scope_en": "ConjuMX, VLK and partnership passages were read. The undated 50 L figure is a company capability statement, not product-specific commercial release or orders.", "locator_zh": "ConjuMX、VLK Linker及Strategic ADC Partners；本輪擷取文字第134–149、158–164行。", "locator_en": "ConjuMX, VLK Linker and Strategic ADC Partners; retrieved-text lines 134–149 and 158–164.", "source_date": "", "data_date": "" } }, { "source_id": "T15", "original_url": "https://www.twse.com.tw/pdf/ch/4746_ch.pdf", "title": "臺灣證券交易所 — 台耀化學股份有限公司個股資訊（4746）", "source_date": "", "data_date": "2026-10-06", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "public_PDF_page_1_text_extraction", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T15.txt", "bytes": 1772, "sha256": "ba685e643b35623eba835472adbb383ccdfb33dfd0520910b69cf481b779f3b1", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "TWSE company profile", "position": "PDF page 1 (tool P0), listing date line 35, name line 42, generation date line 43, ticker line 48" } ], "numeric_support": [ { "field": "ticker", "value": "4746", "unit": "security identifier", "locator": "PDF page 1 / web line 48" }, { "field": "listing_date", "value": "2011-03-01", "unit": "date", "locator": "PDF page 1 / web line 35" }, { "field": "observed_document_generation_date", "value": "2026-10-07", "unit": "date", "locator": "PDF page 1 / web line 43" } ], "supported_summary": "本輪證交所PDF支持台耀化學於TWSE上市、代號4746。", "claim_assessments": [ { "claim_location_id": "ZH-L0605", "status": "supported", "supported_scope": "僅支持本來源所對應子句：本輪證交所PDF支持台耀化學於TWSE上市、代號4746。", "gap": "當前上市／代號支持；原2026-10-06 PDF快照未保存，本輪產製日2026-10-07另列。", "language": "ZH", "line": 605, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": "當前上市／代號支持；原2026-10-06 PDF快照未保存，本輪產製日2026-10-07另列。", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0605", "status": "supported", "supported_scope": "僅支持本來源所對應子句：本輪證交所PDF支持台耀化學於TWSE上市、代號4746。", "gap": "當前上市／代號支持；原2026-10-06 PDF快照未保存，本輪產製日2026-10-07另列。", "language": "EN", "line": 605, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": "當前上市／代號支持；原2026-10-06 PDF快照未保存，本輪產製日2026-10-07另列。", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "partially_supported", "precise_gap": "附件原data_date為2026-10-06，原PDF未保存；本輪同URLPDF明列產製日期2026-10-07。上市／代號可由新讀支持，不能宣稱10/06原快照已核。", "web_refs": [ "turn124view2" ], "observed_publication_date": null, "observed_data_date": "2026-10-07", "observed_data_date_role": "current TWSE PDF production date; not silently substituted for original data_date", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T15.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0605", "language": "ZH", "line": 605, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0605", "language": "EN", "line": 605, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [ "ZH-L0609", "EN-L0609" ], "current_disposition": "Reader date scope corrected to the observed 2026-10-07 PDF; original 2026-10-06 snapshot remains unavailable and is not treated as verified.", "reader_source_note": { "source_id": "T15", "supports_zh": "本輪證交所PDF支持台耀化學為TWSE上市公司、股票代號4746。", "supports_en": "The TWSE PDF read in this round supports Formosa Laboratories’ TWSE-listed status and ticker 4746.", "access_scope_zh": "原2026-10-06 PDF未保存；本輪同URL文件產製日為2026-10-07，與保留的原資料日期分列。", "access_scope_en": "The original 2026-10-06 PDF was not retained. The current same-URL file was generated on 2026-10-07, recorded separately from the unchanged original data date.", "locator_zh": "PDF第1頁公司名稱、上市日期、股票代號及產製日期；擷取文字第35、42–48行。", "locator_en": "PDF page 1: company name, listing date, ticker and generation date; extracted lines 35 and 42–48.", "source_date": "", "data_date": "2026-10-06" } }, { "source_id": "T16", "original_url": "https://www.twse.com.tw/pdf/ch/6589_ch.pdf", "title": "臺灣證券交易所 — 台康生技股份有限公司個股資訊（6589）", "source_date": "", "data_date": "2026-10-07", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "public_PDF_page_1_text_extraction", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T16.txt", "bytes": 1749, "sha256": "f58ea466e90ed83dc2e6ddeb8ce7899263e36b8b83546ccc46d6889abc789f11", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "TWSE company profile", "position": "PDF page 1 (tool P0), listing date line 35, name line 40, generation date line 41, ticker line 46" } ], "numeric_support": [ { "field": "ticker", "value": "6589", "unit": "security identifier", "locator": "PDF page 1 / web line 46" }, { "field": "listing_date", "value": "2025-07-21", "unit": "date", "locator": "PDF page 1 / web line 35" }, { "field": "observed_document_generation_date", "value": "2026-10-07", "unit": "date", "locator": "PDF page 1 / web line 41" } ], "supported_summary": "本輪證交所PDF支持台康生技於TWSE上市、代號6589，非上櫃。", "claim_assessments": [ { "claim_location_id": "ZH-L0604", "status": "supported", "supported_scope": "僅支持本來源所對應子句：本輪證交所PDF支持台康生技於TWSE上市、代號6589，非上櫃。", "gap": null, "language": "ZH", "line": 604, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0604", "status": "supported", "supported_scope": "僅支持本來源所對應子句：本輪證交所PDF支持台康生技於TWSE上市、代號6589，非上櫃。", "gap": null, "language": "EN", "line": 604, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "本輪新讀PDF日期與原data_date一致，原PDF位元組未存，不能主張原件hash一致；本輪只讀所需第1頁文字。", "web_refs": [ "turn124view3" ], "observed_publication_date": null, "observed_data_date": "2026-10-07", "observed_data_date_role": "current TWSE PDF production date; not silently substituted for original data_date", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T16.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0604", "language": "ZH", "line": 604, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0604", "language": "EN", "line": 604, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T16", "supports_zh": "證交所PDF支持台康生技為TWSE上市公司、股票代號6589，上市日期2025-07-21。", "supports_en": "The TWSE PDF supports EirGenix’s TWSE-listed status, ticker 6589 and listing date of 2025-07-21.", "access_scope_zh": "已讀本輪產製於2026-10-07的PDF第1頁文字；日期與原資料日相同，不宣稱原文件位元組一致。", "access_scope_en": "Page 1 text of the PDF generated on 2026-10-07 was read. Its date matches the original record, without asserting identical original-file bytes.", "locator_zh": "PDF第1頁公司名稱、上市日期、股票代號及產製日期；擷取文字第35、40–46行。", "locator_en": "PDF page 1: company name, listing date, ticker and generation date; extracted lines 35 and 40–46.", "source_date": "", "data_date": "2026-10-07" } }, { "source_id": "T17", "original_url": "https://www.twse.com.tw/pdf/ch/6838_ch.pdf", "title": "臺灣證券交易所 — 台新藥股份有限公司個股資訊（6838）", "source_date": "", "data_date": "2026-10-07", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "public_PDF_page_1_text_extraction", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T17.txt", "bytes": 1728, "sha256": "112bb807ed2297ddd35138c2cf3ad88e8e567f02f82a304f347884fdaff6fad5", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "TWSE company profile", "position": "PDF page 1 (tool P0), listing date line 35, name line 40, generation date line 41, ticker line 46" } ], "numeric_support": [ { "field": "ticker", "value": "6838", "unit": "security identifier", "locator": "PDF page 1 / web line 46" }, { "field": "listing_date", "value": "2024-08-13", "unit": "date", "locator": "PDF page 1 / web line 35" }, { "field": "observed_document_generation_date", "value": "2026-10-07", "unit": "date", "locator": "PDF page 1 / web line 41" } ], "supported_summary": "本輪證交所PDF支持台新藥於TWSE上市、代號6838。", "claim_assessments": [ { "claim_location_id": "ZH-L0603", "status": "supported", "supported_scope": "僅支持本來源所對應子句：本輪證交所PDF支持台新藥於TWSE上市、代號6838。", "gap": null, "language": "ZH", "line": 603, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0603", "status": "supported", "supported_scope": "僅支持本來源所對應子句：本輪證交所PDF支持台新藥於TWSE上市、代號6838。", "gap": null, "language": "EN", "line": 603, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "本輪新讀PDF日期與原data_date一致，原PDF位元組未存，不能主張原件hash一致；本輪只讀所需第1頁文字。", "web_refs": [ "turn124view4" ], "observed_publication_date": null, "observed_data_date": "2026-10-07", "observed_data_date_role": "current TWSE PDF production date; not silently substituted for original data_date", "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T17.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0603", "language": "ZH", "line": 603, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0603", "language": "EN", "line": 603, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T17", "supports_zh": "證交所PDF支持台新藥為TWSE上市公司、股票代號6838，上市日期2024-08-13。", "supports_en": "The TWSE PDF supports Formosa Pharmaceuticals’ TWSE-listed status, ticker 6838 and listing date of 2024-08-13.", "access_scope_zh": "已讀本輪產製於2026-10-07的PDF第1頁文字；日期與原資料日相同，不宣稱原文件位元組一致。", "access_scope_en": "Page 1 text of the PDF generated on 2026-10-07 was read. Its date matches the original record, without asserting identical original-file bytes.", "locator_zh": "PDF第1頁公司名稱、上市日期、股票代號及產製日期；擷取文字第35、40–46行。", "locator_en": "PDF page 1: company name, listing date, ticker and generation date; extracted lines 35 and 40–46.", "source_date": "", "data_date": "2026-10-07" } }, { "source_id": "T18", "original_url": "https://www.obipharma.com/investor-overview/corporate-overview/", "title": "OBI Pharma — Corporate Overview", "source_date": "", "data_date": "", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T18.txt", "bytes": 1527, "sha256": "cfad2381b4fc67b8b97cb7066647510a7c71a28c4bcb86dd616a3cbfe55b5a84", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "Corporate Overview / OBI Pharma, Inc.", "position": "web lines 126–132; Stock Code, Market, Date of Listing rows" } ], "numeric_support": [ { "field": "stock_code", "value": "4174.TWO", "unit": "security identifier", "locator": "web line 127" }, { "field": "market", "value": "Taipei Exchange", "unit": "exchange", "locator": "web line 128" }, { "field": "listing_date", "value": "2015-03-23", "unit": "date", "locator": "web line 132" } ], "supported_summary": "官方公司資訊表列4174.TWO、Taipei Exchange，支持浩鼎上櫃身分與4174。", "claim_assessments": [ { "claim_location_id": "ZH-L0601", "status": "supported", "supported_scope": "僅支持本來源所對應子句：官方公司資訊表列4174.TWO、Taipei Exchange，支持浩鼎上櫃身分與4174。", "gap": null, "language": "ZH", "line": 601, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0601", "status": "supported", "supported_scope": "僅支持本來源所對應子句：官方公司資訊表列4174.TWO、Taipei Exchange，支持浩鼎上櫃身分與4174。", "gap": null, "language": "EN", "line": 601, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "未標頁面更新日；這是公司官方上市櫃資訊，不延伸成ADC臨床或合作證據。", "web_refs": [ "turn123view2" ], "observed_publication_date": null, "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T18.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0601", "language": "ZH", "line": 601, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0601", "language": "EN", "line": 601, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T18", "supports_zh": "浩鼎官方資訊表列4174.TWO與Taipei Exchange，支持其上櫃身分及4174代號。", "supports_en": "OBI’s corporate table lists 4174.TWO and Taipei Exchange, supporting TPEx-listed status and ticker 4174.", "access_scope_zh": "已讀公開公司資訊表；頁面未標更新日，僅用於上市櫃身分。", "access_scope_en": "The public corporate table was read. It is undated and is used only for listing identity.", "locator_zh": "Corporate Overview公司資訊表；本輪擷取文字第126–132行。", "locator_en": "Corporate Overview table; retrieved-text lines 126–132.", "source_date": "", "data_date": "" } }, { "source_id": "T19", "original_url": "https://glyconex.com.tw/investors/", "title": "台灣醣聯 — 投資人專區", "source_date": "", "data_date": "", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T19.txt", "bytes": 1403, "sha256": "afc630d54fbc35edd05d6b9790d8cd85c6b848a9d3755d2149d2b3de8e5e7611", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "投資人專區", "position": "web lines 16–24; company name, ticker and trading market" } ], "numeric_support": [ { "field": "ticker", "value": "4168", "unit": "security identifier", "locator": "web line 20" }, { "field": "market", "value": "證券櫃檯買賣中心(上櫃)", "unit": "exchange", "locator": "web line 24" } ], "supported_summary": "公司投資人頁明列台灣醣聯、TPEx 4168與上櫃市場，支持身分／代號。", "claim_assessments": [ { "claim_location_id": "ZH-L0602", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司投資人頁明列台灣醣聯、TPEx 4168與上櫃市場，支持身分／代號。", "gap": null, "language": "ZH", "line": 602, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0602", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司投資人頁明列台灣醣聯、TPEx 4168與上櫃市場，支持身分／代號。", "gap": null, "language": "EN", "line": 602, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "未標頁面更新日；本輪只核上市櫃身分，未採該頁其他財務數字。", "web_refs": [ "turn123view3" ], "observed_publication_date": null, "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T19.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0602", "language": "ZH", "line": 602, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0602", "language": "EN", "line": 602, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T19", "supports_zh": "醣聯官方投資人頁明列TPEx 4168及證券櫃檯買賣中心上櫃身分。", "supports_en": "GlycoNex’s investor page explicitly lists TPEx 4168 and Taipei Exchange-listed status.", "access_scope_zh": "已讀公開身分及交易市場欄位；頁面未標更新日，未採其其他財務數字。", "access_scope_en": "Public identity and trading-market fields were read. The page is undated; its other financial figures were not adopted.", "locator_zh": "投資人專區公司介紹與股票代號／交易市場；本輪擷取文字第16–24行。", "locator_en": "Investor introduction, stock code and trading-market fields; retrieved-text lines 16–24.", "source_date": "", "data_date": "" } }, { "source_id": "T20", "original_url": "https://www.mycenax.com/shareholders-meeting.php?id=5&lang=tw", "title": "永昕生物醫藥 — 有價證券資訊", "source_date": "", "data_date": "", "source_date_role": "retained verbatim from the supplied target JSON; empty string means unknown", "data_date_role": "retained verbatim from the supplied target JSON; new observations are separate", "checked_at": "2026-10-07T10:46:10.944263+00:00", "timezone": "Etc/UTC", "read_level": "targeted_public_HTML_passages", "retrieval_mode": "live_public_web_tool", "access_result": "specified public URL returned readable content; no access barrier encountered", "evidence_materials": [ { "path": "evidence/T20.txt", "bytes": 1472, "sha256": "85c350fe10cd5de0dbb79cd7c0dbb1a8ab6e19736abdedec348c67ac05101ebd", "kind": "authored_minimum_excerpt_and_numeric_support_record" } ], "original_artifact_sha256": null, "original_network_read_time": null, "network_time_note": "Current checked_at records evidence assessment. Web tool origin fetch timestamp is not exposed; not asserted as a historical access time.", "locators": [ { "section": "有價證券資訊", "position": "web lines 125–127; repeated at lines 134–136" } ], "numeric_support": [ { "field": "security_name", "value": "永昕", "unit": "name", "locator": "web line 126" }, { "field": "ticker", "value": "4726", "unit": "security identifier", "locator": "web line 127" }, { "field": "market", "value": "證櫃檯買賣中心掛牌上櫃", "unit": "exchange", "locator": "web line 125" } ], "supported_summary": "公司有價證券頁明列永昕普通股上櫃及4726代號。", "claim_assessments": [ { "claim_location_id": "ZH-L0606", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司有價證券頁明列永昕普通股上櫃及4726代號。", "gap": null, "language": "ZH", "line": 606, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "ZH-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0606", "status": "supported", "supported_scope": "僅支持本來源所對應子句：公司有價證券頁明列永昕普通股上櫃及4726代號。", "gap": null, "language": "EN", "line": 606, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" }, { "claim_location_id": "EN-L0610", "status": "supported", "supported_scope": "本來源的本輪公開核讀／原日期角色；只涵蓋這一來源，非同列其他來源的查核結論。", "gap": null, "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need", "exact_correction_ids": [], "current_disposition": "retained within stated source contribution and evidence boundary" } ], "overall_status": "supported", "precise_gap": "未標頁面更新日；本輪只核上市櫃身分，不用此頁證實ADC能力。", "web_refs": [ "turn123view4" ], "observed_publication_date": null, "status_time_scope": "Assessment of the specified original wording before the corrections in this supplement.", "assessment_scope": "Author evidence assessment of the specified source-dependent contribution; not independent QA or a whole-source/full-report gate.", "minimum_excerpt": { "material_path": "evidence/T20.txt", "locator_within_material": "Minimum verbatim excerpt(s) / 最小原文摘錄; followed by original numeric or structured fields", "storage_note": "The actual minimal original quotation is in the supplied hashed UTF-8 evidence file; not copied again into CSV/JSON." }, "claim_location_ids": [ { "claim_location_id": "ZH-L0606", "language": "ZH", "line": 606, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "ZH-L0610", "language": "ZH", "line": 610, "section": "附錄 B　台灣能力與證據地圖", "subsection": "比較表 F14｜台灣能力地圖：七個主體，三種需求" }, { "claim_location_id": "EN-L0606", "language": "EN", "line": 606, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" }, { "claim_location_id": "EN-L0610", "language": "EN", "line": 610, "section": "Appendix B Taiwan Capabilities and Evidence Map", "subsection": "Table F14｜Taiwan's Capability Map: Seven Entities, Three Types of Need" } ], "applied_corrections": [], "current_disposition": "Original assigned contribution retained within the stated read level and boundary.", "reader_source_note": { "source_id": "T20", "supports_zh": "永昕官方有價證券頁明列普通股上櫃及股票代號4726。", "supports_en": "Mycenax’s securities page explicitly lists its common shares as Taipei Exchange-listed, with ticker 4726.", "access_scope_zh": "已讀公開有價證券資訊；頁面未標更新日，僅用於上市櫃身分。", "access_scope_en": "Public securities information was read. The page is undated and is used only for listing identity.", "locator_zh": "有價證券資訊；本輪擷取文字第125–127行。", "locator_en": "Securities information; retrieved-text lines 125–127.", "source_date": "", "data_date": "" } } ] }